,id,phases,sponsor,collaborators,interventions,locations,enrollment,conditions,Start Date,Max Phase
0,NCT05174637,Phase 1,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",,"Drug: FDA018-ADC,FDA018-ADC,FDA018-Antibody-drug Conjugate",China,78,Advanced/ Metastatic Solid Tumors,2021-10-22,1
1,NCT03489525,Phase 1,MedImmune LLC,,"Dose Escalation, MEDI2228, ADC (antibody drug conjugate),Dose Expansion, MEDI2228, ADC (antibody drug conjugate),Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate),Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)","Spain,Greece,Australia,United States,France",107,Relapsed/Refractory Multiple Myeloma,2018-03-17,1
2,NCT04829604,Phase 2,"Ambrx, Inc.",,"antibody drug conjugate (ADC),ARX788","Australia,United States,Korea, Republic of,France",71,HER2 Positive Metastatic Breast Cancer,2021-10-26,2
3,NCT05156866,Phase 1,"TORL Biotherapeutics, LLC",Translational Research in Oncology,"TORL-2-307-ADC,Drug: TORL-2-307-ADC","Korea, Republic of,United States",70,"Gastric Cancer,Advanced Solid Tumor,Pancreas Cancer,Gastroesophageal Junction Adenocarcinoma",2021-01-12,1
4,NCT01414283,Phase 1,"Progenics Pharmaceuticals, Inc.",,"PSMA ADC,Drug: PSMA ADC",United States,52,Prostate Cancer,2008-10-01,1
5,NCT01414296,Phase 1,"Progenics Pharmaceuticals, Inc.",,"PSMA ADC,Drug: PSMA ADC",United States,10,Prostate Cancer,2009-01-01,1
6,NCT01695044,Phase 2,"Progenics Pharmaceuticals, Inc.",,"PSMA ADC,Drug: PSMA ADC",United States,119,Prostate Cancer,2012-09-01,2
7,NCT04681131,Phase 2,"BioAtla, Inc.",,"CAB-AXL-ADC,Biological: CAB-AXL-ADC,PD-1 inhibitor,Biological: PD-1 inhibitor,BA3011","Germany,Poland,Italy,Spain,Hong Kong,Greece,Taiwan,United States",240,Non-Small-Cell Lung Cancer,2020-08-12,2
8,NCT04329429,Phase 2,"RemeGen Co., Ltd.",,"Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,RC48-ADC,Drug: RC48-ADC",China,57,Biliary Tract Cancer,2020-03-27,2
9,NCT04073602,Phase 2,"RemeGen Co., Ltd.",,"Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,RC48-ADC,Drug: RC48-ADC",China,19,Urothelial Carcinoma,2019-08-19,2
10,NCT04132960,Phase 2,UNICANCER,"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company",DS-8201a,France,186,Breast Tumors,2019-10-21,2
11,NCT02988817,"Phase 2,Phase 1",Genmab,,"Biological: Enapotamab vedotin (HuMax-AXL-ADC),Enapotamab vedotin (HuMax-AXL-ADC)","Belgium,Spain,Netherlands,United Kingdom,United States,Denmark",306,"Thyroid Cancer,Melanoma,Ovarian Cancer,Non Small Cell Lung Cancer (NSCLC),Sarcoma,Cervical Cancer,Solid Tumors,Endometrial Cancer",2016-01-12,2
12,NCT03504488,"Phase 2,Phase 1","BioAtla, Inc.",,"PD-1 inhibitor,Biological: PD-1 inhibitor,BA3021,CAB-ROR2-ADC,Biological: CAB-ROR2-ADC","Germany,Poland,Italy,Spain,Hong Kong,Greece,Taiwan,United States",420,"Non Small Cell Lung Cancer,Head and Neck Cancer,Triple Negative Breast Cancer,Melanoma",2018-06-27,2
13,NCT05205850,"Phase 2,Phase 1","RemeGen Co., Ltd.",,"Drug: RC118-ADC,RC118-ADC,RC118 for injection",China,135,Advanced Solid Tumor,2021-11-17,2
14,NCT06014658,Phase 1,MBrace Therapeutics,,"Drug: Antibody-Drug Conjugate,Antibody-Drug Conjugate",United States,90,Cancer,2023-01-08,1
15,NCT02020135,Phase 2,"Progenics Pharmaceuticals, Inc.",,"PSMA ADC,Drug: PSMA ADC",United States,9,Prostate Cancer,2013-10-01,2
16,NCT04695847,Phase 1,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany","Bispecific antibody drug conjugate (ADC),M1231","Canada,United States",23,"Metastatic Solid Tumors,Non-Small Cell Lung Cancer,Esophageal Cancer",2021-01-13,1
17,NCT03255070,Phase 1,"Ambrx, Inc.",,"antibody drug conjugate (ADC),ARX788","Australia,United States",106,"Solid Tumors,Breast Neoplasms,Gastric Neoplasm",2018-03-20,1
18,NCT04240704,Phase 1,Novartis Pharmaceuticals,,JBH492,"Germany,Israel,Korea, Republic of,Spain,Singapore,Finland,Japan",25,"Non-Hodgkins Lymphoma,Chronic Lymphocytic Leukemia",2020-09-07,1
19,NCT03425279,"Phase 2,Phase 1","BioAtla, Inc.",,"CAB-AXL-ADC,PD-1 inhibitor,Biological: PD-1 inhibitor,Biological: CAB-AXL-ADC","Hong Kong,United States,Taiwan",300,"Myxofibrosarcoma,Undifferentiated Pleomorphic Sarcoma",2018-01-22,2
20,NCT04064359,Phase 1,Oxford BioTherapeutics Ltd,,"OBT076, a CD205-directed antibody-drug conjugate,MEN1309,Drug: OBT076, a CD205-directed antibody-drug conjugate","Belgium,Spain,Greece,United States,France",200,Solid Tumor,2019-07-25,1
21,NCT02001623,"Phase 2,Phase 1",Seagen Inc.,Genmab,"TIVDAK,Drug: Tisotumab Vedotin (HuMax-TF-ADC),Tisotumab Vedotin (HuMax-TF-ADC)","Belgium,Denmark,United States,Sweden,United Kingdom",195,"Endometrium Cancer,Esophagus Cancer,Bladder Cancer,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Cervix Cancer,Ovary Cancer,Lung Cancer(NSCLC),Prostate Cancer (CRPC)",2013-11-14,2
22,NCT04617314,Phase 1,"RemeGen Co., Ltd.",,"RC108 for injection,RC108",China,32,Solid Tumor,2021-03-10,1
23,NCT05564858,Phase 1,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",,"FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib,Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia,Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib,FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia,FDA022-BB05",China,107,Advanced Solid Tumors,2022-09-20,1
24,NCT06440005,Phase 1,"Angiex, Inc.",,"AGX101,ADC",United States,80,"Cancer,Pancreas Cancer,Pancreatic Adenocarcinoma,Locally Advanced Carcinoma,Triple Negative Breast Cancer,Advanced Cancer,Metastatic Solid Tumor",2024-05-01,1
25,NCT05011188,"Phase 2,Phase 1",Rahul Aggarwal,"Fortis Therapeutics, Inc.","G-CSF,FOR46,Pegfilgrastim,anti-CD46 antibody conjugate,XTANDI,Antibody-Drug Conjugate (ADC),Enzalutamide",United States,36,"Metastatic Castration-resistant Prostate Cancer,Prostate Cancer",2022-01-19,2
26,NCT05996952,Phase 2,West China Hospital,"RemeGen Co., Ltd.","RC48-ADC,Drug: RC48-ADC",China,77,Non-muscle Invasive Bladder Cancer,2023-03-08,2
27,NCT06234423,Phase 1,"OnCusp Therapeutics, Inc.",,CUSP06,United States,180,"Solid Tumor,Ovarian Cancer",2024-02-09,1
28,NCT04316442,"Phase 2,Phase 1","Sorrento Therapeutics, Inc.",,"STI-6129,anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)",United States,60,Light Chain (AL) Amyloidosis,2021-04-01,2
29,NCT04662580,Phase 1,"Ambrx, Inc.",Johnson & Johnson,ARX517,United States,262,Prostate Cancer,2021-07-27,1
30,NCT06457997,Phase 1,Pheon Therapeutics,,PHN-010,United States,273,"Advanced Solid Tumor,Ovarian Cancer,Advanced Cancer,Cervical Cancer,Lung Cancer,Colon Cancer,Endometrial Cancer",2024-07-01,1
31,NCT04152499,"Phase 2,Phase 1",Klus Pharma Inc.,,SKB264,"China,Korea, Republic of,Canada,Turkey,United States",1300,"Breast Cancer,Urothelial Carcinoma,Endometrial Carcinoma,Gastric Adenocarcinoma,Small-Cell Lung Cancer,Epithelial Ovarian Cancer,Non-Small Cell Lung Cancer,Head and Neck Squamous Cell Carcinoma,Gastroesophageal Junction Adenocarcinoma",2020-02-28,2
32,NCT04400695,Phase 3,"RemeGen Co., Ltd.",,"Drug: Vinorelbine Tartrate Injection,Xeloda,Drug: RC48-ADC,Drug: Docetaxel Injection,Docetaxel Injection,RC48-ADC,RC48,Navelbine,Drug: Capecitabine Tablets,Paclitaxel Injection,Capecitabine Tablets,Vinorelbine Tartrate Injection,Taxotere,Taxol,Drug: Paclitaxel Injection",China,366,Breast Cancer,2020-04-30,3
33,NCT05103683,Phase 1,"TORL Biotherapeutics, LLC",Translational Research in Oncology,TORL-1-23,United States,90,"Advanced Solid Tumor,Ovarian Cancer,NSCLC,Endometrial Cancer",2021-11-17,1
34,NCT05217693,Phase 1,"Bliss Biopharmaceutical (Hangzhou) Co., Ltd",,BB-1705,China,288,Solid Tumor,2022-06-01,1
35,NCT05308225,"Phase 2,Phase 1","Sorrento Therapeutics, Inc.",,STI-6129,United States,72,Multiple Myeloma,2023-02-01,2
36,NCT04610528,Phase 1,SOLTI Breast Cancer Research Group,Daiichi Sankyo,"U3 1402,Patritumab Deruxtecan",Spain,80,Breast Cancer,2020-12-22,1
37,NCT06198751,Phase 2,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,"7.5 mg/kg of TQB2102 for injection,6.0 mg/kg of TQB2102 for injection",China,104,Breast Cancer,2024-02-05,2
38,NCT05297552,Phase 2,"RemeGen Co., Ltd.",,"JS001,Drug: JS001,RC48-ADC,Drug: RC48-ADC",China,40,Muscle Invasive Bladder Carcinoma,2022-03-17,2
39,NCT04202705,Phase 1,Byondis B.V.,,SYD1875,"France,Belgium",31,Solid Tumor,2020-02-28,1
40,NCT05323045,Phase 1,Byondis B.V.,,BYON3521,"Netherlands,Italy,United Kingdom,Belgium",31,Solid Tumor,2022-03-21,1
41,NCT05514158,Phase 1,"RemeGen Co., Ltd.",,"RC98,RC98 injection,Drug: RC48-ADC,RC48-ADC injection,RC48-ADC,Drug: RC98",China,24,Gastric Cancer,2022-04-08,1
42,NCT05135715,Phase 2,"RemeGen Co., Ltd.",,"Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,RC48-ADC,Drug: RC48-ADC",China,50,"Advanced Melanoma,Melanoma, Stage II,HER2-positive",2021-11-15,2
43,NCT05941507,"Phase 2,Phase 1","LigaChem Biosciences, Inc.","AntibodyChem Biosciences, Inc.","LCB84,Anti-PD-1 monoclonal antibody","Canada,United States",300,Advanced Solid Tumors,2023-10-05,2
44,NCT02874664,Phase 1,Stemcentrx,,"SC16LD6.5,Rovalpituzumab Tesirine","Canada,United States",46,Small Cell Lung Carcinoma,2016-09-01,1
45,NCT05527184,Phase 1,"ImmunoGen, Inc.",,IMGN151,United States,227,"Fallopian Tube Cancer,Primary Peritoneal Carcinoma,High Grade Serous Adenocarcinoma of Ovary,Endometrial Cancer",2023-01-11,1
46,NCT02881138,Phase 1,"RemeGen,RemeGen Co., Ltd.",,"RC48-ADC,Drug: RC48-ADC",China,24,Solid Tumors,2016-03-01,1
47,NCT03366428,Phase 1,"Daiichi Sankyo Co., Ltd.",AstraZeneca,"Experimental product,DS-8201a",Japan,51,Malignant Neoplasm of Breast,2017-12-26,1
48,NCT02552121,"Phase 2,Phase 1","Genmab,Seagen Inc.",Genmab,"Drug: Tisotumab vedotin (HuMax-TF-ADC),Tisotumab vedotin (HuMax-TF-ADC)","Hungary,Belgium,Denmark,United States,United Kingdom",33,"Endometrium Cancer,Lung Cancer (NSCLC),Bladder Cancer,Cervix Cancer,Ovary Cancer,Esophagus Cancer,Prostate Cancer (CRPC)",2015-09-14,2
49,NCT02674568,Phase 2,AbbVie,,"SC16LD6.5,Rovalpituzumab tesirine",,342,Small Cell Lung Cancer,2016-01-25,2
50,NCT05745740,"Phase 2,Phase 1","RemeGen Co., Ltd.",,"Drug: RC48-ADC,RC48-ADC,DV,Drug: Pyrotinib,Pyrotinib",China,26,Non-small Cell Lung Cancer,2023-02-16,2
51,NCT06210815,Phase 1,Shanghai Henlius Biotech,,"HLX42,Anti-EGFR ADC",China,42,Solid Tumor,2024-03-14,1
52,NCT05565807,"Phase 2,Phase 1",Zhejiang ACEA Pharmaceutical Co. Ltd.,,STI-6129,China,84,Relapsed or Refractory Multiple Myeloma,2023-02-09,2
53,NCT06005740,Phase 1,"TORL Biotherapeutics, LLC",Translational Research in Oncology,TORL-4-500,United States,70,"Hepatocellular Carcinoma,Advanced Solid Tumor",2023-12-04,1
54,NCT04965519,Phase 2,"RemeGen Co., Ltd.",,"Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,RC48-ADC,Drug: RC48-ADC",China,120,Gynecological Malignancy,2021-07-07,2
55,NCT02881190,Phase 1,"RemeGen,RemeGen Co., Ltd.",,"RC48-ADC,Drug: RC48-ADC",China,57,Solid Tumors,2015-12-14,1
56,NCT06452706,Phase 2,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",,TQB2102 for injection,China,42,Breast Cancer,2024-07-01,2
57,NCT06431490,"Phase 2,Phase 1","Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",,TQB2102 for injection,China,103,Biliary Tract Cancer,2024-07-01,2
58,NCT06038396,"Phase 2,Phase 1","RemeGen Co., Ltd.",,"RC118 for injection,JS001,RC118,Toripalimab,Toripalimab for injection",China,64,Advanced Solid Tumor,2023-08-03,2
59,NCT03507166,Phase 2,"RemeGen,RemeGen Co., Ltd.",,"Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,RC48-ADC,Drug: RC48-ADC",China,43,"Urothelial Carcinoma,Advanced Cancer",2017-12-28,2
60,NCT03556345,Phase 2,"RemeGen Co., Ltd.",,"Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,RC48-ADC,Drug: RC48-ADC",China,127,"Gastric Cancer,HER2 Overexpressing Gastric Carcinoma",2018-01-06,2
61,NCT05367635,Phase 1,"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.",,SKB315 for injection,China,206,Advanced Solid Tumors,2022-03-16,1
62,NCT05460273,"Phase 2,Phase 1",AstraZeneca,Daiichi Sankyo,"Datopotamab Deruxtecan (Dato-DXd),DS-1062a",China,119,"Triple Negative Breast Cancer,Carcinoma, Non-Small-Cell Lung",2022-07-11,2
63,NCT05525286,"Phase 2,Phase 1",SOTIO Biotech a.s.,,"SOT102,Drug: SOT102","Belgium,Spain,Czechia,United States,France",160,Pancreatic Cancer,2021-07-12,2
64,NCT05652855,"Phase 2,Phase 1",Minghui Pharmaceutical Pty Ltd,,MHB088C for Injection,Australia,48,Advanced or Metastatic Solid Tumors,2023-01-23,2
65,NCT03809013,Phase 2,"RemeGen Co., Ltd.",,"Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,RC48-ADC,Drug: RC48-ADC",China,64,Urothelial Carcinoma,2019-01-07,2
66,NCT01807598,Phase 2,Jason Robert Gotlib,Seagen Inc.,"anti-CD30 antibody-drug conjugate,Adcetris,Brentuximab vedotin,SGN-35,anti-CD30 ADC",United States,10,"Aggressive Systemic Mastocytosis,Systemic Mastocytosis,Mast Cell Leukemia",2013-09-01,2
67,NCT06384807,"Phase 2,Phase 1",Biohaven Therapeutics Ltd.,,"GQ1010,BHV1510,PBI-410",United States,170,Solid Tumor,2024-04-22,2
68,NCT05320588,"Phase 2,Phase 1",BiOneCure Therapeutics Inc.,,"BIO-106,Pembrolizumab,Keytruda",United States,332,"Cancer,Advanced Solid Tumor,Oncology,Advanced Cancer",2022-03-25,2
69,NCT06115642,Phase 1,Shanghai Henlius Biotech,,"Anti-PD-L1 ADC,HLX43",China,36,Advanced Solid Tumor,2023-11-28,1
70,NCT06115902,Phase 1,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",,TQB2102 for injection,China,150,Breast Cancer,2023-11-17,1
71,NCT03052634,"Phase 2,Phase 1","RemeGen Co., Ltd.",,"RC48-ADC 2.0 mg/kg (HER2 Low Expression),RC48-ADC 2.0 mg/kg (HER2 Positive),Drug: RC48-ADC 1.5 mg/kg (HER2 Positive),Drug: RC48-ADC 2.5 mg/kg (HER2 Positive),Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression),Drug: RC48-ADC 2.0 mg/kg (HER2 Positive),RC48-ADC 2.5 mg/kg (HER2 Positive),RC48-ADC 1.5 mg/kg (HER2 Positive)",China,112,Advanced Breast Cancer,2016-12-23,2
72,NCT02277717,Phase 1,Byondis B.V.,,SYD985 (trastuzumab vc-seco-DUBA),"Netherlands,Spain,United Kingdom,Belgium",185,Solid Tumors,2014-10-01,1
73,NCT03748186,Phase 1,"Sutro Biopharma, Inc.",,STRO-002,"United States,Spain",160,"Ovarian Cancer,Endometrioid Adenocarcinoma,Ovarian Carcinoma,Ovary Cancer,Fallopian Tube Cancer,Primary Peritoneal Carcinoma,Endometrial Cancer",2019-02-01,1
74,NCT05652868,Phase 1,Mythic Therapeutics,,MYTX-011,"Korea, Republic of,Spain,Taiwan,Australia,United States,United Kingdom",150,"Advanced Non-Small Cell Non-Squamous Lung Cancer,NSCLC,NSCLC Stage IV,NSCLC Stage IIIB,Advanced Non-Small Cell Squamous Lung Cancer,Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer",2023-03-23,1
75,NCT04280341,Phase 1,Peking University,"RemeGen Co., Ltd.","RC48-ADC in combinaton with JS001,Biological: RC48-ADC in combinaton with JS001",China,50,HER2-Positive Solid Tumors,2019-12-30,1
76,NCT00031187,Phase 2,"Seagen Inc.,Seattle Genetics, Inc.",,"Drug: SGN-15 (cBR96-doxorubicin immunoconjugate),Drug: Taxotere (docetaxel),SGN-15 (cBR96-doxorubicin immunoconjugate),Taxotere (docetaxel)",United States,160,Prostatic Neoplasms,2000-10-01,2
77,NCT03248492,Phase 2,Daiichi Sankyo,"AstraZeneca,Daiichi Sankyo Co., Ltd.","Experimental product,DS-8201a","Belgium,Japan,Italy,Korea, Republic of,Spain,Canada,United States,United Kingdom,France",253,Breast Cancer,2017-08-25,2
78,NCT03505710,Phase 2,Daiichi Sankyo,"AstraZeneca,Daiichi Sankyo Co., Ltd.","Experimental product,DS-8201a,Trastuzumab deruxtecan","Spain,Netherlands,United States,Japan,France",181,Non-Small Cell Lung Cancer,2018-05-21,2
79,NCT03725761,Phase 2,"University of Wisconsin, Madison","Gilead Sciences,National Cancer Institute (NCI)","Sacituzumab Govitecan,IMMU-132",United States,31,Prostate Cancer,2018-10-24,2
80,NCT01432275,,Abbott Diabetes Care,,"Lifescan Verio Pro or,Device: Comparator blood glucose meter,Abbott Freestyle InsuLinx,Device: ADC blood glucose meter with insulin calculator active,ADC blood glucose meter,Comparator blood glucose meter,ADC blood glucose meter with insulin calculator active,Device: ADC blood glucose meter,Bayer Contour USB,Abbott FreeStyle InsuLinx,Roche Accu-Chek Aviva Nano",United Kingdom,179,Diabetes Mellitus,2011-09-01,
81,NCT06265727,"Phase 2,Phase 1",Corbus Pharmaceuticals Inc.,"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.",CRB-701,"Turkey,United States,United Kingdom,Spain",420,"Solid Tumor, Adult",2024-04-01,2
82,NCT06263543,Phase 2,"Reshma L. Mahtani, D.O.",Gilead Sciences,"Sacituzumab govitecan,Trodelvy",United States,75,"Breast Cancer,Metastatic Breast Cancer,Hormone-receptor-positive Breast Cancer,Human Epidermal Growth Factor 2 Low Breast Cancer,Advanced Breast Cancer",2024-06-17,2
83,NCT06155396,Phase 2,"RemeGen Co., Ltd.",,"Disitamab Vedotin,Disitamab Vedotin （RC48-ADC),Zimberelimab",China,116,Cervical Cancer,2024-01-11,2
84,NCT05584709,Phase 1,"Sorrento Therapeutics, Inc.",,"STI-6129,Anti-CD38 antibody drug conjugate",United States,34,Advanced Solid Tumor,2023-03-01,1
85,NCT00126646,Phase 1,MedImmune LLC,,"Procedure: immunotoxin therapy,Procedure: antibody-drug conjugate therapy,immunotoxin therapy,BL22 immunotoxin,Drug: BL22 immunotoxin,antibody-drug conjugate therapy",United States,24,"Leukemia,Lymphoma",2005-02-08,1
86,NCT05980481,"Phase 2,Phase 3","RemeGen Co., Ltd.",,"Disitamab Vedotin,Trastuzumab,Oxaliplatin,Trastuzumab Injection,Drug: RC48-ADC,JS001,Drug: Herceptin,Toripalimab,RC48-ADC,Capecitabine,Drug: Oxaliplatin injection,Drug: Capecitabine,Oxaliplatin injection,Capecitabine Tablets,Drug: Toripalimab",China,130,Gastric Cancer,2023-01-07,3
87,NCT05943379,Phase 2,"RemeGen Co., Ltd.",,"Drug: RC48-ADC in Combination with gemcitabine,RC48-ADC in Combination with gemcitabine",China,85,NMIBC,2023-03-13,2
88,NCT04868344,Phase 1,Shanghai Miracogen Inc.,,MRG003,China,61,Advanced Solid Tumors,2018-05-09,1
89,NCT06224855,Phase 1,"Hangzhou DAC Biotechnology Co., Ltd.",,"Recombinant Humanized Antibody-drug conjugate,DXC006",,110,"Advanced Solid Tumors,Hematological Malignancies",2024-01-24,1
90,NCT05914545,Phase 1,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",,"FZ-AD004-Antibody-drug Conjugate,FZ-AD004",China,121,Advanced and Metastatic Solid Tumor,2023-06-12,1
91,NCT03682796,Phase 1,Triphase Research and Development III Corp.,,TRPH-222,"Canada,United States",32,"Lymphoma, Follicular,Lymphoma, B-Cell,Lymphoma, Large B-Cell, Diffuse,Lymphoma, Mantle-Cell,Lymphoma, Marginal Zone,Lymphoma,Lymphoma, Non-Hodgkin",2018-10-15,1
92,NCT03368196,Phase 1,"Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company",AstraZeneca,DS-8201a,Taiwan,12,"Adenocarcinoma, Gastric,Neoplasm, Breast",2018-04-02,1
93,NCT03650491,Phase 1,"Fortis Therapeutics, Inc.",,FOR46,United States,31,"Multiple Myeloma With Failed Remission,Multiple Myeloma,Multiple Myeloma in Relapse",2019-04-03,1
94,NCT03575819,Phase 1,"Fortis Therapeutics, Inc.",,FOR46,United States,56,Prostate Cancer Metastatic,2019-02-04,1
95,NCT05866354,Phase 1,"Zai Lab (Shanghai) Co., Ltd.",,Tisotumab Vedotin,China,19,Solid Malignancies,2023-06-16,1
96,NCT03384940,Phase 2,"Daiichi Sankyo Co., Ltd.","AstraZeneca,Daiichi Sankyo","DS-8201a,Trastuzumab deruxtecan","Italy,Spain,United Kingdom,United States,Japan",86,Colorectal Neoplasm,2018-02-23,2
97,NCT05464030,Phase 1,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany","M9140,Capecitabine,Bevacizumab","United States,Japan,Spain",180,Colorectal Cancer,2022-08-04,1
98,NCT05797168,"Phase 2,Phase 1",AstraZeneca,,"AZD5335,AZD5305","China,Japan,Israel,Spain,Canada,Taiwan,Australia,United States,United Kingdom",150,"Ovarian Cancer,Lung Adenocarcinoma",2023-06-05,2
99,NCT03500380,"Phase 2,Phase 3","RemeGen Co., Ltd.",,"Drug: RC48-ADC,Drug: Capecitabine,RC48-ADC,Capecitabine,RC48,Drug: Lapatinib,Lapatinib",China,301,"HER2-positive Breast Cancer,Breast Neoplasms,Capecitabine,HER2-positive Advanced Breast With Liver Metastases,Breast Diseases,HER2 Positive Breast Carcinoma",2018-04-24,3
100,NCT05302284,Phase 3,"RemeGen Co., Ltd.",,"Disitamab Vedotin,Carboplatin,Drug: RC48-ADC,JS001,Cisplatin,Toripalimab,RC48-ADC,Drug: Carboplatin,Drug: Cisplatin,Drug: Gemcitabine,Drug: Toripalimab,Gemcitabine",China,452,"Urothelial Carcinoma,HER2-expressing",2022-03-21,3
101,NCT06105008,Phase 2,"RemeGen Co., Ltd.",,"Disitamab Vedotin,RC48-ADC, DV,JS001,Toripalimab",China,80,Breast Neoplasms,2024-12-20,2
102,NCT05751512,Phase 3,Shanghai Miracogen Inc.,,"Cetuximab injection,MRG003,Methotrexate Injection",China,180,Squamous Cell Carcinoma of the Head and Neck,2023-03-01,3
103,NCT04965766,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris",Daiichi Sankyo,"U3-1402,HER3-DXd",France,170,Metastatic Breast Cancer,2021-05-11,2
104,NCT03602079,"Phase 2,Phase 1",Klus Pharma Inc.,,A166,United States,49,"Mucinous Adenocarcinoma Gastric,Recurrent Ovarian Carcinoma,Rectal Cancer Stage III,Cholangiocarcinoma,Solid Tumor,Recurrent Gastric Cancer,Lung Cancer,Liver Cancer,Bile Duct Cancer,Recurrent Renal Cell Cancer,Prostate Cancer,Rectal Cancer,Tonsil Cancer,Mucinous Breast Cancer Recurrent,Bladder Cancer,Recurrent Breast Cancer,Mouth Cancer,Rectal Cancer Stage I,Rare Diseases,Head and Neck Cancer,Mucoepidermoid Carcinoma,Primary Peritoneal Carcinoma,Rectal Cancer Stage II,HER2-positive Breast Cancer,HER2 Gene Mutation,Lip Cancer Stage I,HER2 Positive Gastric Cancer,Recurrent Prostate Cancer,Head and Neck Carcinoma,Tongue Cancer,Recurrent Colon Cancer,Skin Cancer,Salivary Gland Cancer,Salivary Gland Neoplasms,Urologic Cancer,Breast Neoplasm Malignant Primary,Colo-rectal Cancer,Palate Cancer,Salivary Gland Carcinoma,HER-2 Gene Amplification,Cervical Cancer,Larynx Cancer,Pancreatic Cancer,Salivary Gland Tumor",2018-07-16,2
105,NCT04925284,Phase 1,Exelixis,,"XB002,Nivolumab","Belgium,Italy,Korea, Republic of,Spain,Netherlands,Australia,United States,United Kingdom,France",573,"SCCHN,Esophageal SCC,Tissue Factor-Expressing Solid Tumors,Non Small Cell Lung Cancer,Epithelial Ovarian Cancer,Metastatic Castration-resistant Prostate Cancer,Triple Negative Breast Cancer,Hormone Receptor-positive Breast Cancer,Cervical Cancer,Pancreatic Cancer,Endometrial Cancer",2021-06-07,1
106,NCT06238479,Phase 1,Eli Lilly and Company,"Loxo Oncology, Inc.",LY4101174,"Australia,United States,Japan",280,"Advanced Solid Tumor,Ovarian Cancer,Prostate Cancer,Esophageal Cancer,Urinary Bladder Neoplasm,Bladder Cancer,Triple Negative Breast Cancer,Cervical Cancer,Head and Neck Squamous Cell Carcinoma,Pancreatic Cancer,Renal Pelvis Cancer,Metastatic Solid Tumor,Non-small Cell Lung Cancer,Recurrent Solid Tumor",2024-03-05,1
107,NCT01497821,Phase 1,Amgen,,AMG 172,"Germany,United States,France",37,"Clear Cell Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Renal Cell Carcinoma,Renal Cell Adenocarcinoma",2012-01-01,1
108,NCT03734029,Phase 3,Daiichi Sankyo,"AstraZeneca,Daiichi Sankyo Co., Ltd.","Eribulin,Drug: Nab-paclitaxel,Drug: Capecitabine,Drug: Eribulin,Capecitabine,Trastuzumab deruxtecan (DS-8201a),Paclitaxel,Drug: Gemcitabine,Nab-paclitaxel,Drug: Paclitaxel,Drug: Trastuzumab deruxtecan (DS-8201a),Gemcitabine,DS-8201a","Hungary,Belgium,Israel,Italy,Taiwan,United Kingdom,China,United States,Switzerland,Japan,Sweden,Russian Federation,Germany,Austria,Portugal,Korea, Republic of,Spain,Canada,Greece,France",557,Breast Cancer,2018-06-11,3
109,NCT04924699,"Phase 3,Phase 2",Shanghai Miracogen Inc.,,"Trastuzumab Emtansine for Injection,MRG002",China,350,"Advanced Breast Cancer,Metastatic Breast Cancer",2021-06-30,3
110,NCT06224673,Phase 2,"Laura Huppert, MD, BA","Ambrx, Inc.","Biospecimen Collection,Specimen Collection,Antibody-drug Conjugate ARX788,Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788,CT Scan,PET/CT,ARX788,Anvatabart Opadotin,Computed Tomography (CT),Biological Sample Collection",United States,36,"Triple Negative Breast Cancer,Hormone-receptor-positive Breast Cancer,HER2 Low Breast Carcinoma,Hormone Receptor Positive Breast Carcinoma",2024-07-15,2
111,NCT03677596,Phase 4,Pfizer,,"Inotuzumab ozogamicin-dose level 1,inotuzumab ozogamicin-dose level 2,Besponsa","Hungary,Poland,India,Spain,Singapore,Taiwan,Turkey,United States",102,"ACUTE LYMPHOBLASTIC LEUKEMIA,Precursor b-Cell Lymphoblastic Leukemia-Lymphoma,Leukemia",2019-07-01,4
112,NCT05126719,Phase 2,Shanghai Miracogen Inc.,,"Capecitabine tablets,MRG003,Docetaxel injection",China,238,Recurrent or Metastatic Nasopharyngeal Carcinoma,2021-08-04,2
113,NCT04838964,Phase 2,Shanghai Miracogen Inc.,,MRG003,China,80,Advanced or Metastatic Biliary Tract Cancer,2021-04-28,2
114,NCT06048718,Phase 2,MedSIR,Daiichi Sankyo,"Trastuzumab-Deruxtecan (T-DXd),DS-8021a, ENHERTU",Spain,27,"Breast Cancer,Metastatic Breast Cancer",2024-06-05,2
115,NCT04843709,"Phase 2,Phase 1",Shanghai Miracogen Inc.,,MRG004A,"China,United States",181,Advanced or Metastatic Solid Tumors,2021-07-26,2
116,NCT05688605,"Phase 2,Phase 1",Shanghai Miracogen Inc.,,MRG003+HX008,China,18,Advanced Solid Tumors,2022-06-30,2
117,NCT04742153,Phase 2,Shanghai Miracogen Inc.,,MRG002,China,66,Advanced or Metastatic Breast Cancer,2021-05-13,2
118,NCT05293496,Phase 1,MacroGenics,,"lorigerlimab,MGC018,vobramitamab duocarmazine,MGD019",United States,278,"Advanced Solid Tumor,Malignant Melanoma,Pancreatic Ductal Carcinoma,Castration-Resistant Prostatic Cancer,Epithelial Ovarian Cancer,Renal Cell Carcinoma,Hepatocellular Cancer",2022-04-19,1
119,NCT04940325,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris",Daiichi Sankyo,DS-1062a,France,100,Metastatic Lung Cancer,2021-05-12,2
120,NCT04235101,Phase 1,Byondis B.V.,,"SYD985 + Niraparib,(vic-)trastuzumab duocarmazine + Zejula","Netherlands,United Kingdom,Belgium",32,Solid Tumor,2020-06-22,1
121,NCT02564900,Phase 1,"Daiichi Sankyo Co., Ltd.","AstraZeneca,Daiichi Sankyo","DS-8201a (DP1),DS-8201a (DP2),DS-8201a (DP)","United States,Japan",292,Advanced Solid Tumors,2015-09-01,1
122,NCT04714190,Phase 3,"RemeGen Co., Ltd.",,"Aitan,Apatinib Mesylate Tablets,Drug: RC48-ADC,RC48-ADC,Taxol,Drug: Irinotecan Hydrochloride Injection,Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection,Paclitaxel injection,Irinotecan Hydrochloride Injection,Drug: Paclitaxel injection,Drug: Apatinib Mesylate Tablets,CAMPTO",China,351,"Gastric Cancer,HER2 Overexpressing Gastric Carcinoma",2021-01-15,3
123,NCT04300556,"Phase 2,Phase 1",Eisai Inc.,Bristol-Myers Squibb,"Farletuzumab ecteribulin,Prednisolone,MORAb-202,Prednisone,Dexamethasone","France,United States,United Kingdom,Spain",142,Solid Tumor,2020-08-06,2
124,NCT01439152,Phase 1,Bayer,,"BAY94-9343 (Expansion),BAY94-9343 (2.2 mg/kg),BAY94-9343,BAY94-9343 (1.8 mg/kg)",United States,148,Oncology,2011-09-07,1
125,NCT05338957,"Phase 2,Phase 1",Shanghai Miracogen Inc.,,MRG002+HX008,China,30,Advanced Malignant Solid Tumors,2022-08-05,2
126,NCT05872295,Phase 1,Iksuda Therapeutics Ltd.,,IKS014,Australia,165,"Breast Cancer,Gastroesophageal-junction Cancer,Gastric Cancer",2023-09-14,1
127,NCT05754853,Phase 3,Shanghai Miracogen Inc.,,"MRG002,Docetaxel Injection,Pemetrexed Disodium Injection,Paclitaxel Injection,Gemcitabine Hydrochloride for Injection",China,290,Advanced or Metastatic Urothelium Cancer,2023-04-06,3
128,NCT04311034,"Phase 2,Phase 1","RemeGen Co., Ltd.",,RC48,China,37,Non Small Cell Lung Cancer,2018-09-26,2
129,NCT05865990,Phase 2,MedSIR,Daiichi Sankyo,"HER3-DXd,Patritumab deruxtecan","Austria,Spain",60,"Advanced Non-Small Cell Squamous Lung Cancer,Metastatic Breast Cancer,Solid Tumor, Adult",2023-11-24,2
130,NCT05950945,Phase 3,Daiichi Sankyo,AstraZeneca,"Enhertu®,T-DXd,DS-8201a (trastuzumab derextecan),Trastuzumab Deruxtecan","United States,Brazil",250,Breast Cancer,2023-12-30,3
131,NCT05280470,Phase 2,Daiichi Sankyo,Merck Sharp & Dohme LLC,"DS-7300a,Ifinatamab Deruxtecan (I-DXd)","Germany,China,Korea, Republic of,Spain,Taiwan,United States,Japan,France",187,Extensive-stage Small-cell Lung Cancer,2022-03-09,2
132,NCT05276609,Phase 1,"Shanghai Hansoh Biomedical Co., Ltd",,"HS-20093 (Phase Ia: Dose escalation),HS-20093 (Phase Ib: Dose expansion)",China,177,Advanced Solid Tumor,2021-11-28,1
133,NCT05800366,Phase 2,"Jennifer Crombie, MD","Genentech, Inc.","Hydroxydaunomycin,Cytophosphane, Cytoxan,Rituxan,Prednisolone, Methylprednisolone,Glofitamab,Polatuzumab,Doxorubicin Hydrochloride,Prednisone,RO7082859,Rituximab,Polatuzumab vedotin, DCDS4501S, RG7596,Cyclophosphamide",United States,40,"Lymphoma, Large B-Cell, Diffuse,Lymphoma",2023-04-06,2
134,NCT06465069,Phase 1,Eli Lilly and Company,"Loxo Oncology, Inc.",LY4052031,United States,220,"Advanced Solid Tumor,Ovarian Cancer,Prostate Cancer,Esophageal Cancer,Urinary Bladder Neoplasm,Bladder Cancer,Triple Negative Breast Cancer,Cervical Cancer,Head and Neck Squamous Cell Carcinoma,Pancreatic Cancer,Renal Pelvis Cancer,Metastatic Solid Tumor,Non-small Cell Lung Cancer,Recurrent Solid Tumor",2024-06-01,1
135,NCT04887870,"Phase 3,Phase 2",Mirati Therapeutics Inc.,,"OPDIVO,Ipilimumab,PADCEV,Pembrolizumab,YERVOY,KEYTRUDA,Nivolumab,Enfortumab Vedotin-Ejfv,Sitravatinib,MGCD516",United States,55,Advanced or Metastatic Solid Malignancies,2021-06-30,3
136,NCT03894150,Phase 1,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",,"Drug: F0002-ADC,F0002-ADC",China,45,Refractory or Recurrent CD30+ Hematologic Malignancies,2019-03-26,1
137,NCT05748171,Phase 2,Pfizer,,"Inotuzumab ozogamicin,R3,ALLR3,Besponsa","Switzerland,Germany,Austria,Belgium,Poland,Hungary,Israel,Italy,Spain,Netherlands,Norway,Greece,Czechia,Slovakia,Finland,Sweden,Denmark,France",100,ACUTE LYMPHOBLASTIC LEUKEMIA,2023-05-17,2
138,NCT04410224,Phase 1,Kirilys Therapeutics Inc.,,ASN004,United States,19,Solid Tumor,2022-04-08,1
139,NCT03383692,Phase 1,"Daiichi Sankyo Co., Ltd.",AstraZeneca,"Ritonavir,Itraconazole,Orungal,Norvir,Sporanox,DS-8201a","Korea, Republic of,Taiwan,Japan",40,Neoplasm Metastasis,2018-01-12,1
140,NCT06112704,Phase 2,Hansoh BioMedical R&D Company,,HS-20093,China,220,Advanced Solid Tumor,2024-02-06,2
141,NCT02565758,Phase 1,AbbVie,,ABBV-085,"France,United States,Spain",85,"Carcinoma of the Breast,Advanced Solid Tumors,Squamous Cell Carcinoma of the Head and Neck,Undifferentiated Pleomorphic Sarcoma",2015-09-18,1
142,NCT00052000,Phase 1,"Millennium Pharmaceuticals, Inc.",,MLN2704 (DM1 conjugated monoclonal antibody MLN591),United States,29,Prostate Cancer,2002-11-01,1
143,NCT00070837,"Phase 2,Phase 1","Millennium Pharmaceuticals, Inc.",,MLN2704 (DM1 conjugated monoclonal antibody MLN591),United States,46,Prostatic Neoplasms,2003-10-01,2
144,NCT04042701,Phase 1,Daiichi Sankyo,"Merck Sharp & Dohme LLC,AstraZeneca UK Limited","Pembrolizumab,Trastuzumab deruxtecan (DS-8201a)","France,United States,United Kingdom,Spain",115,"Breast Cancer,Non-small Cell Lung Carcinoma",2020-02-10,1
145,NCT05410418,Phase 2,Washington University School of Medicine,"Institute for Follicular Lymphoma,Genentech, Inc.","Mosunetuzumab,DCDS4501A,RO7030816,BTCT4465A,RO5541077,Polatuzumab vedotin",United States,34,"Follicular Lymphoma,Lymphoma, Follicular",2022-10-24,2
146,NCT00258856,Phase 2,"Sanofi Pasteur, a Sanofi Company",,"Polysaccharide Diphtheria Conjugate Vaccine,Menactra®",United States,234,"Meningitis,Meningococcal Infection",2006-01-01,2
147,NCT06203210,Phase 3,Daiichi Sankyo,Merck Sharp & Dohme LLC,"Amrubicin,Topotecan,Lurbinectedin,Ifinatamab deruxtecan,I-DXd","Poland,Brazil,Hungary,Belgium,Italy,Netherlands,Taiwan,United Kingdom,Romania,China,Australia,United States,Switzerland,Japan,Germany,Austria,Portugal,Korea, Republic of,Spain,Canada,Greece,Turkey,Czechia,France",468,Small Cell Lung Cancer,2024-05-21,3
148,NCT04142242,Phase 3,"Sanofi Pasteur, a Sanofi Company",,"Blood sample,MenQuadfi,Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine,MenACYW Conjugate vaccine","United States,Puerto Rico",471,Meningococcal Infection (Healthy Volunteers),2019-10-04,3
149,NCT01856933,Phase 2,"Heinrich Elinzano, MD","University of Texas,Rhode Island Hospital,Progenics Pharmaceuticals, Inc.","PSMA ADC,Drug: PSMA ADC",United States,6,"Gliosarcoma,GBM,Glioblastoma Multiforme",2013-05-01,2
150,NCT03953833,Phase 1,"Shanghai Pharmaceuticals Holding Co., Ltd",,Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.,China,30,HER2-positive Breast Cancer,2019-04-01,1
151,NCT05887609,Phase 2,"University of Colorado, Denver","ImmunoGen, Inc.","Olaparib,MIRV,IMGN853,Mirvetuximab Soravtansine",United States,53,"Fallopian Tube Cancer,Peritoneal Cancer,Ovary Cancer",2023-10-03,2
152,NCT06132958,Phase 3,Merck Sharp & Dohme LLC,"European Network for Gynaecological Oncological Trial groups(ENGOT),GOG Foundation","Doxorubicin,Sacituzumab tirumotecan,ADRIAMYCIN®,TAXOL®,Paclitaxel,SKB264 MK-2870","Poland,Brazil,Belgium,Israel,Italy,Netherlands,Denmark,United Kingdom,Argentina,Norway,Singapore,Australia,Ireland,Finland,Japan,Switzerland,Sweden,United States,Puerto Rico,Austria,Korea, Republic of,Spain,Canada,Chile,Greece,Malaysia,Czechia,France",710,Endometrial Cancer,2023-12-06,3
153,NCT05755048,Phase 3,Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,,"Control drug: Trastuzumab emtansine (Kadcyla, T-DM1),Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)",China,314,Breast Cancer,2023-03-28,3
154,NCT06244485,Phase 1,Daiichi Sankyo,,"Dato-DXd,T-DXd,ENHERTU,Valemetostat tosylate,DS-1062a,DS-3201b,DS-8201a","United States,Japan",210,Advanced Solid Tumor,2024-02-16,1
155,NCT04205630,Phase 2,Byondis B.V.,,"Trastuzumab vc-seco-DUBA,SYD985,(vic-)trastuzumab duocarmazine","Russian Federation,Serbia,Ukraine,Poland,Korea, Republic of,Singapore,United States",64,Endometrial Cancer,2020-05-28,2
156,NCT00071955,Phase 2,Genitope Corporation,,"sargramostim,autologous immunoglobulin idiotype-KLH conjugate vaccine","Canada,United States",,Lymphoma,2003-03-01,2
157,NCT01577758,Phase 1,"Millennium Pharmaceuticals, Inc.",,MLN0264,United States,41,Advanced Gastrointestinal Malignancies,2012-06-01,1
158,NCT03529110,Phase 3,Daiichi Sankyo,"AstraZeneca,Daiichi Sankyo Co., Ltd.","Drug: Ado-trastuzumab emtansine (T-DM1),Drug: Trastuzumab deruxtecan (T-DXd),Ado-trastuzumab emtansine (T-DM1),Trastuzumab deruxtecan (T-DXd),T-DM1,DS-8201a","Germany,Belgium,China,Italy,Korea, Republic of,Brazil,Spain,Canada,Hong Kong,United Kingdom,Taiwan,Australia,United States,Japan,France",524,Breast Cancer,2018-04-13,3
159,NCT04175847,"Phase 2,Phase 1","RemeGen Co., Ltd.",,"RC88,RC88 for Injection",China,200,Solid Tumor,2020-04-14,2
160,NCT00856297,Phase 3,Novartis Vaccines,GlaxoSmithKline,"Licensed comparator,Quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier,MenACWY-CRM conjugate vaccine",United States,389,Meningococcal Meningitis,2009-02-01,3
161,NCT01396070,Phase 2,Youn Kim,Seagen Inc.,"SGN-35,Adcetris,Brentuximab vedotin",United States,36,"Sezary Syndrome,Non-Hodgkin Lymphoma (NHL),Cutaneous T-cell Lymphoma (CTCL),Mycosis Fungoides,Cutaneous Lymphoma",2011-05-01,2
162,NCT04878029,Phase 1,Emory University,"Exelixis,National Cancer Institute (NCI)","Cabozantinib S-malate,Cabometyx,XL-184,Enfortumab Vedotin,BMS-907351,Cometriq,XL184,Questionnaire Administration,AGS 22ME,AGS-22M6E,Anti-Nectin 4 ADC ASG-22CE,Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E,ASG-22CE,Quality-of-Life Assessment,Quality of Life Assessment,Enfortumab Vedotin-ejfv,Padcev",United States,32,"Locally Advanced Urothelial Carcinoma,Metastatic Urothelial Carcinoma,Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation,Unresectable Urothelial Carcinoma",2021-07-23,1
163,NCT01631552,"Phase 2,Phase 1",Gilead Sciences,,"hRS7-SN38,Sacituzumab Govitecan-hziy (SG),IMMU-132",United States,515,"Ovarian Epithelial Cancer,Esophageal Cancer,Gastric Adenocarcinoma,Hormone-refractory Prostate Cancer,Small Cell Lung Cancer,Endometrial Cancer,Hepatocellular Carcinoma,Carcinoma Breast Stage IV,Urinary Bladder Neoplasms,Glioblastoma Multiforme,Triple Negative Breast Cancer,Cervical Cancer,Head and Neck Cancers- Squamous Cell,Pancreatic Cancer,Renal Cell Cancer,Non-small Cell Lung Cancer",2012-12-17,2
164,NCT03424603,Phase 1,"Sutro Biopharma, Inc.",,STRO-001,United States,70,"Multiple Myeloma,B-cell Lymphoma,B Cells--Tumors,Diffuse Large B Cell Lymphoma,Follicular Lymphoma,Mantle Cell Lymphoma,Indolent Lymphoma,Non Hodgkin Lymphoma",2018-02-22,1
165,NCT06107686,Phase 2,"MediLink Therapeutics (Suzhou) Co., Ltd.",,YL202 should be intravenously infused,China,200,"Breast Cancer,HNSCC,NSCLC,Locally Advanced or Metastatic Solid Tumors",2023-12-15,2
166,NCT06057922,"Phase 2,Phase 1","MediLink Therapeutics (Suzhou) Co., Ltd.",,YL201 for Injection,China,640,Advanced Solid Tumor,2023-09-22,2
167,NCT05991388,"Phase 3,Phase 2",University of Birmingham,"Regeneron Pharmaceuticals,Cancer Research UK,Fight Kids Cancer,ADC Therapeutics SA","REGN-1979,Carboplatin,Etoposide Phosphate,CAR T-cells (TBC),Loncastuximab tesirine,Odronextamab,ADCT-402,Ifosfamide,Rituximab,Etoposide,Dexamethasone",,210,B-cell Non Hodgkin Lymphoma,2024-05-01,3
168,NCT05434234,Phase 1,"MediLink Therapeutics (Suzhou) Co., Ltd.",,YL201,"China,United States",196,Advanced Solid Tumor,2022-05-25,1
169,NCT00148824,Phase 2,French National Agency for Research on AIDS and Viral Hepatitis,Wyeth is now a wholly owned subsidiary of Pfizer,"23-valent pneumococcal conjugate vaccine (vaccine),7-valent pneumococcal conjugate vaccine (vaccine)",,212,HIV Infections,2003-02-01,2
170,NCT04494425,Phase 3,AstraZeneca,"Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo","Nab-Paclitaxel,DS-8201a; T-DXd,Capecitabine,Trastuzumab deruxtecan,Paclitaxel","Poland,Brazil,Hungary,Belgium,India,Saudi Arabia,Israel,Italy,Netherlands,Taiwan,Denmark,United Kingdom,Mexico,China,Argentina,Singapore,Australia,United States,Sweden,Japan,Russian Federation,Germany,Austria,Portugal,Korea, Republic of,Spain,Canada,France",866,Advanced or Metastatic Breast Cancer,2020-07-24,3
171,NCT04622774,"Phase 2,Phase 1","ImmunoGen, Inc.",MacroGenics,IMGC936,"United States,Italy,Spain",56,Advanced Solid Tumor,2020-10-26,2
172,NCT02952729,Phase 1,Mersana Therapeutics,,XMT-1522,United States,120,"Advanced Nonsmall Cell Lung Cancer,Advanced Breast Cancer,Advanced Gastric Cancer",2016-11-21,1
173,NCT03386513,"Phase 2,Phase 1","ImmunoGen, Inc.",,IMGN632,"Germany,Italy,Spain,United States,United Kingdom,France",179,"Myeloproliferative Neoplasm,Blastic Plasmacytoid Dendritic Cell Neoplasm",2018-01-02,2
174,NCT02567851,Phase 2,University of Birmingham,"Millennium Pharmaceuticals, Inc.,Leukaemia Lymphoma Research","Brentuximab Vedotin,Adcetris",United Kingdom,38,Hodgkin Disease,2014-02-01,2
175,NCT05143229,Phase 1,University of Kansas Medical Center,"Novartis Pharmaceuticals,Gilead Sciences","Piqray,Alpelisib,Sacituzumab govitecan,Trodelvy",United States,18,Breast Cancer,2022-03-28,1
176,NCT01026038,Phase 3,Pfizer,,13-valent pneumococcal conjugate vaccine,France,263,"13-valent Pneumococcal Vaccine,Immunization,Antibody Response,Safety",2010-04-01,3
177,NCT00743652,Phase 3,Pfizer,,13-valent Pneumococcal Conjugate Vaccine,United States,373,"13-valent Pneumococcal Vaccine,Pneumococcal Disease",2009-01-01,3
178,NCT04587687,Phase 2,Joseph Tuscano,"Seagen Inc.,National Cancer Institute (NCI)","Anti-CD30 Monoclonal Antibody-MMAE SGN-35,Treanda,Adcetris,Ribomustin,Anti-CD30 Antibody-Drug Conjugate SGN-35,Bendamustine Hydrochloride,cAC10-vcMMAE,Bendamustin Hydrochloride,Levact,SGN-35,Cytostasan Hydrochloride,Brentuximab Vedotin,ADC SGN-35,SyB L-0501,Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35,Bendeka",United States,23,"Recurrent Follicular Lymphoma,Refractory Follicular Lymphoma",2020-12-04,2
179,NCT05200364,Phase 1,"Sutro Biopharma, Inc.",,"STRO-002,Avastin,Bevacizumab",United States,58,"Ovarian Cancer,Ovarian Carcinoma,Ovary Cancer,Fallopian Tube Cancer,Primary Peritoneal Carcinoma",2022-03-22,1
180,NCT03316638,"Phase 2,Phase 1",Pierre Fabre Medicament,,"W0101 - Cohort A2,W0101 - Cohort A1,Dose escalation Phase,W0101 - Expansion Phase,Expansion Phase","France,Spain",316,Advanced or Metastatic Solid Tumors,2017-11-24,2
181,NCT06235216,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,"Gilead Sciences,MFAR","Sacituzumab govitecan,Trodelvy",Spain,42,"Anaplastic Thyroid Cancer,Differentiated Thyroid Cancer",2024-02-01,2
182,NCT05613088,Phase 2,Bristol-Myers Squibb,Eisai Inc.,"Caelyx,BMS-986445,Bendalis,Hycamtin,Farletuzumab Ecteribulin,Topotecan,Paclitaxel,Pegylated Liposomal Doxorubicin (PLD),MORAb-202","Belgium,Israel,Italy,Korea, Republic of,Spain,Chile,Australia,United States,Japan",90,"Neoplasms, Ovarian",2023-02-01,2
183,NCT04036461,Phase 1,Celgene,,"CC-99712,BMS-986405,GSI (Gamma secretase inhibitor)","Italy,Spain,Canada,United States,France",160,Multiple Myeloma,2019-08-26,1
184,NCT01847781,Phase 2,Karolinska University Hospital,Pfizer,Prevenar13,Sweden,20,IgG Deficiency,2013-05-01,2
185,NCT05405621,Phase 1,Bio-Thera Solutions,,"Recombinant Humanized Anti-B7H3 Monoclonal Antibody-Exatecan Conjugate,BAT8009 for Injection",China,48,Locally Advanced/Metastatic Solid Tumours,2022-08-02,1
186,NCT06188559,Phase 2,Eisai Inc.,"Bliss Biopharmaceutical (Hangzhou) Co., Ltd",BB-1701,"United States,Japan",135,Breast Cancer,2024-04-10,2
187,NCT05629585,Phase 3,AstraZeneca,"SWOG Clinical Trials Partnerships,Daiichi Sankyo","MEDI4736,KEYTRUDA®,Pembrolizumab,Dato-DXd,Capecitabine,Durvalumab,Datopotamab deruxtecan (Dato-DXd, DS-1062a),XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord","Germany,Puerto Rico,Belgium,China,Japan,Italy,Korea, Republic of,Brazil,Spain,Canada,Greece,Taiwan,United Kingdom,United States,Sweden,Denmark,France",1075,Breast Cancer,2022-11-28,3
188,NCT03281824,Phase 1,"Alteogen, Inc.",,ALT-P7 (HM2-MMAE),"Korea, Republic of",27,HER2-positive Breast Cancer,2018-01-11,1
189,NCT01475006,Phase 1,Amgen,,AMG 595,"Australia,United States",32,"Anaplastic Astrocytomas,Glioblastoma Multiforme,Advanced Malignant Glioma",2012-02-01,1
190,NCT05838521,Phase 2,Yale University,Gilead Sciences,"Sacituzumab govitecan,Trodelvy",United States,20,Cervical Cancer,2023-06-02,2
191,NCT04647916,Phase 2,SWOG Cancer Research Network,"Gilead Sciences,National Cancer Institute (NCI)","Trodelvy,RS7-SN38,hRS7-SN38 Antibody Drug Conjugate,IMMU-132,Sacituzumab Govitecan,Sacituzumab Govitecan-hziy",United States,44,"Anatomic Stage IV Breast Cancer AJCC v8,Prognostic Stage IV Breast Cancer AJCC v8,Metastatic Malignant Neoplasm in the Brain,Metastatic HER2 Negative Breast Carcinoma,Invasive Breast Carcinoma",2021-06-08,2
192,NCT05980416,Phase 1,Elevation Oncology,,EO-3021,"United States,Japan",120,"Neoplasms,Pancreas Neoplasm,Stomach Neoplasm,Digestive System Neoplasm,Neoplasms by Site,Gastrointestinal Neoplasms",2023-08-10,1
193,NCT04982224,"Phase 2,Phase 1",Regeneron Pharmaceuticals,,"REGN5093-M114,Cemiplimab",United States,237,Advanced NSCLC,2021-11-09,2
194,NCT04644068,"Phase 2,Phase 1",AstraZeneca,,"Carboplatin,Dato-DXd,T- Dxd,Paclitaxel,AZD5305,Camizestrant","Russian Federation,Hungary,Poland,China,Japan,Italy,Korea, Republic of,Spain,Canada,Czechia,Australia,United States,United Kingdom",804,"Breast Cancer,Ovarian Cancer,Prostate Cancer,Gastric Cancer,Bladder Cancer,Endometrial Cancer,Small Cell Lung Cancer Only in Module 5,Additional Indications Below for Module 4 and 5,Colorectal Cancer,Cervical Cancer,Pancreatic Cancer,Biliary Cancer,Non-small Cell Lung Cancer",2020-11-12,2
195,NCT05940896,Phase 1,"RemeGen Co., Ltd.",,"Disitamab vedotin,RC48-ADC",China,24,Solid Tumor,2023-06-29,1
196,NCT04251416,Phase 2,Yale University,Gilead Sciences,"Sacituzumab Govitecan,IMMU-132",United States,50,Endometrial Carcinoma,2020-03-17,2
197,NCT04039230,"Phase 2,Phase 1",Massachusetts General Hospital,Pfizer,"Talazoparib,Sacituzumab Govitecan",United States,75,Breast Cancer,2019-10-09,2
198,NCT04450732,Phase 1,"GeneQuantum Healthcare (Suzhou) Co., Ltd.",,GQ1001,"China,Australia,United States",96,"HER2-positive Breast Cancer,HER2-positive Biliary Tract Cancer,HER2-Positive Salivary Gland Carcinomas,HER2-Positive Advanced Solid Tumor",2020-07-07,1
199,NCT05948826,Phase 1,"TORL Biotherapeutics, LLC",Translational Research in Oncology,TORL-3-600,"Canada,United States",70,"Advanced Solid Tumor,Colorectal Cancer",2023-09-29,1
200,NCT01270698,Phase 1,Gilead Sciences,,"IMMU-130,hMN14-SN38",United States,26,Metastatic Colorectal Cancer,2011-05-01,1
201,NCT02529553,Phase 1,Eli Lilly and Company,,LY3076226,"Canada,United States",25,"Metastatic Cancer,Advanced Cancer",2015-09-01,1
202,NCT04278144,"Phase 2,Phase 1","Bolt Biotherapeutics, Inc.",Bristol-Myers Squibb,"Opdivo,Nivolumab,BDC-1001","Korea, Republic of,Italy,Spain,United States,France",390,"HER2-positive Gastroesophageal Cancer,HER2-positive Breast Cancer,HER2-positive Colorectal Cancer,HER2-positive Solid Tumors,HER2-positive Endometrial Cancer",2020-02-24,2
203,NCT05399654,"Phase 2,Phase 1",Tallac Therapeutics,,TAC-001,"Australia,United States",200,Advanced or Metastatic Solid Tumors,2022-06-28,2
204,NCT06154343,Phase 1,"GeneQuantum Healthcare (Suzhou) Co., Ltd.",,GQ1005,China,150,HER2 Expressing or Mutated Advanced Malignant Solid Tumors,2022-11-23,1
205,NCT05489211,Phase 2,AstraZeneca,Daiichi Sankyo,"Carboplatin,Prednisolone,DS-1062a,MEDI5752,MEDI4736,Rilvegostomig,Xeloda,Capecitabine,AZD5305,Bevacizumab,Paraplatin,Prednisone/ prednisolone,Folinic acid,AZD2936,Datopotamab deruxtecan (Dato-DXd),Volrustomig,Durvalumab,IMFINZI,Leucovorin LV,5-Fluorouracil,Saruparib,Adrucil,Avastin","Germany,Poland,China,Japan,Italy,Korea, Republic of,Spain,Canada,Taiwan,Turkey,United States,Switzerland,United Kingdom,France",531,"Ovarian Cancer,Gastric Cancer,Urothelial Cancer,Metastatic Castration-resistant Prostate Cancer,Colorectal Cancer,Endometrial Cancer,Biliary Tract Cancer",2022-09-06,2
206,NCT06238687,"Phase 2,Phase 1","Tasly Pharmaceutical Group Co., Ltd","Sutro Biopharma, Inc.",STRO-002,China,132,Neoplasm Malignant,2023-11-08,2
207,NCT06373406,"Phase 2,Phase 1",Minghui Pharmaceutical (Hangzhou) Ltd,,MHB036C,China,200,Advanced Solid Tumor,2023-05-18,2
208,NCT06036121,Phase 1,Adcentrx Therapeutics,,ADRX-0706,United States,114,Solid Tumors,2023-09-26,1
209,NCT03159117,Phase 1,Memorial Sloan Kettering Cancer Center,Pfizer,"PF-06688992,GD3 ADC",United States,7,Melanoma,2017-05-16,1
210,NCT04538742,"Phase 2,Phase 1",AstraZeneca,"Daiichi Sankyo Company, Limited","MEDI4736,Pertuzumab,DS-8201a, T-DXd,Tucatinib,Durvalumab,Trastuzumab deruxtecan,Paclitaxel,ONT-380","Russian Federation,Germany,Poland,India,Italy,Korea, Republic of,Brazil,Spain,Canada,Taiwan,Turkey,Australia,United States,United Kingdom,France",245,Metastatic Breast Cancer,2020-12-28,2
211,NCT06106152,Phase 1,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Westlake Therapeutics,"PD -1/PD-L1 monoclonal antibody,WTX212A injection,autologous red blood cell PD-1 inhibitor conjugate,PD -1/PD-L1antibody",China,20,Advanced Lung Cancer,2023-12-05,1
212,NCT03260491,Phase 1,Daiichi Sankyo,,"HER3-DXd (FL-DP),HER3-DXd (CTM-3 Lyo-DP),HER3-DXd (CTM-1 Lyo-DP)","Korea, Republic of,Spain,Netherlands,Taiwan,United States,Japan",309,Non-Small Cell Lung Cancer (NSCLC),2017-10-30,1
213,NCT06480240,"Phase 2,Phase 1","OBI Pharma, Inc",,OBI-992,United States,117,Advanced Solid Tumor,2024-06-12,2
214,NCT06413615,Phase 2,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",,FDA022-BB05,China,150,Advanced Solid Tumor,2024-05-13,2
215,NCT02606305,"Phase 2,Phase 1","ImmunoGen, Inc.",,"Carboplatin,Pegylated Liposomal Doxorubicin,Pembrolizumab,Mirvetuximab soravtansine,Bevacizumab,IMGN853","Canada,United States,Spain,Belgium",264,"Epithelial Ovarian Cancer,Fallopian Tube Cancer,Primary Peritoneal Cancer",2016-03-02,2
216,NCT06362252,"Phase 2,Phase 1",Daiichi Sankyo,Merck Sharp & Dohme LLC,"Ifinatamab deruxtecan,Carboplatin,Atezolizumab,Etoposide,I-DXd",,149,Extensive Stage-small Cell Lung Cancer,2024-06-17,2
217,NCT04434040,Phase 2,Dana-Farber Cancer Institute,"Stand Up To Cancer,Genentech, Inc.","Tecentriq,Sacituzumab govitecan,Atezolizumab,Trodelvy, IMMU-132",United States,40,"Breast Cancer,Residual Cancer,Triple Negative Breast Cancer,Circulating Tumor DNA",2020-07-02,2
218,NCT06074588,Phase 3,Merck Sharp & Dohme LLC,,"SKB264, MK-2870,Sacituzumab tirumotecan,Pemetrexed,Docetaxel,ALIMTA®,TAXOTERE®","China,Israel,Korea, Republic of,Thailand,Brazil,Canada,Hong Kong,Chile,Taiwan,Malaysia,Australia,United States",556,Non-small Cell Lung Cancer (NSCLC),2023-11-12,3
219,NCT04189614,Phase 1,AbbVie,Pfizer,"ABBV-647,Cofetuzumab Pelidotin","Israel,Korea, Republic of,Spain,Taiwan,United States,Japan",65,"Cancer,Non-small Cell Lung Cancer (NSCLC)",2020-02-13,1
220,NCT04724018,Phase 1,Dana-Farber Cancer Institute,Gilead Sciences,"Sacituzumab Govitecan (SG),Enfortumab vedotin-ejfv (EV),Trodelvy,Padcev",United States,24,"Metastatic Urothelial Carcinoma,Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter,Bladder Cancer,Urothelial Cancer",2021-05-20,1
221,NCT02822586,Phase 1,Virginia Commonwealth University,Seagen Inc.,"Adcetris,Brentuximab vedotin,TSEB,TSEB Therapy,total skin electron beam",United States,5,"Mycosis Fungoides,Sézary Syndrome",2016-12-19,1
222,NCT02631876,Phase 3,"ImmunoGen, Inc.",Gynecologic Oncology Group,"Paclitaxel,Topotecan,Pegylated liposomal doxorubicin,Mirvetuximab soravtansine","Russian Federation,Serbia,Belgium,United States,Italy,Spain,Canada,Bosnia and Herzegovina,Czechia,Ireland,Switzerland,United Kingdom,France",366,"Epithelial Ovarian Cancer,Ovarian Cancer,Primary Peritoneal Carcinoma,Fallopian Tube Cancer",2016-03-02,3
223,NCT05498597,Phase 1,Multitude Therapeutics Inc.,"Tigermed Consulting Co., Ltd",AMT-151,"China,Australia",30,"Endometrial Clear Cell Adenocarcinoma,Advanced Cancer,Advanced Carcinoma,Pancreatic Ductal Adenocarcinoma,Endometrial Cancer,Ovarian Cancer,Ovarian Clear Cell Carcinoma,Endometrial Adenocarcinoma,Endometrial Endometrioid Adenocarcinoma,Triple Negative Breast Cancer,Ovarian Mucinous Adenocarcinoma,Ovarian Clear Cell Adenocarcinoma,Ovarian Epithelial Cancer,Malignant Pleural Mesothelioma,Ovarian Carcinoma,Advanced Solid Tumor,Endometrial Serous Adenocarcinoma,Lung Adenocarcinoma,Ovarian Endometrioid Adenocarcinoma",2023-01-25,1
224,NCT05374512,Phase 3,AstraZeneca,Daiichi Sankyo,"Carboplatin,Eribulin mesylate,Datopotamab deruxtecan (Dato-DXd, DS-1062a),Dato-DXd,Capecitabine,Paclitaxel,Nab-paclitaxel","Poland,Brazil,Hungary,Belgium,India,Italy,Taiwan,United Kingdom,Mexico,China,Argentina,Singapore,United States,Japan,Germany,Korea, Republic of,Thailand,Spain,Canada,Philippines,Turkey,South Africa,France",600,Breast Cancer,2022-05-16,3
225,NCT05775471,Phase 2,Jonsson Comprehensive Cancer Center,"Merck Sharp & Dohme LLC,Seagen Inc.","BIOPSY_TYPE,Enfortumab Vedotin,MK-3475,Pembrolizumab,AGS 22ME,Biospecimen Collection,Anti-Nectin 4 ADC ASG-22CE,Lambrolizumab,Bx,Biopsy,Biospecimen Collected,Ureteronephrectomy,Magnetic Resonance Urography,Biological Sample Collection,AGS-22M6E,Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E,ASG-22CE,MR Urography,SCH 900475,Enfortumab Vedotin-ejfv,Padcev,Nephroureterectomy,Specimen Collection,Keytruda",United States,21,Renal Pelvis and Ureter Urothelial Carcinoma,2024-12-01,2
226,NCT05701527,Phase 1,"EDDC (Experimental Drug Development Centre), A*STAR Research Entities",Parexel,"EBC-129,Pembrolizumab","Singapore,United States",84,Advanced Solid Tumours,2023-04-28,1
227,NCT03696771,Phase 1,Novartis Pharmaceuticals,,NJH395,"Korea, Republic of,United States,Italy,Japan",18,NON-breast HER2+ Malignancies,2018-12-27,1
228,NCT06028932,Phase 2,Yale University,Gilead Sciences,"Sacituzumab govitecan,IMMU-132",United States,20,Ovarian Carcinoma,2024-01-08,2
229,NCT03023722,Phase 2,Yale University,Bayer,anetumab ravtansine,United States,18,Pancreatic Cancer,2017-05-11,2
230,NCT04595565,Phase 3,German Breast Group,"Gilead Sciences,Cancer Trials Ireland,ETOP IBCSG Partners Foundation,Spanish Breast Cancer Research Group (GEICAM),Austrian Breast & Colorectal Cancer Study Group,UNICANCER","Carboplatin,Platinol,Xeloda,Trodelvy,Cisplatin,Capecitabine,Paraplatin,Sacituzumab govitecan","Germany,Austria,Belgium,Spain,Ireland,Switzerland,France",1332,"HER2-negative Breast Cancer,Triple Negative Breast Cancer",2020-10-28,3
231,NCT05445778,Phase 3,"ImmunoGen, Inc.",GOG Foundation,"MIRV,Mirvetuximab soravtansine plus Bevacizumab,Bevacizumab","Belgium,Israel,Italy,Korea, Republic of,Spain,Canada,Philippines,Czechia,Australia,United States,United Kingdom",418,"Fallopian Tube Cancer,Peritoneal Cancer,Ovarian Cancer",2022-12-27,3
232,NCT05271604,Phase 2,"BioAtla, Inc.",,"PD-1 inhibitor,Ozuriftamab Vedotin",United States,80,"Recurrent Squamous Cell Carcinoma of the Head and Neck,Metastatic Squamous Cell Carcinoma of the Head and Neck,Head and Neck Cancer,Squamous Cell Carcinoma of Head and Neck,Metastatic Cancer",2022-12-13,2
233,NCT03543813,"Phase 2,Phase 1",CytomX Therapeutics,,CX-2029,"United States,Korea, Republic of,United Kingdom,Spain",133,"Esophageal Cancer,Solid Tumor, Adult,Diffuse Large B Cell Lymphoma,Non Small Cell Lung Cancer,Head and Neck Cancer",2018-06-15,2
234,NCT06298058,Phase 1,Shanghai Institute Of Biological Products,"Shanghai Pulmonary Hospital, Shanghai, China","Her3-ADC,SIBP-A13 formulation for injection",,144,Advanced Solid Tumor,2024-03-12,1
235,NCT05867563,Phase 1,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",,TQB2103 for injection,China,71,Advanced Malignant Neoplasm,2023-07-04,1
236,NCT03245736,Phase 2,Seagen Inc.,Genmab,"TIVDAK,Tisotumab Vedotin","United States,United Kingdom",5,"Endometrium Cancer,Prostate Cancer,Squamous Cell Carcinoma of the Head and Neck,Bladder Cancer,Cervix Cancer,Ovary Cancer,Esophagus Cancer,Lung Cancer, Nonsmall Cell",2017-08-23,2
237,NCT05798156,Phase 2,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"Roche Pharma AG,Charite University, Berlin, Germany,Arbeitsgemeinschaft medikamentoese Tumortherapie,University of Salzburg,Zentrum für Klinische Studien Leipzig,Hoffmann-La Roche","Glofitamab,Polatuzumab vedotin,Obinutuzumab,Rituximab","Germany,Austria",80,"Lymphoma, Large B-Cell, Diffuse",2023-03-20,2
238,NCT05653271,Phase 1,"Acepodia Biotech, Inc.",,"Fludarabine,Cyclophosphamide,Obinutuzumab,ACE1831","United States,Taiwan",42,"DLBCL,B-cell Lymphoma,Primary Mediastinal Large B Cell Lymphoma,Marginal Zone Lymphoma,Follicular Lymphoma,Non Hodgkin Lymphoma",2023-01-21,1
239,NCT02099058,Phase 1,AbbVie,,"Telisotuzumab vedotin,Erlotinib,Osimertinib,Nivolumab,ABBV-399","Belgium,United States,Italy,Korea, Republic of,Netherlands,Taiwan,Finland,Japan,France",237,Advanced Solid Tumors Cancer,2014-01-15,1
240,NCT00674947,Phase 1,Biogen,,BIIB015,United States,55,Solid Tumors,2008-06-01,1
241,NCT05965479,Phase 2,University of Southampton,"AstraZeneca,Natera, Inc.","Enhertu,Trastuzumab deruxtecan",United Kingdom,25,Gastrooesophageal Cancer,2024-04-10,2
242,NCT00624819,Phase 3,GlaxoSmithKline,,"Synflorix,Prevenar,Havrix,Varilrix,Infanrix hexa,GSK1024805A",Poland,524,"Streptococcus Pneumoniae Vaccines,Infections, Streptococcal",2008-03-03,3
243,NCT06100874,Phase 2,Adrienne G. Waks,Gilead Sciences,"Trastuzumab,Trodelvy,Herceptin Hylecta,Sacituzumab Govitecan,Herceptin,Trastuzumab and Hyaluronidase-oysk",United States,40,"Breast Cancer Female,Her 2 Positive Breast Cancer,Breast Cancer Metastatic",2023-11-20,2
244,NCT02073487,Phase 2,The Methodist Hospital Research Institute,"Celgene Corporation,Novartis","Trastuzumab,Pertuzumab,tykerb,Perjeta,Kadcyla,trastuzumab emtansine,Paclitaxel,Abraxane,nab-paclitaxel,Lapatinib,T-DM1,Taxol,Herceptin",United States,32,Breast Cancer,2014-02-01,2
245,NCT03737955,Phase 2,University of Washington,Pfizer,"Gemtuzumab Ozogamicin,Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody,Quality-of-Life Assessment,Mylotarg,CDP-771",United States,36,Acute Myeloid Leukemia,2018-11-30,2
246,NCT05622890,Phase 3,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",,"MIRV,IMGN853,Mirvetuximab Soravtansine",China,35,"Epithelial Ovarian Cancer,Peritoneal Cancer,Fallopian Tube Cancer",2022-08-18,3
247,NCT04143711,"Phase 2,Phase 1",Dragonfly Therapeutics,,"DF1001,Sacituzumab Govitecan-hziy,Nab paclitaxel,Nivolumab","Belgium,Netherlands,United States,Denmark,France",378,"Solid Tumor, Adult",2019-11-11,2
248,NCT06176261,Phase 2,"Sarah Sammons, MD",Daiichi Sankyo,"Datopotamab Deruxtecan,DS-1062; DS-1062a, Dato-DXd",United States,58,"Breast Cancer,Metastatic Triple-Negative Breast Carcinoma,Breast Cancer Female,ER Positive Breast Cancer,HER2 Negative Breast Carcinoma,ER-negative Breast Cancer,HER2-negative Breast Cancer",2023-12-26,2
249,NCT01125527,Phase 3,Novartis Vaccines,,"Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib),Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)",China,700,Haemophilus Influenzae Type b (Hib) Infection,2009-08-01,3
250,NCT01060904,Phase 1,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","dacarbazine,brentuximab vedotin,SGN-35,vinblastine,doxorubicin,bleomycin","Canada,United States",51,"Disease, Hodgkin",2010-01-01,1
251,NCT02485119,Phase 1,Bayer,,BAY94-9343,Japan,12,Neoplasms,2015-08-14,1
252,NCT05123482,"Phase 2,Phase 1",AstraZeneca,,"Drug: AZD8205,Drug: AZD8205 and AZD2936 (Rilvegostomig),AZD8205 and AZD2936 (Rilvegostomig),AZD8205","Hungary,Belgium,China,Poland,Italy,Thailand,Korea, Republic of,Spain,Canada,Netherlands,United Kingdom,Taiwan,Australia,United States,Japan",340,"Breast Cancer,Ovarian Cancer,Endometrial Cancer,Biliary Tract Carcinoma",2021-10-13,2
253,NCT04296890,Phase 3,"ImmunoGen, Inc.",,"MIRV,IMGN853,Mirvetuximab Soravtansine","Germany,Belgium,Poland,Israel,Italy,United States,Spain,Czechia,Australia,Ireland,Bulgaria",106,"Epithelial Ovarian Cancer,Peritoneal Cancer,Fallopian Tube Cancer",2020-07-23,3
254,NCT04014075,Phase 2,Daiichi Sankyo,AstraZeneca,"Drug: Trastuzumab deruxtecan,DS-8201a,Trastuzumab deruxtecan","Belgium,Italy,Spain,United States,United Kingdom",79,"Adenocarcinoma - GEJ,Adenocarcinoma Gastric Stage IV With Metastases",2019-08-07,2
255,NCT06415487,Phase 1,"Acepodia Biotech, Inc.",,"Fludarabine,Cyclophosphamide,ACE2016,Pembrolizumab",United States,30,"Locally Advanced Solid Tumor,Metastatic Solid Tumor",2024-05-31,1
256,NCT03835819,Phase 2,Dana-Farber Cancer Institute,"ImmunoGen, Inc.,Merck Sharp & Dohme LLC","Elahere,Pembrolizumab,Mirvetuximab soravtansine,IMGN853,Keytruda",United States,18,Endometrial Cancer,2020-01-02,2
257,NCT05547321,Phase 1,Oncomatryx Biopharma S.L.,,"OMTX705,Pembrolizumab,Keytruda (trademark),NA at this moment","United States,Spain",120,Advanced Solid Tumor,2022-10-20,1
258,NCT04822337,"Phase 2,Phase 1",Wake Forest University Health Sciences,"Amgen,GlaxoSmithKline","Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin",United States,70,Multiple Myeloma,2021-05-19,2
259,NCT02980341,"Phase 2,Phase 1","Daiichi Sankyo Co., Ltd.",Daiichi Sankyo,"U3-1402,Patritumab Deruxtecan","United States,Japan",184,Metastatic Breast Cancer,2016-11-28,2
260,NCT06219941,Phase 2,AstraZeneca,,"Irinotecan,5-FU,l-leucovorin,Camptosar,CMG901,LV,Nanoliposomal Irinotecan,ONIVYDE,AZD0901,I-LV,Gemzar,5-Fluorouracil,Gemcitabine,Leucovorin","Poland,Japan,Georgia,Korea, Republic of,Spain,Canada,Singapore,Moldova, Republic of,Taiwan,Malaysia,Australia,United States,United Kingdom",123,"Gastric Cancer,Pancreatic Adenocarcinoma,Gastroesophageal Junction Cancer",2023-12-13,2
261,NCT05735496,Phase 1,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",,TQB2102 injection,China,71,Advanced Cancer,2023-02-01,1
262,NCT04556773,Phase 1,AstraZeneca,"Daiichi Sankyo Company, Limited,Daiichi Sankyo Co., Ltd.","Capivasertib,MEDI4736,AZD5363,DS-8201a, T-DXd,Capecitabine,Durvalumab,Taxol A,Trastuzumab deruxtecan,Paclitaxel,Fulvestrant,Anastrozol,Anastrozole","Russian Federation,Belgium,Mexico,Korea, Republic of,Brazil,Canada,Taiwan,Australia,United States,France",138,Metastatic Breast Cancer,2020-12-17,1
263,NCT06233942,Phase 1,BeiGene,,"Tislelizumab,BG-C9074",Australia,150,Advanced Solid Tumor,2024-04-12,1
264,NCT00947856,Phase 2,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","Adcetris,brentuximab vedotin","United States,France",110,"Lymphoma, Large-Cell, Anaplastic,Disease, Hodgkin,Lymphoma, Non-Hodgkin",2009-07-01,2
265,NCT06359002,Phase 1,Byondis B.V.,,BYON4413,"Netherlands,Spain,Belgium",100,"Relapsed / Refractory AML,Relapsed / Refractory MDS",2024-06-01,1
266,NCT06336707,Phase 1,Hansoh BioMedical R&D Company,,"HS-20089,Cisplatin / carboplatin,Adebrelimab,Bevacizumab",,1048,Advanced Solid Tumors,2024-04-08,1
267,NCT06003231,Phase 2,Seagen Inc.,,"RC48, RC48-ADC,disitamab vedotin","Canada,Australia,United States",160,"Carcinoma, Squamous Cell of Head and Neck,Carcinoma, Non-Small-Cell Lung,Endometrial Neoplasms,Ovarian Neoplasms",2023-11-14,2
268,NCT06422520,Phase 1,BeiGene,,"Tislelizumab,BGB-C354",,62,Advanced Solid Tumor,2024-06-24,1
269,NCT01472887,Phase 2,Sanofi,,SAR3419,"Belgium,Poland,Israel,Italy,Spain,Turkey,Czechia,United States,United Kingdom",61,Diffuse Large B-cell Lymphoma,2012-01-01,2
270,NCT06112379,Phase 3,AstraZeneca,Daiichi Sankyo,"MEDI4736,Doxorubicin,Epirubicin,Carboplatin,Olaparib,KEYTRUDA®,Pembrolizumab,Dato-DXd,Capecitabine,Durvalumab,Datopotamab deruxtecan (Dato-DXd, DS-1062a),Paclitaxel,LYNPARZA®,XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord,Cyclophosphamide","Poland,Turkey,Brazil,Vietnam,Hungary,Belgium,India,Italy,Taiwan,United Kingdom,China,Hong Kong,Singapore,Australia,Bulgaria,Switzerland,Japan,United States,Germany,Austria,Korea, Republic of,Thailand,Spain,Canada,Malaysia,France",1728,Breast Cancer,2023-11-14,3
271,NCT01470456,Phase 2,Sanofi,,"rituximab,SAR3419","Norway,Austria,France",50,Diffuse Large B-Cell Lymphoma,2011-11-01,2
272,NCT05804864,Phase 1,"Xuanzhu Biopharmaceutical Co., Ltd.",,KM501,China,96,Advanced Solid Tumors,2023-04-01,1
273,NCT06303505,"Phase 2,Phase 1",Tubulis GmbH,,TUB-040,United States,100,"Ovarian Cancer,Non-small Cell Lung Cancer",2024-05-01,2
274,NCT04246047,Phase 3,GlaxoSmithKline,,"Bortezomib,Drug: Dexamethasone,Belantamab mafodotin,Drug: Belantamab mafodotin,Drug: Bortezomib,Drug: Daratumumab,Dexamethasone,Daratumumab","Poland,Brazil,Belgium,Israel,Italy,Netherlands,Czechia,United Kingdom,China,Australia,United States,Japan,Russian Federation,Germany,Korea, Republic of,Spain,Canada,Greece,New Zealand,France",571,Multiple Myeloma,2020-01-27,3
275,NCT05535244,"Phase 2,Phase 1",Hoffmann-La Roche,,"Cevostamab,Tocilizumab","Germany,Belgium,Israel,Italy,Spain,Australia,United States,France",90,Multiple Myeloma,2022-10-18,2
276,NCT00891176,Phase 3,GlaxoSmithKline,,"MenitorixTM,InfanrixTM hexa,PrevenarTM,InfanrixTM penta,InfanrixTM IPV/Hib,Pneumococcal conjugate vaccine GSK1024850A,InfanrixTM IPV,MeningitecTM,NeisVac-CTM","Germany,Spain,Poland",582,"Haemophilus Influenzae Type b,Neisseria Meningitidis",2009-05-14,3
277,NCT06103864,Phase 3,AstraZeneca,Daiichi Sankyo,"MEDI4736,Carboplatin,Pembrolizumab,Dato-DXd,Datopotamab deruxtecan (Dato-DXd, DS-1062a),Durvalumab,Paclitaxel,Nab-paclitaxel,Gemcitabine","Poland,Brazil,Vietnam,India,Italy,Taiwan,United Kingdom,Mexico,China,Argentina,Singapore,Australia,United States,Japan,Germany,Korea, Republic of,Thailand,Spain,Canada,Philippines,Turkey,South Africa,France",625,Breast Cancer,2023-11-23,3
278,NCT06147037,Phase 1,Fusion Pharmaceuticals Inc.,AstraZeneca,"[111In]-FPI-2107,FPI-2053,[225Ac]-FPI-2068","Canada,United States",110,"Metastatic Colorectal Carcinoma,Advanced Solid Tumor,Head and Neck Squamous Cell Carcinoma,Pancreatic Ductal Adenocarcinoma,Non-small Cell Lung Cancer",2024-07-31,1
279,NCT06429761,Phase 4,AstraZeneca,,Trastuzumab deruxtecan,,100,BREAST CANCER,2024-09-30,4
280,NCT05104866,Phase 3,AstraZeneca,Daiichi Sankyo,"Vinorelbine,Eribulin,Eribulin Mesylate,Datopotamab deruxtecan (Dato-DXd, DS-1062a),Dato-DXd,Capecitabine,Gemcitabine","Poland,Brazil,Hungary,Belgium,India,Italy,Netherlands,Taiwan,United Kingdom,China,Argentina,United States,Japan,Russian Federation,Germany,Korea, Republic of,Spain,Canada,South Africa,France",732,Breast Cancer,2021-10-18,3
281,NCT05609968,Phase 3,Merck Sharp & Dohme LLC,Gilead Sciences,"MK-3475,Trodelvy®,Pembrolizumab,Keytruda®,Sacituzumab Govitecan","Poland,Estonia,Turkey,Brazil,Peru,Israel,Italy,Taiwan,United Kingdom,Romania,China,Australia,Lithuania,United States,Japan,Germany,Korea, Republic of,Thailand,Canada,Chile,Greece,Philippines,Latvia,Malaysia",614,"Carcinoma, Non-Small-Cell Lung",2023-02-06,3
282,NCT03724747,Phase 1,Bayer,,"BAY2315497 Injection,Darolutamide(BAY1841788)","United States,Finland,United Kingdom",63,Metastatic Castration Resistant Prostate Cancer (mCRPC),2018-12-18,1
283,NCT02884726,Phase 1,Bristol-Myers Squibb,,BMS-986148,Japan,8,Advanced Cancer,2016-10-14,1
284,NCT03856541,Phase 1,"Jiangsu HengRui Medicine Co., Ltd.",,"HTI-1066,SHR-A1403",China,9,Advanced Solid Tumor,2019-02-13,1
285,NCT05687266,Phase 3,AstraZeneca,,"Carboplatin,Pembrolizumab,Cisplatin,Pemetrexed,Durvalumab,Dato-DXd,Paclitaxel,MEDI4736, Imfinzi,Datopotamab deruxtecan","Poland,Brazil,Vietnam,Hungary,India,Peru,Italy,Taiwan,United Kingdom,Denmark,Mexico,China,Bulgaria,Sweden,Japan,United States,Germany,Austria,Korea, Republic of,Spain,Canada,Greece,Turkey,France",1280,NSCLC,2022-12-29,3
286,NCT01100502,Phase 3,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","SGN-35,Adcetris,placebo,brentuximab vedotin","Romania,Russian Federation,Serbia,Germany,Hungary,Poland,Italy,Spain,Czechia,Bulgaria,United States,United Kingdom,France",329,"Disease, Hodgkin",2010-04-30,3
287,NCT05456685,Phase 2,"ImmunoGen, Inc.",,"MIRV,Carboplatin,Mirvetuximab soravtansine,IMGN853","Belgium,Georgia,Spain,Canada,United States,United Kingdom",114,"Primary Peritoneal Cancer,High Grade Ovarian Cancer,Fallopian Tube Cancer",2022-09-28,2
288,NCT00848926,Phase 2,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","SGN-35,ADCETRIS,brentuximab vedotin","Belgium,Italy,Canada,United States,France",102,"Disease, Hodgkin",2009-02-01,2
289,NCT04879329,Phase 2,Seagen Inc.,Merck Sharp & Dohme LLC,"pembrolizumab,KEYTRUDA®,RC48-ADC,disitamab vedotin","Belgium,Japan,Israel,Argentina,Spain,Canada,Chile,Australia,United States,United Kingdom",332,Urothelial Carcinoma,2022-05-03,2
290,NCT03828292,Phase 1,GlaxoSmithKline,,"Bortezomib,Pomalidomide,Dexamethasone,Belantamab mafodotin",Japan,15,Multiple Myeloma,2019-03-14,1
291,NCT05922501,Phase 2,Massachusetts General Hospital,"Sanofi,GlaxoSmithKline","Isatuximab,Belantamab mafodotin,GSK2857916,SAR650984,Pomalidomide,Dexamethasone",United States,50,"Refractory Multiple Myeloma,Multiple Myeloma,Relapsed Cancer",2024-06-18,2
292,NCT04147819,Phase 1,Bayer,,BAY2701439,"United States,United Kingdom",14,Cancers With HER2 Expression,2020-07-02,1
293,NCT06014190,Phase 2,Hansoh BioMedical R&D Company,,HS-20089,China,460,"Fallopian Tube Cancer,Ovarian Cancer,Endometrial Cancer,Primary Peritoneal Cancer",2023-12-18,2
294,NCT06227117,Phase 2,"RemeGen Co., Ltd.",,"Disitamab Vedotin Injection （12 weeks）,Epirubicin,Carboplatin,Sequential Epirubicin,DV,RC48-ADC,JS001,Toripalimab （18weeks）,Disitamab Vedotin Injection （18 weeks）,CTX, cyclophosphamide,Sequential CTX,Toripalimab （12weeks）",China,120,Breast Cancer,2023-07-27,2
295,NCT05425550,,Palleos Healthcare GmbH,mobile Health AG,medidux™ app,Switzerland,585,Breast Cancer,2022-08-29,
296,NCT01874054,"Phase 2,Phase 1",Seagen Inc.,,"Adcetris; SGN-35,bendamustine,brentuximab vedotin",United States,55,Hodgkin Disease,2013-06-01,2
297,NCT06397768,Phase 3,"Sanofi Pasteur, a Sanofi Company",,"Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine,Placebo,RotaTeq®,VARIVAX®,RSVt vaccine,Pentacel®,Hepatitis B vaccine,Streptococcus pneumoniae vaccine,Vaxelis®,PREVNAR 20®,Varicella virus vaccine,M-M-R® II,Rotavirus vaccine,534,Measles, mumps, and rubella vaccine,Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine,RECOMBIVAX HB® or alternate monovalent hepatitis B vaccine","United States,Puerto Rico",2226,RSV Immunization,2024-05-13,3
298,NCT01026415,Phase 1,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","ketoconazole,ADCETRIS; SGN-35,rifampin,midazolam,brentuximab vedotin,SGN-35",United States,73,"Lymphoma, Large-Cell, Anaplastic,Carcinomas,Lymphoma, Non-Hodgkin,Disease, Hodgkin,Neoplasms",2009-12-01,1
299,NCT06161025,"Phase 3,Phase 2",Daiichi Sankyo,Merck Sharp & Dohme LLC,"Pegylated Liposomal Doxorubicin,R-DXd,Topotecan,DS-6000a,Paclitaxel,PLD,Gemcitabine","China,Korea, Republic of,Taiwan,Japan",650,Solid Cancer,2024-02-27,3
300,NCT01712490,Phase 3,Takeda,Seagen Inc.,"dacarbazine,Adriamycin,brentuximab vedotin,SGN-35,vinblastine,doxorubicin,ADCETRIS®,DTIC,bleomycin","Poland,Brazil,Hungary,Belgium,Italy,Taiwan,United Kingdom,Denmark,Norway,Hong Kong,Australia,United States,Japan,Russian Federation,Korea, Republic of,Spain,Canada,Turkey,Czechia,South Africa,France",1334,Hodgkin Lymphoma,2012-11-09,3
301,NCT06178159,Phase 2,"RemeGen Co., Ltd.",,"DV,RC48-ADC,JS001,Toripalimab,Disitamab Vedotin Injection,Pertuzumab Injection",China,80,Breast Cancer,2023-11-28,2
302,NCT01224821,Phase 2,GlaxoSmithKline,,Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab,,47,"Lymphoma, Non-Hodgkin",1995-12-01,2
303,NCT05169658,Phase 2,University of Washington,"Genentech, Inc.","ADC DCDS4501A,1905409-39-3,RO5072759,RG-7828,GA-101,RO 5072759,RG7828,Mosunetuzumab,CD20/CD3 BiMAb BTCT4465A,GA101,RO-5072759,RG 7828,DCDS4501A,RO7030816,Anti-CD20 Monoclonal Antibody R7159,FCU 2711,huMAB(CD20),Antibody-Drug Conjugate DCDS4501A,Mosunetuzumab-axgb,R7159,BTCT 4465A,Gazyva,Polivy,Lunsumio,Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A,Polatuzumab Vedotin,949142-50-1,polatuzumab vedotin-piiq,BTCT-4465A,BTCT4465A,1313206-42-6,RG7596,Ro 5541077-000,Obinutuzumab",United States,42,"Indolent B-Cell Non-Hodgkin Lymphoma,Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Marginal Zone Lymphoma,Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Grade 2 Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 3a Follicular Lymphoma,Non-Hodgkin Lymphoma",2022-03-23,2
304,NCT02572167,"Phase 2,Phase 1",Seagen Inc.,Bristol-Myers Squibb,"SGN-35, ADCETRIS,nivolumab,BMS-936558, OPDIVO,brentuximab vedotin",United States,93,Hodgkin Lymphoma,2015-10-31,2
305,NCT03657043,Phase 2,Seagen Inc.,Genmab,"TIVDAK,tisotumab vedotin","Belgium,United States,Italy,Spain,Ireland,Denmark",98,"Fallopian Tube Cancer,Peritoneal Cancer,Ovarian Cancer",2019-03-20,2
306,NCT03544281,"Phase 2,Phase 1",GlaxoSmithKline,Iqvia Pty Ltd,"Bortezomib,Lenalidomide,Dexamethasone,Belantamab mafodotin","Spain,Canada,Australia,United States,United Kingdom",153,Multiple Myeloma,2018-09-20,2
307,NCT02724163,Phase 3,University of Birmingham,"National Cancer Institute, France,Cancer Research UK,Assistance Publique - Hôpitaux de Paris,Pfizer","Cyclophosphamide,Busulfan,Fludarabine,Cytarabine,Mitoxantrone,Liposomal daunorubicin,Mylotarg,Gemtuzumab ozogamicin","New Zealand,Australia,Ireland,Switzerland,United Kingdom,France",700,Acute Myeloid Leukaemia,2016-04-01,3
308,NCT05948865,Phase 1,"Conjupro Biotherapeutics, Inc.",,"CPO301,SYS6010","Canada,United States",102,"Cancer,Cancer, Lung",2023-06-06,1
309,NCT03474107,Phase 3,"Astellas Pharma Global Development, Inc.",Seagen Inc.,"Enfortumab Vedotin,ASG-22CE,Vinflunine,Paclitaxel,Docetaxel,ASG-22ME","Belgium,Italy,Netherlands,Taiwan,Denmark,United Kingdom,Argentina,Australia,United States,Switzerland,Japan,Russian Federation,Germany,Austria,Portugal,Korea, Republic of,Spain,Canada,France",608,"Bladder Cancer,Ureteral Cancer,Urothelial Cancer",2018-06-27,3
310,NCT04484623,Phase 3,GlaxoSmithKline,,"Bortezomib,Pomalidomide,Dexamethasone,Belantamab mafodotin","Russian Federation,Germany,Poland,China,Japan,Israel,Italy,Korea, Republic of,Brazil,Spain,Greece,Czechia,Turkey,New Zealand,Australia,United States,United Kingdom,France",357,Multiple Myeloma,2020-10-01,3
311,NCT00322049,"Phase 2,Phase 1",U.S. Army Medical Research and Development Command,GlaxoSmithKline,"Tetravalent live attenuated dengue vaccine,Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine",Thailand,51,Dengue,2004-02-01,2
312,NCT03262935,Phase 3,Byondis B.V.,,"Vinorelbine (Vino),Capecitabine (Cap),SYD985,Trastuzumab vc-seco-DUBA,Trastuzumab (T),Physician's choice,Lapatinib (Lap),(vic-)trastuzumab duocarmazine,Eribulin (Eri)","Belgium,Italy,Spain,Canada,Netherlands,Singapore,United Kingdom,United States,Sweden,Denmark,France",437,Metastatic Breast Cancer,2017-12-15,3
313,NCT03523585,Phase 3,Daiichi Sankyo,"AstraZeneca,Daiichi Sankyo Co., Ltd.","Trastuzumab,Investigator's Choice Comparative Therapy,Capecitabine,Trastuzumab deruxtecan,T-DXd,Lapatinib,DS-8201a","Germany,Belgium,Japan,Israel,Italy,Korea, Republic of,Brazil,Spain,Greece,Turkey,Czechia,Australia,United States,United Kingdom,France",608,Breast Cancer,2018-08-01,3
314,NCT04639986,Phase 3,Gilead Sciences,,"Capecitabine Oral Product,Xeloda,Gemcitabine Injection,GS-0132,Navelbine,IMMU-132,Gemzar,Eribulin Mesylate Injection,Vinorelbine injection,Sacituzumab Govitecan-hziy,Trodelvy™,Halaven","China,Korea, Republic of,Taiwan",331,Metastatic Breast Cancer,2020-11-23,3
315,NCT04487756,"Phase 2,Phase 1","Instituto Oncologico Dr Rosell,Instituto Oncológico Dr Rosell","Fundacion Clinic per a la Recerca Biomédica,Roche Pharma AG","ADC Vaccine,Carboplatin,Biological: ADC Vaccine,Tecentriq,Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine,Drug: Carboplatin,Atezolizumab 1200 mg in 20 ML Injection,Carboplatino (Teva/Accord/Pharmacia),Drug: Atezolizumab 1200 mg in 20 ML Injection",Spain,20,Extensive-stage Small Cell Lung Cancer,2020-07-22,2
316,NCT02326584,Phase 1,Seagen Inc.,,"SGN-CD33A,High dose cytarabine for consolidation,Daunorubicin,vadastuximab talirine,Standard dose cytarabine for induction",United States,116,"Acute Myeloid Leukemia,Acute Myelogenous Leukemia",2014-12-01,1
317,NCT05647122,Phase 1,AstraZeneca,,"AZD9592,Osimertinib,5-Fluorouracil (5-FU),Bevacizumab,Leucovorin","China,Italy,Korea, Republic of,Spain,Canada,Taiwan,Malaysia,Australia,United States,Japan,France",162,"Carcinoma Non-small Cell Lung,Head and Neck Neoplasms,Advanced Solid Tumours,Colorectal Neoplasms",2022-12-22,1
318,NCT05279300,Phase 1,CStone Pharmaceuticals,,CS5001,"China,Australia,United States",156,"Advanced Solid Tumor,Advanced Lymphoma",2022-03-28,1
319,NCT06400472,Phase 1,Eli Lilly and Company,"Loxo Oncology, Inc.",LY4170156,United States,220,"Pancreatic Neoplasm,Uterine Cervical Neoplasms,Carcinoma, Non-Small-Cell Lung,Ovarian Neoplasms,Colorectal Neoplasms,Triple Negative Breast Neoplasms,Endometrial Neoplasms",2024-05-06,1
320,NCT04381832,"Phase 2,Phase 1","Arcus Biosciences, Inc.",Gilead Sciences,"AB928,Quemliclustat,Trodelvy,SG,Etrumadenant,Zimberelimab,AB680,Docetaxel,AB122,Xtandi,Taxotere,Enzalutamide","Canada,United States",173,"Androgen-Resistant Prostatic Neoplasms,Castration Resistant Prostatic Neoplasms,Prostatic Cancer, Castration-Resistant,Prostatic Neoplasms, Castration-Resistant",2020-07-07,2
321,NCT05954143,Phase 2,"Bolt Biotherapeutics, Inc.",Hoffmann-La Roche,"Perjeta®,Pertuzumab,BDC-1001","United States,Italy,Spain",66,"HER2-positive Breast Cancer,Metastatic Breast Cancer",2023-11-30,2
322,NCT04786847,Phase 1,Telix Pharmaceuticals (Innovations) Pty Limited,,177Lu-DOTA-TLX591,Australia,30,Metastatic Prostate Cancer,2022-01-30,1
323,NCT05327530,Phase 2,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics","NKTR-255,M6223,GS-0132,IMMU-132,Avelumab,Sacituzumab Govitecan,MSB0010718C,Trodelvy™","Germany,Belgium,Italy,Korea, Republic of,Spain,Canada,Greece,Taiwan,United Kingdom,Australia,United States,Denmark,France",252,Locally Advanced or Metastatic Urothelial Carcinoma,2022-08-17,2
324,NCT05149768,Phase 2,Lawson Health Research Institute,Seagen Inc.,"Brentuximab vedotin,ADCETRIS, SGN-35",Canada,11,Diffuse Cutaneous Systemic Sclerosis,2024-02-14,2
325,NCT01969643,Phase 1,Seagen Inc.,,"Trastuzumab,LV,ladiratuzumab vedotin,SGN-LIV1A,Herceptin",United States,290,"Triple Negative Breast Neoplasms,HER2 Positive Breast Neoplasms,HER2 Mutations Breast Neoplasms,Hormone Receptor Positive Breast Neoplasms",2013-10-22,1
326,NCT01826877,Phase 1,Jonsson Comprehensive Cancer Center,"Kite, A Gilead Company","DC-AdGMCAIX,ADC,dendritic cells transduced with AdGMCA9 expressing GM-CSF-carbonic anhydrase IX fusion protein,AdGMCAIX-transduced autologous dendritic cells,laboratory biomarker analysis,autologous dendritic cells,therapeutic autologous dendritic cells",United States,12,"Clear Cell Renal Cell Carcinoma,Stage IV Renal Cell Cancer,Recurrent Renal Cell Cancer",2013-01-14,1
327,NCT06043674,Phase 2,Christine Ryan,"Genentech, Inc.","Polatuzumab Vedotin,Atezolizumab,Glofitamab,Tecentriq,RO5072759, GA101, GAZYVA, GAZYVARO,RO7082859,Actemra,Obinutuzumab,Tocilizumab",United States,66,"Richter's Transformation,Chronic Lymphocytic Leukemia",2024-01-22,2
328,NCT05494918,Phase 1,Alphamab (Australia) Co Pty Ltd.,,"anti-Her2 ADC JSKN003,JSKN003",Australia,45,"Metastatic Solid Tumors,Advanced Solid Tumors",2022-09-02,1
329,NCT01026233,Phase 1,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","SGN-35,brentuximab vedotin","Germany,United States",52,"Lymphoma, Large-Cell, Anaplastic,Disease, Hodgkin,Lymphoma, Non-Hodgkin",2010-01-01,1
330,NCT05577715,Phase 2,Bristol-Myers Squibb,Eisai Inc.,"Farletuzumab Ecteribulin,BMS-986445,MORAb-202","Belgium,Spain,Chile,Australia,United States,France",50,"Carcinoma, Non-Small-Cell Lung",2022-11-14,2
331,NCT05870748,"Phase 3,Phase 2","Sutro Biopharma, Inc.","European Network of Gynaecological Oncological Trial Groups (ENGOT),Asia-Pacific Gynecologic Oncology Trials Group (APGOT),GOG Foundation","Pegylated liposomal doxorubicin,Topotecan,STRO-002,Luvelta,Neulasta,Luveltamab tazevibulin,Pegfilgrastim,Paclitaxel,Gemcitabine","Israel,Korea, Republic of,Canada,Singapore,Australia,United States",600,"Ovarian Cancer,Platinum-resistant Ovarian Cancer,Epithelial Ovarian Cancer,Primary Peritoneal Cancer,Fallopian Tube Cancer",2023-07-12,3
332,NCT01716806,Phase 2,Seagen Inc.,Bristol-Myers Squibb,"Adcetris; SGN-35,dacarbazine,brentuximab vedotin,nivolumab,bendamustine","Canada,United States",131,"Peripheral T Cell Lymphoma,Hodgkin Disease",2012-10-31,2
333,NCT03525678,Phase 2,GlaxoSmithKline,,"Belantamab mafodotin lyophilized powder,,Belantamab mafodotin frozen liquid","Germany,Italy,Spain,Canada,Australia,United States,United Kingdom,France",221,",Multiple Myeloma",2018-03-05,2
334,NCT00866047,Phase 2,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","SGN-35,ADCETRIS,brentuximab vedotin","Belgium,Canada,United States,United Kingdom,France",58,"Lymphoma, Large-Cell, Anaplastic,Lymphoma, Non-Hodgkin",2009-03-01,2
335,NCT05581589,Phase 2,University of Washington,Gilead Sciences,"excision of the lymph node,Radical Cystectomy,Trodelvy,RS7-SN38,Sacituzumab Govitecan,Lymph Node Excision,hRS7-SN38 Antibody Drug Conjugate,IMMU-132,Lymphadenectomy,Complete Cystectomy,Lymph Node Dissection,Sacituzumab Govitecan-hziy",United States,18,"Stage II Bladder Cancer AJCC v8,Stage IIIA Bladder Cancer AJCC v8,Muscle Invasive Bladder Carcinoma",2023-06-15,2
336,NCT05756569,Phase 2,Emory University,"Astellas Pharma Inc,Seagen Inc.,National Cancer Institute (NCI),Merck Sharp & Dohme LLC","Enfortumab Vedotin,Computerized Axial Tomography,MK-3475,Magnetic Resonance Imaging Scan,Pembrolizumab,MRI Scan,CAT Scan,Computed Tomography,MRI,Computed Axial Tomography,AGS 22ME,Biospecimen Collection,Anti-Nectin 4 ADC ASG-22CE,Lambrolizumab,NMR Imaging,NMRI,Biospecimen Collected,Biological Sample Collection,AGS-22M6E,Computerized Tomography,Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E,CT Scan,tomography,ASG-22CE,MR,CT,CAT,SCH 900475,Enfortumab Vedotin-ejfv,Nuclear Magnetic Resonance Imaging,Padcev,Questionnaire Administration,Magnetic Resonance Imaging,Magnetic Resonance,MR Imaging,Specimen Collection,Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance,Keytruda",United States,25,"Metastatic Bladder Carcinoma,Urachal Adenocarcinoma,Bladder Squamous Cell Carcinoma,Stage III Bladder Cancer AJCC v8,Malignant Ureter Neoplasm,Unresectable Bladder Carcinoma,Stage IV Bladder Cancer AJCC v8,Malignant Urethral Neoplasm,Bladder Adenocarcinoma,Malignant Renal Pelvis Neoplasm,Locally Advanced Bladder Carcinoma",2023-09-26,2
337,NCT02038010,Phase 1,Northwestern University,"Novartis,National Cancer Institute (NCI)","BYL719,phosphoinositide 3-kinase inhibitor BYL719,pharmacological studies,pharmacological study,Kadcyla,trastuzumab-MCC-DM1 antibody-drug conjugate,trastuzumab-MCC-DM1,laboratory biomarker analysis,ado-trastuzumab emtansine,T-DM1,trastuzumab-DM1,PI3K inhibitor BYL719",United States,17,"Stage IV Breast Cancer,Stage IIIC Breast Cancer,HER2-positive Breast Cancer,Stage IIIB Breast Cancer,Recurrent Breast Cancer,Stage IIIA Breast Cancer",2014-05-21,1
338,NCT06241898,Phase 1,"Bliss Biopharmaceutical (Hangzhou) Co., Ltd",,BB-1709,China,300,Solid Tumor,2023-10-01,1
339,NCT05064358,Phase 2,GlaxoSmithKline,,Belantamab mafodotin,"Poland,Brazil,India,Italy,Taiwan,United Kingdom,Mexico,Argentina,Australia,United States,Ireland,Switzerland,Germany,Korea, Republic of,Thailand,Spain,Canada,Greece,France",177,Multiple Myeloma,2022-03-03,2
340,NCT00430846,Phase 1,Seagen Inc.,,"SGN-35,brentuximab vedotin",United States,45,"Lymphoma, Large-Cell, Anaplastic,Disease, Hodgkin,Lymphoma, Non-Hodgkin",2006-11-01,1
341,NCT01902329,Phase 1,Seagen Inc.,,"SGN-CD33A,vadastuximab talirine,HMA",United States,195,"Acute Myeloid Leukemia,Acute Myelogenous Leukemia,Acute Promyelocytic Leukemia",2013-07-01,1
342,NCT05313243,Phase 2,Yale University,Merck Sharp & Dohme LLC,"Pembrolizumab,Adcetris,Brentuximab vedotin,Keytruda",United States,43,T-Cell Lymphoma,2023-07-10,2
343,NCT03198689,Phase 2,Lawson Health Research Institute,Seagen Inc.,"Brentuximab Vedotin,ADCETRIS, SGN-35",Canada,11,Diffuse Cutaneous Systemic Sclerosis,2019-05-07,2
344,NCT02064387,Phase 1,GlaxoSmithKline,,GSK2857916,"Canada,United States,United Kingdom",79,Multiple Myeloma,2014-07-29,1
345,NCT05633615,Phase 2,SWOG Cancer Research Network,"Genentech, Inc.,National Cancer Institute (NCI)","ADC DCDS4501A,Computerized Axial Tomography,Cyclophosphamid monohydrate,WR- 138719,Positron Emission Tomography,Mosunetuzumab,RG7828,CD20/CD3 BiMAb BTCT4465A,Mitoxan,RG 7828,Cyclophosphamidum,Cicloxal,FCU 2711,Computerized Tomography,Ciclofosfamide,Fluradosa,BTCT 4465A,JCAR 017,PET Scan,Polivy,Clafen,Axicabtagene Ciloleucel,Fludarabine,Patient Observation,Cyclophosphamide Monohydrate,Neosar,Active Surveillance,BTCT-4465A,PET,Cytophosphan,expectant management,2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate,Biospecimen Collection,proton magnetic resonance spectroscopic imaging,Tisagenlecleucel,deferred therapy,DCDS4501A,RO7030816,Watchful Waiting,Biospecimen Collected,Antibody-Drug Conjugate DCDS4501A,Cyclophosphanum,CT Scan,CT,CTL019 T-cells,KTE C19,Medical Imaging, Positron Emission Tomography,CTL019,CYCLO-cell,polatuzumab vedotin-piiq,Ciclofosfamida,Syklofosfamid,Ro 5541077-000,PT,Cyclostine,Carloxan,Fosfaseron,RG-7828,Observation,CAT Scan,CART19,Computed Tomography,Computed Axial Tomography,(-)-Cyclophosphamide,Cyclostin,Positron-Emission Tomography,Cycloblastine,Claphene,Genuxal,Biological Sample Collection,KTE-C19 CAR,Cyclophosphane,tomography,CAT,Genoxal,Cyclophospham,Tisagenlecleucel-T,Cytophosphane,Yescarta,Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A,Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017,Kymriah,Cyclophosphan,Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017,KTE-C19,Revimmune,Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017,CART-19,Positron Emission Tomography Scan,Cytoxan,Ledoxina,CTX,CP monohydrate,Specimen Collection,Lisocabtagene Maraleucel,Breyanzi,Cyclophosphamide,JCAR017,Polatuzumab Vedotin,BTCT4465A,RG7596,Cycloblastin",United States,396,"Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma,Refractory Diffuse Large B-Cell Lymphoma,Primary Mediastinal (Thymic) Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma,Recurrent Diffuse Large B-Cell Lymphoma,Transformed Follic Lymph to Diff Large B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma",2023-06-12,2
346,NCT06439771,Phase 2,"MediLink Therapeutics (Suzhou) Co., Ltd.",,YL202 should be intravenously infused,China,180,Locally Advanced or Metastatic Breast Cancer,2024-04-23,2
347,NCT04686305,Phase 1,AstraZeneca,Daiichi Sankyo,"MEDI4736,DS-8201a, Trastuzumab deruxtecan,Carboplatin,Rilvegostomig,Other Name: AZD2936,Volrustomig,Cisplatin,Pemetrexed,Durvalumab,T-DXd,Other Name: MEDI5752","Malaysia,Poland,Belgium,Israel,Italy,Thailand,Korea, Republic of,Spain,Canada,Netherlands,Singapore,Philippines,Taiwan,Turkey,Australia,United States,France",248,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,2021-03-09,1
348,NCT01309789,Phase 1,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","cyclophosphamide,vincristine,brentuximab vedotin,SGN-35,doxorubicin,prednisone","United States,United Kingdom",39,"Lymphoma, Large-Cell, Anaplastic,Lymphoma, T-cell,Lymphoma, NK-cell",2011-02-01,1
349,NCT02581878,Phase 1,Bayer,,BAY1862864,"Sweden,United Kingdom",21,"Lymphoma, Non-Hodgkin",2015-11-20,1
350,NCT01015911,Phase 1,Seagen Inc.,,SGN-75,United States,58,"Carcinoma, Renal Cell,Lymphoma, Non-Hodgkin",2009-11-01,1
351,NCT00772070,Phase 2,"Sanofi Pasteur, a Sanofi Company",,"Menomune®,A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)",United States,173,"Meningitis,Meningococcemia,Neisseria Meningitidis",2003-03-01,2
352,NCT05628857,Phase 2,"RemeGen Co., Ltd.",,RC108,China,240,Digestive Cancer,2022-11-11,2
353,NCT05911295,Phase 3,Seagen Inc.,"Merck Sharp & Dohme LLC,RemeGen Co., Ltd.","RC48, RC48-ADC,disitamab vedotin,carboplatin,KEYTRUDA®,cisplatin,gemcitabine,Gemzar,pembrolizumab","Canada,Singapore,Taiwan,Australia,United States",700,Urothelial Carcinoma,2023-09-22,3
354,NCT01796171,"Phase 2,Phase 1",Nordic Nanovector,ICON Clinical Research,"12.5 mBq/kg Betalutin,60 mg/m2 lilotomab,20 MBq/kg Betalutin,15 MBq/kg Betalutin,100 mg/m2 lilotomab,10 MBq/kg Betalutin,40 mg lilotomab,Rituximab","Poland,Hungary,Belgium,Israel,Italy,Netherlands,United Kingdom,Denmark,Norway,Singapore,Australia,Ireland,Finland,Switzerland,Sweden,United States,Austria,Korea, Republic of,Croatia,Canada,Spain,Turkey,Czechia,France",191,"Follicular Lymphoma,Non-Hodgkin Lymphoma",2012-12-01,2
355,NCT05511844,Phase 1,"Orum Therapeutics USA, Inc.",,ORM-5029,United States,87,"HER2-positive Breast Cancer,HER-2 Protein Overexpression,HER-2 Gene Amplification,HER2 Gene Mutation",2022-10-03,1
356,NCT03438396,Phase 2,Seagen Inc.,"European Network of Gynaecological Oncological Trial Groups (ENGOT),Genmab,Gynecologic Oncology Group,Belgian Gynaecological Oncology Group","TIVDAK,tisotumab vedotin","Germany,Belgium,Italy,Spain,Czechia,United States,Sweden,Denmark",102,Cervical Cancer,2018-06-12,2
357,NCT01909934,Phase 4,Takeda,"Takeda Development Center Americas, Inc.","SGN-35,ADCETRIS,Brentuximab vedotin","Romania,Hungary,Belgium,Poland,Portugal,Spain,Croatia,Turkey,Czechia,United Kingdom",50,Lymphoma,2014-01-30,4
358,NCT05764954,Phase 1,Memorial Sloan Kettering Cancer Center,NovoCure Ltd.,NovoTTF-200T System,United States,25,Adenocarcinoma of Lung,2023-08-04,1
359,NCT06157892,"Phase 2,Phase 1",Seagen Inc.,"RemeGen Co., Ltd.","RC48, RC48-ADC,TUKYSA, ONT-380, ARRY-380,tucatinib,disitamab vedotin","Canada,United States",198,"Breast Neoplasms,Triple Negative Breast Neoplasms,Stomach Neoplasms,HER2 Positive Breast Neoplasms,Gastroesophageal Junction Adenocarcinoma,HER2 Low Breast Neoplasms",2024-05-20,2
360,NCT01777152,Phase 3,Seagen Inc.,"Millennium Pharmaceuticals, Inc.","Adcetris; SGN-35,cyclophosphamide,vincristine,brentuximab vedotin,doxorubicin,prednisone","Romania,Germany,Hungary,Poland,Israel,Italy,Korea, Republic of,Spain,Canada,United Kingdom,Taiwan,Czechia,Australia,United States,Denmark,France",452,"T-Cell Lymphoma,Anaplastic Large-Cell Lymphoma,Non-Hodgkin Lymphoma",2013-01-31,3
361,NCT01166490,Phase 1,Seagen Inc.,"Agensys, Inc.",ASG-5ME,United States,51,"Gastric Neoplasms,Pancreatic Neoplasms",2010-07-01,1
362,NCT06464055,"Phase 2,Phase 1","GeneQuantum Healthcare (Suzhou) Co., Ltd.",,"Dose Escalation,Dose Expansion1,Dose Expansion2,phase II",China,220,Advanced Malignant Solid Tumors,2024-05-23,2
363,NCT06365853,Phase 2,"ImmunoGen, Inc.",,"Mirvetuximab Soravtansine,Prednisolone acetate ophthalmic suspension 1% eye drops,MIRV,Lubricating Eye Drops,Brimonidine tartrate ophthalmic solution eye drops,IMGN853","Belgium,United States,Italy,Spain,Canada,Australia,Ireland,France",100,"Folate Receptor-Alpha Positive,Recurrent Ovarian Cancer",2024-06-30,2
364,NCT05041257,Phase 2,"ImmunoGen, Inc.",,"MIRV,Mirvetuximab soravtansine,IMGN853","Belgium,United States,Italy,Spain,Canada,Australia,Ireland,France",79,"Fallopian Tube Cancer,Peritoneal Cancer,Ovarian Cancer",2021-08-31,2
365,NCT00198380,Phase 2,Intergroupe Francophone de Cancerologie Thoracique,AstraZeneca,Gefitinib,France,90,"Pneumonic-type Adenocarcinoma (P-ADC),Lung Adenocarcinoma With Bronchiolo-alveolar Feature",2005-04-01,2
366,NCT06144723,"Phase 2,Phase 1",Hansoh BioMedical R&D Company,,HS-20105,,402,Advanced Solid Tumor,2024-03-01,2
367,NCT01997333,Phase 2,Celldex Therapeutics,,"CDX-011,Capecitabine","Germany,Belgium,Italy,Spain,Canada,Australia,United States,United Kingdom,France",327,Metastatic gpNMB Over-expressing Triple Negative Breast Cancer,2013-11-01,2
368,NCT04209855,Phase 3,"ImmunoGen, Inc.","European Network of Gynaecological Oncological Trial Groups (ENGOT),Gynecologic Oncology Group","Pegylated liposomal doxorubicin,Mirvetuximab Soravtansine,Topotecan,Paclitaxel,MIRV,IMGN853","Poland,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Ukraine,China,Australia,Bulgaria,United States,Russian Federation,Germany,Serbia,Portugal,Korea, Republic of,Spain,Canada,Czechia,France",453,"Epithelial Ovarian Cancer,Peritoneal Cancer,Fallopian Tube Cancer",2019-12-31,3
369,NCT06039202,Phase 2,"Holy Stone Healthcare Co., Ltd",,"Nim-HA cinjugate,CA102N,Trifluridine/tipiracil,TAS-102,Bevacizumab",,100,Metastatic Colorectal Cancer,2024-01-01,2
370,NCT01421667,Phase 2,Seagen Inc.,,"Adcetris; SGN-35,rituximab,brentuximab vedotin","Canada,United States",176,"Lymphoma, Non-Hodgkin,Lymphoma, B-Cell,Lymphoma, T-Cell,Lymphoma, Large B-Cell, Diffuse",2011-08-01,2
371,NCT01461538,Phase 2,Seagen Inc.,,"Adcetris; SGN-35,brentuximab vedotin",United States,84,"Acute Myeloid Leukemia,Solid Tumors,Anemia, Refractory, With Excess of Blasts,Acute Lymphoid Leukemia",2011-10-01,2
372,NCT05135273,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),"Novavax,Malaria Research and Training Center, Bamako, Mali","Pfs230D1-EPA/Matrix-M Vaccine,Verorab Rabies Vaccine",Mali,80,"Malaria,Falciparum",2021-10-22,1
373,NCT04177823,Phase 1,GlaxoSmithKline,,Belantamab mafodotin,China,6,Multiple Myeloma,2019-12-09,1
374,NCT05263479,Phase 1,"Shanghai Hansoh Biomedical Co., Ltd",,"HS-20089 (Phase Ia：Dose escalation ),HS-20089 (Phase Ib: Dose expansion)",China,177,Advanced Solid Tumor,2022-01-05,1
375,NCT01950364,Phase 1,"Millennium Pharmaceuticals, Inc.",,"Brentuximab vedotin and rifampicin,SGN-35,brentuximab vedotin","Lithuania,Spain,Belgium",20,"Anaplastic Large-cell Lymphoma,Hodgkin Lymphoma",2013-11-01,1
376,NCT01786096,Phase 1,Seagen Inc.,,SGN-CD19A,United States,92,"Precursor B-cell Lymphoblastic Leukemia-Lymphoma,Burkitt Lymphoma",2013-02-01,1
377,NCT02216890,Phase 1,Seagen Inc.,,SGN-CD70A,United States,38,"Diffuse, Large B-Cell, Lymphoma,Mantle-Cell Lymphoma,Renal Cell Carcinoma,Follicular Lymphoma, Grade 3",2014-08-01,1
378,NCT04207190,Phase 1,Roswell Park Cancer Institute,Pfizer,"WAY-CMA-676,Gemtuzumab Ozogamicin,Questionnaire Administration,BMN-673,Talazoparib Tosylate,Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody,hP67.6-Calicheamicin,Quality of Life Assessment,Quality-of-Life Assessment,Talzenna,BMN 673,gemtuzumab,Mylotarg,Talazoparib,CDP-771,CMA-676",United States,24,"Refractory Acute Myeloid Leukemia,Recurrent Acute Myeloid Leukemia",2020-10-23,1
379,NCT05575804,"Phase 2,Phase 1",Fudan University,"GeneQuantum Healthcare (Suzhou) Co., Ltd.","pyrotinib+capecitabine,GQ1001+pyrotinib",China,75,Advanced/ Metastatic Her-2 Positive Breast Cancer,2022-10-01,2
380,NCT03219333,Phase 2,Astellas Pharma Inc,Seagen Inc.,"ASG-22ME,Enfortumab vedotin,ASG-22CE","Germany,Italy,Korea, Republic of,Spain,Netherlands,United States,Japan,France",219,"Carcinoma, Transitional Cell,Renal Pelvis Neoplasms,Urothelial Cancer,Urethral Neoplasms,Urinary Bladder Neoplasms,Ureteral Neoplasms,Urologic Neoplasms",2017-10-08,2
381,NCT04086264,"Phase 2,Phase 1","ImmunoGen, Inc.",,"Decitabine,Vidaza,Venclexta,IMGN632,CD123-targeted ADC,Venetoclax,Azacitidine,Venclyxto","Germany,Italy,Spain,United States,United Kingdom,France",218,Acute Myeloid Leukemia,2019-11-06,2
382,NCT06106945,"Phase 2,Phase 1",AstraZeneca,,AZD0305,"Germany,China,Spain,Canada,Australia,United States,Japan,France",84,Multiple Myeloma,2023-12-05,2
383,NCT02227199,"Phase 2,Phase 1",University of Washington,"Seagen Inc.,National Cancer Institute (NCI)","Anti-CD30 Monoclonal Antibody-MMAE SGN-35,Paraplatin AQ,Carboplatin,Adcetris,Demethyl Epipodophyllotoxin Ethylidine Glucoside,IFO-Cell,Lastet,Ifolem,IFX,Iso-Endoxan,Iphosphamid,ADC SGN-35,Nealorin,Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35,Naxamide,Laboratory Biomarker Analysis,Carbotec,Ribocarbo,Mitoxana,MJF-9325,EPEG,Anti-CD30 Antibody-Drug Conjugate SGN-35,VP 16-213,JM-8,Iphosphamide,SGN-35,VP-16-213,Novoplatinum,Asta Z-4942,Cyfos,Paraplatin,Platinwas,Displata,Etoposide,Asta Z 4942,Isoendoxan,Ifomida,Vepesid,Isophosphamide,Z-4942,cAC10-vcMMAE,Ercar,Carboplat,Carboplatino,VP-16,Carbosin,Ifoxan,MJF 9325,Seromida,Carboplatin Hexal,Tronoxal,Ifex,Ifomide,Paraplatine,Ifosfamidum,CBDCA,IFO,Brentuximab Vedotin,Ifosfamide,Holoxan,Z 4942,Toposar,Holoxane,Blastocarb,Carbosol",United States,45,"Refractory Hodgkin Lymphoma,Recurrent Hodgkin Lymphoma",2014-10-10,2
384,NCT06340568,Phase 3,BioNTech SE,DualityBio Inc.,"Paclitaxel,BNT323/DB-1303,Doxorubicin",,468,Endometrial Cancer,2024-08-01,3
385,NCT06034275,Phase 1,"Vincerx Pharma, Inc.",,VIP943,United States,36,"Acute Myeloid Leukemia,B-cell Acute Lymphoblastic Leukemia,High-risk Myelodysplastic Syndrome",2023-09-13,1
386,NCT06195709,Phase 3,Institut Curie,Zionexa,"Standardized endocrine therapy regimen,Standardized chemotherapy regimen,Endocrine therapy combined with the local treatment of FES-negative lesions,Endocrine therapy,Chemotherapy",France,300,Breast Carcinoma,2024-05-27,3
387,NCT03698552,"Phase 2,Phase 1",M.D. Anderson Cancer Center,"ADC Therapeutics S.A.,National Cancer Institute (NCI)","ADCT-602 (CN); hLL2-cys-PBD (SY); ADCT602 (CN); ADCT 602 (CN); hLL2-cys-SG3249 (SY); ; ADC ADCT-602,ADCT-602",United States,65,"CD22 Positive,Refractory B Acute Lymphoblastic Leukemia,Recurrent B Acute Lymphoblastic Leukemia,Blasts 5 Percent or More of Bone Marrow Nucleated Cells,Philadelphia Chromosome Positive",2018-08-24,2
388,NCT06034470,Phase 1,Fred Hutchinson Cancer Center,"ImmunoGen, Inc.","Beta-Cytosine Arabinoside,Cytarabinum,Blood Pool Scan,MUGA Scan,Fluradosa,2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-,Aracytin,Gated Heart Pool Scan,MUGA,G-CSF,Fludarabine,Alexan,Arabine,U 19920,G CSF,Idarubicin,Biopsy, Bone Marrow,2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-,Arabinofuranosylcytosine,Echocardiography,Biospecimen Collection,Cytosar,Equilibrium Radionuclide Angiography,Gated Blood Pool Imaging,1-Beta-D-arabinofuranosylcytosine,Antibody-drug Conjugate IMGN632,4-Demethoxydaunorubicin,Biospecimen Collected,4-DMDR,.beta.-Cytosine arabinoside,CSF3,1-.beta.-D-Arabinofuranosylcytosine,IMGN632,RNVG,U-19920,WR-28453,SYMA Scanning,Cytosine Arabinoside,ARA-cell,Cytarabine,Aracytine,Pluripoietin,Granulocyte Colony Stimulating Factor,Bone Marrow Biopsy,Radionuclide Ventriculogram Scan,1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone,Udicil,IMGN 632,Multi-Gated Acquisition Scan,Biological Sample Collection,Pivekimab Sunirine,Multigated Acquisition Scan,EC,Colony-Stimulating Factor 3,CD123-targeted ADC IMGN632,Anti-CD123 ADC IMGN632,Cytosine-beta-arabinoside,Radionuclide Ventriculography,Cytarbel,Starasid,IMGN-632,Cytosine-.beta.-arabinoside,Aracytidine,Arabinosylcytosine,Bone Marrow Aspiration,Biopsy of Bone Marrow,Colony-Stimulating Factor (Granulocyte),1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone,Synchronized Multigated Acquisition Scanning,Tarabine PFS,Granulocyte Colony-Stimulating Factor,CHX-3311,Colony Stimulating Factor 3,Erpalfa,1.beta.-D-Arabinofuranosylcytosine,Ara-C,4-Demethoxydaunomycin,Specimen Collection",United States,30,"Myeloproliferative Neoplasm,Mixed Phenotype Acute Leukemia,Acute Myeloid Leukemia,Myelodysplastic Syndrome,Myelodysplastic/Myeloproliferative Neoplasm",2023-12-18,1
389,NCT01983540,Phase 3,"Sanofi Pasteur, a Sanofi Company",,"DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine,Infanrix hexa + Prevenar + Rotarix vaccine,DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine","Colombia,Costa Rica",558,"Diphtheria,Poliomyelitis,Tetanus,Whooping Cough,Haemophilus Influenzae Type b,Hepatitis B",2013-10-01,3
390,NCT02610348,,"Sanofi Pasteur, a Sanofi Company",,"DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines,DTaP-HB-IPV and Pneumococcal polysaccharide vaccines",Thailand,122,Hepatitis B,2015-11-01,
391,NCT02573324,Phase 3,AbbVie,Radiation Therapy Oncology Group,"Temozolomide,ABT-414,Placebo for ABT-414,Radiation,Depatuxizumab mafodotin","Brazil,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Mexico,China,Argentina,New Zealand,Hong Kong,Singapore,Colombia,Australia,Ireland,Switzerland,United States,Russian Federation,Germany,Austria,Portugal,Korea, Republic of,Spain,Canada,Czechia,South Africa,France",691,"Gliosarcoma,Glioblastoma",2015-01-04,3
392,NCT04946370,"Phase 2,Phase 1",Weill Medical College of Cornell University,"Merck Sharp & Dohme LLC,United States Department of Defense","Androgen receptor pathway inhibitor,Pembrolizumab,225Ac-J591,68Ga-PSMA-HBED-CC,68Ga-PSMA-11",United States,76,Prostate Cancer,2021-08-12,2
393,NCT00654901,Phase 3,"Sanofi Pasteur, a Sanofi Company",,"Infanrix Hexa™,DTaP-IPV-Hep B-PRP~T vaccine (Batch 1),DTaP-IPV-Hep B-PRP~T vaccine (Batch 3),DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)",Mexico,881,"Pertussis,Diphtheria,Tetanus,Haemophilus Influenzae Type B Infection,Hepatitis B,Poliomyelitis",2008-03-01,3
394,NCT01786135,Phase 1,Seagen Inc.,,SGN-CD19A,United States,64,"Precursor B-cell Lymphoblastic Leukemia-Lymphoma,Lymphoma, Large B-Cell, Diffuse,Lymphoma, Mantle-Cell,Lymphoma, Follicular,Burkitt Lymphoma",2013-02-01,1
395,NCT03786081,"Phase 2,Phase 1",Seagen Inc.,"Belgian Gynaecological Oncology Group,GOG Foundation,Merck Sharp & Dohme LLC,Genmab,European Network of Gynaecological Oncological Trial Groups (ENGOT)","TIVDAK,Carboplatin,KEYTRUDA®,Pembrolizumab,Tisotumab Vedotin,Bevacizumab,Paraplatin,Avastin","Belgium,United States,Italy,Spain,Netherlands,United Kingdom,Turkey,Czechia,Ireland,Denmark",214,Cervical Cancer,2019-02-27,2
396,NCT03284723,Phase 1,Pfizer,,"PF-06804103,PF-06804103 + Palbociclib +Letrozole","Russian Federation,Italy,Korea, Republic of,Spain,Australia,United States",95,Breast Neoplasms,2017-11-01,1
397,NCT01590966,Phase 3,"University Hospital, Ghent",UCB Pharma SA,"administration of Cimzia®,Immunoscintigraphy with radiolabeled Cimzia®.",Belgium,41,"Rheumatoid Arthritis,Axial and Peripheral Spondyloarthritis",2012-10-18,3
398,NCT03288545,"Phase 2,Phase 1","Astellas Pharma Global Development, Inc.","Merck Sharp & Dohme LLC,Seagen Inc.","ASG-22CE,carboplatin,PADCEV,cisplatin,gemcitabine,enfortumab vedotin (EV),pembrolizumab,ASG-22ME,Keytruda","Puerto Rico,Italy,Spain,Canada,United States,France",348,"Carcinoma, Transitional Cell,Renal Pelvis Neoplasms,Urothelial Cancer,Urethral Neoplasms,Urinary Bladder Neoplasms,Ureteral Neoplasms,Urologic Neoplasms",2017-10-11,2
399,NCT01990534,Phase 4,"Millennium Pharmaceuticals, Inc.",,"SGN-35,ADCETRIS,Brentuximab Vedotin","Malaysia,Germany,Poland,Thailand,Spain,Turkey,Czechia",60,Hodgkin Lymphoma,2014-03-14,4
400,NCT05350917,Phase 2,The First Affiliated Hospital of Zhengzhou University,"BeiGene,RemeGen Co., Ltd.,Jiangsu Hengrui Pharmaceutical Co., Ltd.","DisitamabVedotin,Tislelizumab,Pyrotinib maleate",,20,HER2-positive or Mutated Advanced Colorectal Cancer,2022-06-20,2
401,NCT02222922,Phase 1,Pfizer,,"PF-06647020 combined with Avelumab,PF-06647020 Q2W,PF-06647020 Q3W,fluconazole","United States,Spain",138,Neoplasms,2014-10-17,1
402,NCT00861744,Phase 2,GlaxoSmithKline,,"Varivax®,M-M-R® II (Merck and Co),GSK Biological's investigational vaccine 209762,Havrix®,Prevnar®","United States,Puerto Rico",1259,"Rubella,Measles,Measles-Mumps-Rubella Vaccine,Mumps",2009-06-03,2
403,NCT06123494,Phase 3,"Jiangsu HengRui Medicine Co., Ltd.",,"SHR-A1811,Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan",China,360,HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma,2024-01-09,3
404,NCT00012064,"Phase 2,Phase 1","Lisata Therapeutics, Inc.",,therapeutic autologous dendritic cells,United States,56,Melanoma (Skin),2000-07-01,2
405,NCT01444781,Phase 3,"Sanofi Pasteur, a Sanofi Company",,"Infanrix hexa™,DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide,Prevenar™,DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine,DTaP-IPV-Hep B-PRP~T combined vaccine,DTaP-IPV-Hep B-PRP~T vaccine,DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide","Colombia,Costa Rica",1106,"Diphtheria,Poliomyelitis,Tetanus,Whooping Cough,Hepatitis B",2011-09-01,3
406,NCT05702229,Phase 2,AstraZeneca,,"AZD7789,FOLFOX,Rilvegostomig,XELOX,Volrustomig,Capecitabine,AZD0901,5-Fluorouracil","China,Korea, Republic of,Spain,United Kingdom,Taiwan,United States,Japan",240,Gastric Cancer,2023-01-16,2
407,NCT02343406,Phase 2,AbbVie,European Organisation for Research and Treatment of Cancer - EORTC,"Temozolomide,Gleostine,ABT-414,TMZ,Lomustine,Depatuxizumab mafodotin","Poland,Hungary,Belgium,Italy,Netherlands,Taiwan,United Kingdom,Mexico,Singapore,Australia,Ireland,Finland,Switzerland,United States,Germany,Austria,Korea, Republic of,Spain,Canada,Czechia,France",266,Glioblastoma,2015-02-17,2
408,NCT00051571,Phase 2,Seagen Inc.,,"Docetaxel,SGN-15",United States,60,"Carcinoma, Non-Small-Cell Lung",,2
409,NCT06065371,Phase 1,Henry Ford Health System,Gilead Sciences,"Sacituzumab govetican,Trodelvy,Capecitabine,Xeloda",,20,Gastrointestinal Cancer,2024-06-01,1
410,NCT02340208,"Phase 2,Phase 1",Helix BioPharma Corporation,Pharm-Olam International,L-DOS47,Poland,76,Non-Small Cell Lung Cancer,2012-05-01,2
411,NCT04592419,Phase 3,Kodiak Sciences Inc,,"Aflibercept,Sham Procedure,Eylea,KSI-301","Germany,Puerto Rico,Hungary,Poland,Israel,Italy,Spain,Latvia,Czechia,Slovakia,United States,France",568,"Macular Edema,Retinal Vein Occlusion",2020-09-25,3
412,NCT00356408,Phase 3,UCB Pharma,,"CDP870,Cimzia,Certolizumab pegol,CZP","Canada,Germany,United States",106,Crohn's Disease,2007-01-01,3
413,NCT05579366,"Phase 2,Phase 1",ProfoundBio US Co.,,"PRO1184 intravenous infusion of PRO1184,PRO1184","China,United States",374,"Mesothelioma,Ovarian Cancer,Breast Adenocarcinoma,Hormone Receptor-positive/Her2 Negative Breast Cancer,Non-small Cell Lung Cancer,Triple Negative Breast Cancer,Fallopian Tube Cancer,High Grade Epithelial Ovarian Cancer,Primary Peritoneal Carcinoma,Endometrial Cancer",2022-12-07,2
414,NCT02677155,Phase 2,Oslo University Hospital,"Merck Sharp & Dohme LLC,Norwegian Cancer Society","Radiotherapy,GM-CSF,Pembrolizumab,Sagramostim,Mabthera,Rituximab,Autologous dendritic cells,Anti-PD1",Norway,10,Follicular Lymphoma,2016-01-01,2
415,NCT04203641,"Phase 2,Phase 1",Helix BioPharma Corporation,Theradex,"Doxorubicin,L-DOS47",United States,20,Pancreas Cancer,2019-12-11,2
416,NCT05283330,Phase 1,Orano Med LLC,,²¹²Pb-DOTAM-GRPR1,United States,30,"Breast Cancer,NSCLC,Cutaneous Melanoma,Prostate Cancer Metastatic,Cervical Cancer,Colon Cancer",2022-12-22,1
417,NCT04964089,Phase 3,Kodiak Sciences Inc,,"Aflibercept,Sham Procedure,Eylea,KSI-301","United States,Puerto Rico",557,Wet Age-related Macular Degeneration,2021-06-23,3
418,NCT05600686,Phase 2,Joseph Tuscano,"ADC Therapeutics S.A.,National Cancer Institute (NCI)","Doxorubicin,Hydroxyldaunorubicin,Ruxience,Deltison,Deltacortene,Paracort,Cyclophosphamid monohydrate,WR- 138719,Rituximab Biosimilar PF-05280586,Vincristine,Prednicort,Mitoxan,Cyclophosphamidum,VP 16-213,Decorton,Cicloxal,Etoposide,VP 16,Vepesid,Adriablastin,PRED,Rituximab Biosimilar CT-P10,Ciclofosfamide,Rayos,VP16,Clafen,Rituxan,Neosar,Cyclophosphamide Monohydrate,rituximab biosimilar TQB2303,Cortancyl,Demethyl Epipodophyllotoxin Ethylidine Glucoside,Rituximab,Cytophosphan,Predniment,PF-05280586,2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate,EPEG,Prednidib,Lisacort,Delta-Dome,Rituximab PVVR,Cyclophosphanum,Prednitone,Rituximab Biosimilar RTXM83,IDEC-C2B8 Monoclonal Antibody,Vincrystine,Perrigo Prednisone,VP-16,Rituximab Biosimilar IBI301,Ofisolona,Panasol-S,Monoclonal Antibody IDEC-C2B8,Adasone,ABP 798,Rituximab ARRX,Rituximab Biosimilar BI 695500,CYCLO-cell,Hydroxyl Daunorubicin,Predicorten,Ciclofosfamida,Syklofosfamid,Deltacortisone,Prednisonum,Cyclostine,Carloxan,Fosfaseron,Prednilonga,Rituximab-arrx,SK-Prednisone,Servisone,Loncastuximab Tesirine,1, 2-Dehydrocortisone,rituximab-abbs,Prednisone Intensol,ADCT-402,VP-16-213,Decortisyl,MabThera,(-)-Cyclophosphamide,Cyclostin,Rituximab Biosimilar SAIT101,Cycloblastine,Claphene,Prednicen-M,Genuxal,Cyclophosphane,Orasone,Genoxal,Cyclophospham,Cytophosphane,VCR,Chimeric Anti-CD20 Antibody,Rituximab ABBS,Rituximab Biosimilar ABP 798,Econosone,Zynlonta,Cyclophosphan,.delta.1-Cortisone,Delta 1-Cortisone,IDEC-C2B8,Toposar,Panafcort,Deltasone,Lastet,Deltra,Rituximab Biosimilar SIBP-02,Revimmune,Loncastuximab Tesirine-lpyl,Rituximab Biosimilar GB241,IDEC-102,Predicor,Deltadehydrocortisone,Cytoxan,Meticorten,Leurocristine,Ledoxina,CT-P10,Metacortandracin,RTXM83,Riabni,Rituximab-pvvr,Promifen,CTX,Rituximab Biosimilar JHL1101,CP monohydrate,Hydroxydaunomycin,C2B8 Monoclonal Antibody,Dacortin,Truxima,BI 695500,DeCortin,Cyclophosphamide,Meprosona-F,Anti-CD19 PBD-conjugate ADCT-402,Prednisone,Cycloblastin,ADC ADCT-402",United States,24,"Double-Expressor Lymphoma,High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements,High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",2023-05-24,2
419,NCT05627960,Phase 1,A&G Pharmaceutical Inc.,University of Maryland Greenebaum Cancer Center,AG-01 Compound,United States,77,"Non Small Cell Lung Cancer,Triple Negative Breast Cancer,Hormone-Resistant Breast Cancer,Mesothelioma",2022-02-14,1
420,NCT01825317,,Neuronix Ltd,"company: K The Power,Chungnam National University Hospital","NICE,Control device,Sham device,NeuroAD","Korea, Republic of",32,Alzheimer's Disease,2013-03-01,
421,NCT01280552,Phase 2,Precision Life Sciences Group,,"ICT-107,Placebo DC",United States,124,Glioblastoma Multiforme,2011-01-01,2
422,NCT05261750,"Phase 2,Phase 1",PT. Prodia Stem Cell Indonesia,,"Auto-Dendritic Adjuvant Therapy,Allo-Dendritic-Secretome Adjuvant Therapy",Indonesia,15,Nasopharyngeal Cancer,2022-04-30,2
423,NCT03743298,Phase 1,"Aivita Biomedical, Inc.",,AV-MEL-1,United States,20,Metastatic Melanoma,2021-04-21,1
424,NCT00377715,Phase 2,"Medivation, Inc.",,"Placebo,Dimebon",Russian Federation,183,Alzheimer's Disease,2005-09-01,2
425,NCT00777608,Phase 1,Merck Sharp & Dohme LLC,,"Donepezil 5 - 10 mg,Comparator: Placebo 5mg (run in),Comparator: Placebo 5-10 mg,Donepezil 10 mg",,106,Alzheimer's Disease,2008-12-01,1
426,NCT02049489,Phase 1,Precision Life Sciences Group,,ICT-121 DC vaccine,United States,20,Glioblastoma Multiforme,2013-12-01,1
427,NCT03531918,"Phase 2,Phase 1",Fred Hutchinson Cancer Center,Pfizer,"Cytarbel,Leustatin,Starasid,2CDA,Alexan,Arabine,U 19920,Mitoxantrone Hydrochloride,Mitozantrone Hydrochloride,2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-,Arabinofuranosylcytosine,143011-72-7,Mitoxantroni Hydrochloridum,Cytosine-.beta.-arabinoside,Laboratory Biomarker Analysis,Aracytidine,2-CdA,Onkotrone,Cytarabinum,WAY-CMA-676,Arabinosylcytosine,Cytosar,1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone,Mitoxantrone Dihydrochloride,Gemtuzumab Ozogamicin,Beta-cytosine Arabinoside,Udicil,1-Beta-D-arabinofuranosylcytosine,Pralifan,Cladribine,DHAQ,1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone,Cladribina,RWJ-26251,CdA,.beta.-Cytosine arabinoside,Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody,hP67.6-Calicheamicin,1-.beta.-D-Arabinofuranosylcytosine,Tarabine PFS,Recombinant Colony-Stimulating Factor 3,rhG-CSF,Leustatine,Neotalem,2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-,Mylotarg,Aracytin,U-19920,CDP-771,CHX-3311,WR-28453,Novantrone,DHAD,Erpalfa,Leustat,1.beta.-D-Arabinofuranosylcytosine,Recombinant Granulocyte Colony-Stimulating Factor,Ara-C,CL 232315,Cytosine-beta-arabinoside,Cytosine Arabinoside,ARA-cell,gemtuzumab,Dihydroxyanthracenedione Dihydrochloride,Mitroxone,Cytarabine,Aracytine,CMA-676",United States,66,Acute Myeloid Leukemia,2018-09-14,2
428,NCT04690387,Phase 1,"Aivita Biomedical, Inc.","PT AIVITA Biomedika Indonesia,Indonesia Ministry of Health,National Institute of Health Research and Development, Ministry of Health Republic of Indonesia","GM-CSF,AV-COVID-19",Indonesia,27,COVID-19,2020-12-07,1
429,NCT00086333,Phase 2,Seagen Inc.,,"SGN-15, Docetaxel",United States,30,Non-Small Cell Lung Carcinoma,2004-07-01,2
430,NCT02771340,Phase 1,"Iconic Therapeutics, Inc.",,"human Immuno-conjugate 1,ICON-1",United States,10,"Choroid Neoplasm,Uveal Melanoma",2016-05-01,1
431,NCT01068509,Phase 2,Prima BioMed Ltd,,Cvac,"Australia,United States",63,Epithelial Ovarian Cancer,2010-07-01,2
432,NCT05100641,Phase 3,"Aivita Biomedical, Inc.",,"Autologous monocytes,AV-GBM-1",,672,Primary Glioblastoma,2024-01-01,3
433,NCT04834544,Phase 2,Peking University Third Hospital,SOTIO a.s.,"DCVAC/OvCa,Placebo",China,75,"Epithelial Ovarian Carcinoma,Primary Peritoneal Carcinoma,Fallopian Tube Carcinoma",2021-04-19,2
434,NCT01617629,Phase 2,Prima BioMed Ltd,,MUC1 Dendritic Cell Vaccine (Cvac),"Australia,United States",9,Epithelial Ovarian Cancer,2011-12-01,2
435,NCT04160494,Phase 1,Darell Bigner,"Istari Oncology, Inc.,National Cancer Institute (NCI),Genentech, Inc.","D2C7-IT (4613.2 ng/mL via convection-enhanced delivery),D2C7-IT (6920 ng/mL via convection-enhanced delivery),Tecentriq,Atezolizumab (1200 mg every three weeks)",United States,18,Malignant Glioma,2020-02-25,1
436,NCT03543358,Phase 2,AbbVie,,"rovalpituzumab tesirine,SC16LD6.5",United States,3,Cancer,2018-09-10,2
437,NCT03610360,"Phase 3,Phase 2",Amphera BV,TMC Pharma,MesoPher,"Belgium,Italy,Netherlands,United Kingdom,France",176,Mesothelioma,2018-06-21,3
438,NCT05007496,Phase 2,"Aivita Biomedical, Inc.","PT AIVITA Biomedika Indonesia,Central Army Hospital RSPAD Gatot Soebroto,Kariadi Hospital",AV-COVID-19,Indonesia,145,COVID-19,2021-04-14,2
439,NCT00815607,Phase 1,Alaunos Therapeutics,,"INXN-3001,INXN-1001",United States,12,Melanoma,2009-04-01,1
440,NCT04744831,Phase 2,Daiichi Sankyo,AstraZeneca,"DS-8201a 6.4 mg/kg Q3W,Drug: DS-8201a 6.4 mg/kg Q3W,DS-8201a 5.4 mg/kg Q3W,T-DXd,Drug: DS-8201a 5.4 mg/kg Q3W","Belgium,Korea, Republic of,Italy,Spain,United Kingdom,Taiwan,Australia,United States,Japan,France",122,Advanced Colorectal Cancer,2021-01-19,2
441,NCT02358889,Phase 2,"Iconic Therapeutics, Inc.",,"Sham injection,hI-con1,Lucentis®,ranibizumab,human Immuno-conjugate 1",United States,88,"Choroidal Neovascularization,Age-related Macular Degeneration",2015-02-01,2
442,NCT00420888,"Phase 3,Phase 2",Active Biotech AB,,"ABR-217620/naptumomab estafenatox,Referon-A,naptumomab estafenatox,IFN-alpha","Romania,Russian Federation,Ukraine,Bulgaria,United Kingdom",526,Renal Cell Carcinoma,2007-01-01,3
443,NCT06477419,Phase 2,Memorial Sloan Kettering Cancer Center,Gilead Sciences,Sacituzumab govitecan-hziy,United States,33,"Mesothelioma; Pleura,Mesotheliomas Pleural,Mesothelioma",2024-06-21,2
444,NCT06390995,"Phase 2,Phase 1",Takeda,,"TAK-853,Mirvetuximab Soravtansine",Japan,25,"Solid Tumors,Ovarian Cancer",2024-05-20,2
445,NCT06378242,"Phase 2,Phase 1","RemeGen Co., Ltd.",,"Disitamab Vedotin for injection,RC48",China,24,High-risk Non-muscle Invasive Bladder Cancer,2024-04-23,2
446,NCT06329869,Phase 2,National Taiwan University Hospital,Gilead Sciences,Sacituzumab govitecan,,35,Esophageal Squamous Cell Carcinoma,2024-05-01,2
447,NCT06248515,Phase 2,Georgetown University,Gilead Sciences,Sacituzumab govitecan-hziy,United States,18,"Thymoma,Thymic Carcinoma",2024-04-25,2
448,NCT06238921,"Phase 2,Phase 1",H. Lee Moffitt Cancer Center and Research Institute,Gilead Sciences,"Trodelvy,Sacituzumab govitecan,Zimberelimab,Stereotactic Radiation",United States,31,"Breast Cancer,Triple Negative Breast Cancer",2024-06-01,2
449,NCT06227156,Phase 2,"RemeGen Co., Ltd.",,"Disitamab Vedotin Injection,DV,RC48",China,40,Castration-resistant Prostate Cancer,2024-04-08,2
450,NCT06174987,Phase 3,Daiichi Sankyo,AstraZeneca,"T-DXd,DS8201a","Belgium,Japan,Italy,Korea, Republic of,Spain,Taiwan,Australia,United States,United Kingdom,France",50,"Metastatic Cancer,Advanced Cancer",2024-01-05,3
451,NCT06167317,Phase 1,Gilead Sciences,,"GS-0132,GS-0201,IMMU-132,Sacituzumab Govitecan,Trodelvy™","Israel,United States",254,Advanced Solid Tumors,2024-01-09,1
452,NCT06133517,Phase 2,Fundación para el Progreso de la Oncología en Cantabria,Apices Soluciones S.L.,"Trodelvy,Sacituzumab govitecan,Zimberelimab,Domvanalimab",Spain,70,Urothelial Bladder Carcinoma,2024-07-01,2
453,NCT06123468,"Phase 2,Phase 1",Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,Gilead Sciences,"Sacituzumab govitecan,Trodelvy","Germany,Austria",56,Esophagogastric Adenocarcinoma,2024-04-17,2
454,NCT05884320,Phase 2,M.D. Anderson Cancer Center,Gilead Sciences,Sacituzumab Govitecan,United States,30,"Salivary Gland Cancers,Gland",2023-07-27,2
455,NCT05833867,Phase 1,Omar Mian,"Varian Inc,Gilead Sciences","Adaptive Radiotherapy,Sacituzumab govitecan,TRODELVY",United States,20,"Muscle-Invasive Bladder Carcinoma,Localized Muscle Invasive Bladder Urothelial Carcinoma",2024-04-01,1
456,NCT05552001,Phase 3,UNICANCER,Gilead Sciences,"Sacituzumab govitecan,trodelvy",France,96,"Triple Negative Breast Cancer,Metastatic Breast Cancer",2023-10-05,3
457,NCT05260957,Phase 2,Lazaros Lekakis,"Genentech, Inc.","Polatuzumab Vedotin,Polatuzumab,CAR-T Cell Therapy,BTCT4465A,RO5541077,Chimeric antigen receptor T-Cell Therapy,Mosunetuzumab,Polivy",United States,40,"Aggressive Non-Hodgkin Lymphoma,Relapsed Non Hodgkin Lymphoma,Refractory Non-Hodgkin Lymphoma",2022-12-14,2
458,NCT05119907,Phase 2,Gilead Sciences,,"Sacituzumab Govitecan-hziy,IMMU-132,Trodelvy™,GS-0132",China,300,Solid Tumor,2021-10-12,2
459,NCT05113966,Phase 2,"G1 Therapeutics, Inc.",,"Trodelvy,G1T28,IMMU-132,Trilaciclib,CDK 4/6 inhibitor,Sacituzumab Govitecan-hziy",United States,30,Triple Negative Breast Cancer,2021-11-22,2
460,NCT05101096,"Phase 2,Phase 1",Gilead Sciences,,"Sacituzumab Govitecan-hziy,IMMU-132,Trodelvy™,GS-0132",Japan,143,"Advanced Solid Tumor,HR+/HER2- Metastatic Breast Cancer,Metastatic Urothelial Cancer,Metastatic Triple-Negative Breast Cancer",2021-10-20,2
461,NCT04617522,Phase 1,Gilead Sciences,,"Sacituzumab Govitecan-hziy,IMMU-132,GS-0132","United States,France",30,"Advanced or Metastatic Solid Tumor,Liver Failure",2021-04-06,1
462,NCT04454437,Phase 2,Gilead Sciences,,"Sacituzumab Govitecan-hziy,IMMU-132,Trodelvy™,GS-0132",China,80,Metastatic Triple-negative Breast Cancer,2020-10-23,2
463,NCT03995706,Phase 1,The University of Texas Health Science Center at San Antonio,Gilead Sciences,Sacituzumab Govitecan,United States,26,Glioblastoma,2019-07-17,1
464,NCT03964727,Phase 2,Gilead Sciences,,"Sacituzumab Govitecan-hziy,IMMU-132,GS-0132","Belgium,Spain,Canada,Hong Kong,Taiwan,Australia,United States,France",165,Metastatic Solid Tumor,2019-10-15,2
465,NCT03832361,Phase 2,Alessandro Santin,"ImmunoGen, Inc.","mirvetuximab soravtansine,IMGN853",United States,50,Endometrial Cancer,2020-07-15,2
466,NCT03677154,"Phase 2,Phase 1",Hoffmann-La Roche,,"Mosunetuzumab Subcutaneous (SC),Polatuzumab Vedotin,Mosunetuzumab Intravenous (IV),Tocilizumab","Poland,Israel,Korea, Republic of,Spain,Taiwan,United States",188,Diffuse Large B-cell Lymphoma,2019-05-23,2
467,NCT03329690,Phase 2,"Daiichi Sankyo Co., Ltd.",AstraZeneca,"Experimental product,Physician's Choice,Standard of Care,DS-8201a","Korea, Republic of,Japan",233,"Neoplasm, Gastrointestinal",2017-11-02,2
468,NCT03086239,Phase 1,AbbVie,,Rovalpituzumab tesirine,Japan,29,Small Cell Lung Cancer,2017-04-28,1
469,NCT02991911,Phase 1,MedImmune LLC,,"MEDI3726 Post-Chemo,MEDI3726 & Enzalutamide Combo,MEDI3726 Pre-Chemo","United States,Switzerland,United Kingdom",33,Metastatic Castration Resistant Prostate Cancer,2017-01-06,1
470,NCT02576548,Phase 1,MedImmune LLC,,MEDI4276,United States,47,HER2 Expressing Breast or Gastric/Stomach Cancers,2015-09-23,1
471,NCT06401824,Phase 2,Maastricht University Medical Center,Gilead Sciences,"Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab,sacituzumab govitecan; zirabev",Netherlands,25,"Brain Metastases, Adult,NSCLC Stage IV",2024-07-01,2
472,NCT02175433,Phase 1,"Astellas Pharma Global Development, Inc.",,AGS67E,"Canada,United States",71,"Relapsed Lymphoid Malignancy,Refractory Lymphoid Malignancy",2014-10-14,1
473,NCT02171143,Phase 1,"Astellas Pharma Global Development, Inc.",,"Placebo,ASP2409",United States,58,"Rheumatoid Arthritis,Pharmacokinetics of ASP2409",2012-04-01,1
474,NCT02150070,Phase 1,"Astellas Pharma Global Development, Inc.",,"ASP2408,Placebo",United States,32,"Pharmacokinetics of ASP2408,Healthy Subjects",2011-08-01,1
475,NCT02140125,Phase 1,Astellas Pharma Inc,,"ASP2408,Placebo",Japan,24,"Healthy,Pharmacokinetics of ASP2408",2012-08-01,1
476,NCT02125435,Phase 1,"Astellas Pharma Global Development, Inc.",,"ASP2408,Placebo",United States,65,"Pharmacokinetics of ASP2408,Healthy Subjects",2011-01-01,1
477,NCT02052375,Phase 1,"Astellas Pharma Global Development, Inc.",,"ASP2408,Placebo",United States,24,"Rheumatoid Arthritis,Pharmacokinetics of ASP2408",2012-06-01,1
478,NCT01901653,"Phase 2,Phase 1",Stemcentrx,,Rovalpituzumab tesirine (SC16LD6.5),United States,82,Recurrent Small Cell Lung Cancer,2013-07-01,2
479,NCT01741727,Phase 1,"AbbVie (prior sponsor, Abbott)",,ABT-414,"Canada,United States",57,Squamous Cell Tumors,2012-10-01,1
480,NCT01638936,"Phase 2,Phase 1",Biotest Pharmaceuticals Corporation,Biotest,"Indatuximab Ravtansine,BT062 , intravenous administration",United States,64,Multiple Myeloma,2012-07-03,2
481,NCT01485588,"Phase 2,Phase 1","Iconic Therapeutics, Inc.",,"hI-con1™ 60µl,hI-con1™ 300µl,hI-con1™ 150µl",United States,18,Neovascular Age-Related Macular Degeneration,2010-12-01,2
482,NCT01335958,Phase 1,"Genentech, Inc.",,DMUC5754A,United States,77,"Ovarian Cancer, Pancreatic Cancer",2011-04-01,1
483,NCT01001442,"Phase 2,Phase 1",Biotest Pharmaceuticals Corporation,Biotest,"BT062,Indatuximab ravtansine",United States,35,Multiple Myeloma,2010-08-01,2
484,NCT00944905,Phase 1,Bristol-Myers Squibb,,MDX-1203,United States,46,"Renal Cell Carcinoma,Non-hodgkin's Lymphoma",2009-07-01,1
485,NCT00071539,Phase 2,"Teva Branded Pharmaceutical Products R&D, Inc.",,"TP-38,TP38,immunotoxin",,56,Recurrent Glioblastoma Multiforme,2003-10-01,2
486,NCT00056537,Phase 1,Active Biotech AB,,"CD3; 5T4FabV18-SEA/E-120; naptumomab estafenatox; Anyara,ABR-217620","United States,United Kingdom,Norway",44,"Non-Small-Cell Lung Carcinoma,Pancreatic Cancer,Renal Cell Carcinoma",2003-04-01,1
487,NCT03000257,Phase 1,AbbVie,,"Venetoclax,Budigalimab,ABBV-181,Rovalpituzumab Tesirine","Austria,Belgium,United States,Spain,Canada,Taiwan,Australia,Finland,Japan,France",182,Advanced Solid Tumors,2016-12-14,1
488,NCT05520723,Phase 2,MedSIR,Gilead Sciences,"Trodelvy,Filgrastim,Imodium,Neupogen,Sacituzumab govitecan,Granulocyte Colony-Stimulating Factor,Loperamide",Spain,50,"Breast Cancer,Triple Negative Breast Cancer",2023-02-07,2
489,NCT06271837,Phase 2,AstraZeneca,"Daiichi Sankyo Co., Ltd.","T-DXd,DS-8201a,Trastuzumab deruxtecan",China,50,Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer),2024-02-18,2
490,NCT06172127,Phase 2,MedSIR,Hoffmann-La Roche,"Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection,Trastuzumab deruxtecan,PHESGO,T-DXd,Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection,Pertuzumab-Trastuzumab FDC SC",,165,HER2-positive Breast Cancer,2024-05-01,2
491,NCT06071871,Phase 2,"University College, London",Hoffmann-La Roche,"Gazyvaro,Glofitamab,Columvi,Polatuzumab vedotin,Obinutuzumab,Polivy",,99,Large B-cell Lymphoma,2024-04-30,2
492,NCT06058988,Phase 2,Memorial Sloan Kettering Cancer Center,AstraZeneca,"T-DXd,Trastuzumab deruxtecan",United States,30,"Brain Cancer,Leptomeningeal Metastasis,Recurrent Glioblastoma,Glioblastoma,Metastatic Cancer",2023-09-22,2
493,NCT05982678,Phase 2,The Netherlands Cancer Institute,"AstraZeneca,Daiichi Sankyo",Trastuzumab deruxtecan,Netherlands,72,HER2-positive Breast Cancer,2024-05-02,2
494,NCT05957757,Phase 2,RenJi Hospital,"BeiGene,RemeGen Co., Ltd.","Disitamab Vedotin,Tislelizumab,RC48",China,20,"HER2,Non-Muscle Invasive Bladder Cancer",2023-08-05,2
495,NCT05795101,Phase 2,"Filipa Lynce, MD","AstraZeneca,Daiichi Sankyo","Enhertu,Durvalumab,Trastuzumab deruxtecan",United States,63,"Breast Cancer,HER2 Low Breast Adenocarcinoma,HER2-positive Breast Cancer,Inflammatory Breast Cancer Stage III,Invasive Breast Cancer",2023-05-04,2
496,NCT05765851,Phase 1,Daiichi Sankyo,AstraZeneca,"Enhertu®,T-DXd,DS-1103a,DS-8201a (trastuzumab derextecan)","Canada,France,United States,Spain",78,"Breast Cancer,Advanced Solid Tumor",2023-05-30,1
497,NCT05744375,Phase 2,Spanish Breast Cancer Research Group,AstraZeneca,"Enhertu,Trastuzumab deruxtecan",Spain,41,"Metastatic Breast Cancer,Locally Advanced Breast Cancer",2023-09-28,2
498,NCT05704829,Phase 2,West German Study Group,AstraZeneca,"ENHERTU,Standard-of-Care,Chemotherapy+T+P,Trastuzumab deruxtecan",Germany,402,HER2-positive Early Breast Cancer,2023-12-01,2
499,NCT05633979,Phase 1,M.D. Anderson Cancer Center,Daiichi Sankyo,"Valemetostat,Trastuzumab deruxtecan",United States,37,Breast Cancer,2023-02-09,1
500,NCT05246514,Phase 2,AstraZeneca,Daiichi Sankyo,"T-DXd, DS-8201a,Trastuzumab deruxtecan",China,72,HER2-mutant Non-Small Cell Lung Cancer,2022-07-13,2
501,NCT05034887,Phase 2,National Cancer Center Hospital East,"Daiichi Sankyo Co., Ltd.","Trastuzumab Deruxtecan (T-DXd),DS-8201a",Japan,37,"Gastroesophageal Junction Adenocarcinoma,Gastric Adenocarcinoma",2022-01-31,2
502,NCT01829711,Phase 3,MedImmune LLC,,"Moxetumomab pasudotox,IV Bag Protectant for Moxetumomab pasudotox","Germany,Serbia,Belgium,Poland,Israel,Italy,United States,Spain,Canada,Norway,Czechia,Ireland,United Kingdom,France",80,"Leukemia, Hairy Cell",2013-04-29,3
503,NCT04989816,Phase 2,AstraZeneca,"Daiichi Sankyo Co., Ltd.","DS8201a; AZD4552; T-DXd,Trastuzumab Deruxtecan",China,95,Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,2021-08-20,2
504,NCT04986579,Phase 2,Dana-Farber Cancer Institute,"AstraZeneca,Gilead Sciences,Daiichi Sankyo,Paxman Coolers Limited,Eisai Inc.","Eribulin,Trodelvy,Enhertu,Trastuzumab deruxtecan,Scalp Cooling Cap,Paxman Scalp Cooling System,IMMU-132,Sacituzumab govitecan,DS-8201a,Halaven",United States,120,"Metastatic Breast Cancer,Chemotherapy-induced Alopecia",2021-10-07,2
505,NCT04970901,Phase 1,ADC Therapeutics S.A.,,"Polatuzumab Vedotin,Mosunetuzumab,Glofitamab,ADCT-402,Loncastuximab Tesirine,Obinutuzumab,ZYNLONTA","Belgium,Italy,Spain,Czechia,United States,United Kingdom",200,"Refractory B-Cell Non-Hodgkin Lymphoma,B-Cell Non-Hodgkin Lymphoma,Relapsed B-Cell Non-Hodgkin Lymphoma",2022-06-17,1
506,NCT04784715,Phase 3,AstraZeneca,Daiichi Sankyo,"Pertuzumab,Trastuzumab,Placebo,DS-8201a; T-DXd,Trastuzumab deruxtecan,Taxane","Brazil,Hungary,Belgium,India,Peru,Saudi Arabia,Israel,Italy,Taiwan,Denmark,United Kingdom,Romania,Mexico,China,Argentina,United States,Sweden,Japan,Russian Federation,Germany,Korea, Republic of,Spain,Canada,Philippines,Turkey,South Africa,France",1157,Breast Cancer; HER2-positive; Metastatic,2021-04-26,3
507,NCT04752059,Phase 2,Medical University of Vienna,Daiichi Sankyo,"Enhertu,Ds8201a,Trastuzumab deruxtecan",Austria,15,Breast Cancer Stage IV,2020-07-28,2
508,NCT04739761,Phase 3,AstraZeneca,Daiichi Sankyo,"fam-trastuzumab deruxtecan-nxki,Trastuzumab Deruxtecan","Switzerland,Germany,Poland,Belgium,Ireland,Japan,Portugal,Italy,United States,Spain,Canada,Netherlands,Norway,United Kingdom,Australia,Finland,Sweden,Denmark",506,Breast Cancer,2021-06-22,3
509,NCT04644237,Phase 2,Daiichi Sankyo,AstraZeneca,Trastuzumab deruxtecan,"Italy,Korea, Republic of,Spain,Canada,Netherlands,Taiwan,Australia,United States,Japan,France",152,Non-Small Cell Lung Cancer,2021-03-19,2
510,NCT04639219,Phase 2,AstraZeneca,"Daiichi Sankyo Co., Ltd.","DS-8201a (T-DXd),Trastuzumab deruxtecan","Belgium,Japan,Italy,Korea, Republic of,Spain,Canada,United States,Denmark,France",102,"Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast",2020-12-30,2
511,NCT04482309,Phase 2,AstraZeneca,"Daiichi Sankyo Co., Ltd.","T-DXd,DS-8201a,Trastuzumab deruxtecan","Russian Federation,Poland,Belgium,India,Italy,Thailand,Brazil,Spain,Canada,Netherlands,Korea, Republic of,United Kingdom,Taiwan,Czechia,Australia,United States,Japan",468,"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer,Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",2020-08-18,2
512,NCT04420598,Phase 2,MedSIR,Daiichi Sankyo,"(DS-8201a),Trastuzumab deruxtecan","Portugal,Spain",41,"Leptomeningeal Metastasis,HER2-positive Breast Cancer,Advanced Breast Cancer,Brain Metastases",2020-05-25,2
513,NCT01030536,"Phase 2,Phase 1",MedImmune LLC,,"CAT-8015 30 mcg/kg,CAT-8015 20 mcg/kg,CAT-8015 60 mcg/kg,CAT-8015 50 mcg/kg,CAT-8015 40 mcg/kg","United States,Poland",23,"Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia",2010-02-15,2
514,NCT00659425,Phase 1,MedImmune LLC,National Cancer Institute (NCI),CAT-8015 (Moxetumomab Pasudotox),"Canada,United States",57,"Non-Hodgkin's Lymphoma,Acute Lymphoblastic Leukemia",2008-09-01,1
515,NCT00586924,Phase 1,MedImmune LLC,Cambridge Antibody Technology,"CAT 8015 (Moxetumomab Pasudotox),Moxetumomab Pasudotox (CAT 8015)","United States,Poland",49,Hairy Cell Leukemia,2007-05-10,1
516,NCT06448013,Phase 1,M.D. Anderson Cancer Center,"Kura Oncology, Inc.","ABT-199,Mylotarg,Venetoclax,GDC-0199,Ziftomenib,Gemtuzumab ozogamicin,Gemtuzumab",United States,22,Acute Myeloid Leukemia,2024-11-29,1
517,NCT06254495,Phase 1,Seagen Inc.,,SGN-35C,United States,170,"Lymphoma, Large-Cell, Anaplastic,Lymphoma, T-Cell, Peripheral,Hodgkin Disease,Lymphoma, Large B-Cell, Diffuse",2024-05-31,1
518,NCT06186986,Phase 3,University Medical Center Groningen,Takeda,"Brentuximab vedotin,89ZR-Brentuximab",,20,Diffuse Large B-cell-lymphoma,2024-01-01,3
519,NCT06120504,Phase 1,Seagen Inc.,,SGN-35T,"United States,Spain",110,"Lymphoma, Large-Cell, Anaplastic,Lymphoma, T-Cell, Cutaneous,Lymphoma, Large B-Cell, Diffuse,Lymphoma, T-Cell, Peripheral,Hodgkin Disease,Lymphoma, Non-Hodgkin",2024-02-29,1
520,NCT05442554,Phase 4,Takeda,,"SGN-35,Brentuximab vedotin",China,10,T-Cell Lymphoma,2023-07-20,4
521,NCT05414500,Phase 1,University of Alabama at Birmingham,"Kyowa Kirin, Inc.,Seagen Inc.","Brentuximab vedotin,Mogamulizumab",United States,10,"Cutaneous T Cell Lymphoma,Mycosis Fungoides",2023-05-01,1
522,NCT05357794,Phase 2,M.D. Anderson Cancer Center,Seagen Inc.,"SGN-35,Adcetris,Brentuximab vedotin",United States,30,Mycosis Fungoides,2022-10-13,2
523,NCT05316246,Phase 2,Shanghai Zhongshan Hospital,"Takeda,BeiGene",Brentuximab Vedotin in Combination with Tislelizumab,,40,NK/T Cell Lymphoma Nos,2022-06-01,2
524,NCT04849910,"Phase 2,Phase 1",Vor Biopharma,,"VOR33,gemtuzumab ozogamicin,Mylotarg","Canada,United States",24,"Leukemia, Myeloid, Acute,Myelodysplastic Syndromes",2021-12-16,2
525,NCT01156753,Phase 2,Celldex Therapeutics,,"CDX-011,""Investigator's Choice"" chemotherapy",United States,120,Breast Cancer,2010-07-01,2
526,NCT04070768,Phase 1,John Quigley,"AbbVie,Pfizer","Venetoclax,Gemtuzumab Ozogamicin,GO",United States,18,Acute Myeloid Leukemia,2019-09-06,1
527,NCT00704158,"Phase 2,Phase 1",CuraGen Corporation,,CR011-vcMMAE,United States,42,Breast Cancer,2008-06-01,2
528,NCT03727750,Phase 4,Pfizer,,Gemtuzumab Ozogamicin,"Hungary,Poland,Spain,Canada,United States,United Kingdom",51,"Safety,ECG,Pharmacokinetics",2019-07-03,4
529,NCT03671018,"Phase 2,Phase 1",Hoffmann-La Roche,,"Mosunetuzumab (IV),Mosunetuzumab (SC),BTCT4465A,Rituximab,Polatuzumab vedotin,Tocilizumab","Belgium,Spain,Canada,United States,United Kingdom",422,B-cell Non-Hodgkin Lymphoma,2018-09-25,2
530,NCT03587844,Phase 2,Memorial Sloan Kettering Cancer Center,Seagen Inc.,brentuximab vedotin,United States,58,"Mycosis Fungoides,Lymphomatoid Papulosis,Sezary Syndrome",2018-07-03,2
531,NCT00412828,"Phase 2,Phase 1",CuraGen Corporation,,CR011-vcMMAE,United States,117,Unresectable Stage III or Stage IV Melanoma,2006-06-01,2
532,NCT03374332,Phase 2,Brown University,"The Miriam Hospital,Rhode Island Hospital,Pfizer","Mylotarg,Donor Leukocytes,Gemtuzumab Ozogamicin (GO)",United States,11,Acute Myeloid Leukemia,2019-12-31,2
533,NCT03264131,Phase 2,UNC Lineberger Comprehensive Cancer Center,Seagen Inc.,"CHEP,Brentuximab Vedotin",United States,16,"Adult T-Cell Leukemia/Lymphoma,Lymphatic Diseases,Lymphoma",2018-10-15,2
534,NCT03222492,"Phase 2,Phase 1",National Institute of Allergy and Infectious Diseases (NIAID),"Rho Federal Systems Division, Inc.,PPD,Seagen Inc.,Immune Tolerance Network (ITN)","Adcetris®,Placebo,Placebo for brentuximab vedotin,Brentuximab Vedotin",United States,17,"Scleroderma,Diffuse Cutaneous Systemic Sclerosis,dcSSc",2017-09-20,2
535,NCT03217643,Phase 2,Imagine Institute,Takeda,Brentuximab Vedotin,France,14,Enteropathy Associated T-cell Lymphoma,2018-02-07,2
536,NCT05834296,"Phase 2,Phase 1","Alzamend Neuro, Inc.","bioRASI, LLC","Placebo,ALZN002 (autologous DCs pulsed with E22W mutant peptide).",United States,30,Alzheimer Disease,2023-07-05,2
537,NCT02939014,Phase 2,Takeda,,Brentuximab Vedotin,China,39,"Lymphoma, Large-Cell, Anaplastic,Hodgkin Disease",2016-11-07,2
538,NCT02611323,"Phase 2,Phase 1",Hoffmann-La Roche,,"Venetoclax,Obinutuzumab,Rituximab,Polatuzumab Vedotin","Australia,United States,Italy",133,Non-Hodgkin's Lymphoma,2016-03-09,2
539,NCT02280785,Phase 2,Samsung Medical Center,"Millennium Pharmaceuticals, Inc.","Adcetris,Brentuximab vedotin","Korea, Republic of",33,Non-Hodgkin Lymphoma,2014-11-01,2
540,NCT02164006,Phase 1,"TG Therapeutics, Inc.",,"brentuximab vedotin: Adcetris,TGR-1202 + brentuximab vedotin",United States,16,Hodgkin's Lymphoma,2014-06-11,1
541,NCT01851200,Phase 2,Fondazione Michelangelo,"Millennium Pharmaceuticals, Inc.,Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","SGN-35,Brentuximab Vedotin,Adcetris",Italy,9,Germ Cell Cancer,2013-05-01,2
542,NCT01700751,Phase 1,Washington University School of Medicine,Seagen Inc.,"Adcetris,brentuximab vedotin",United States,17,"Leukemia, Acute Myeloid,Myelodysplastic Syndromes,Leukemia, Lymphoblastic,Acute",2013-02-25,1
543,NCT01691898,"Phase 2,Phase 1","Genentech, Inc.",,"GA101, Gazyva, Gazyvaro,Polatuzumab Vedotin,MabThera/Rituxan,Pinatuzumab Vedotin,DCDS4501A,Rituximab,Obinutuzumab,DCDT2980S","Germany,Italy,Canada,Netherlands,United States,France",231,"Follicular Lymphoma,Diffuse Large B-Cell Lymphoma",2012-09-27,2
544,NCT01596218,Phase 1,Massachusetts General Hospital,"Dana-Farber Cancer Institute,Seagen Inc.","SGN-35,Brentuximab Vedotin",United States,35,Graft vs. Host Disease,2012-07-01,1
545,NCT01578967,,UNC Lineberger Comprehensive Cancer Center,Seagen Inc.,"SGN-35,ABVD,Adcetris,Brentuximab vedotin",United States,41,"Hodgkin Lymphoma, Adult",2012-04-01,
546,NCT01508312,Phase 2,Memorial Sloan Kettering Cancer Center,"Hôpitaux Universitaires Henri Mondor, France,Seagen Inc.","brentuximab vedotin (SGN-35),Brentuximab Vedotin (SGN-35)",United States,46,Hodgkin's Lymphoma,2012-01-05,2
547,NCT01492088,"Phase 2,Phase 1","Millennium Pharmaceuticals, Inc.",,"SGN-35,ADCETRIS,Brentuximab vedotin","Germany,Mexico,Italy,Spain,Netherlands,United States,United Kingdom,France",36,"Relapsed or Refractory Anaplastic Large-cell Lymphoma,Relapsed or Refractory Hodgkin Lymphoma",2012-04-16,2
548,NCT01352520,Phase 2,M.D. Anderson Cancer Center,Seagen Inc.,"SGN-35,Brentuximab vedotin",United States,79,"Skin Lymphoma,Lymphomatoid Papulosis,Lymphoma, Primary Cutaneous Anaplastic Large Cell,Mycosis Fungoides,Cutaneous Lymphomas,Hematologic Disorder,Lymphoma,CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma",2011-06-01,2
549,NCT01290549,Phase 1,"Genentech, Inc.",,"Polatuzumab Vedotin,DCDS4501A,Rituximab","Canada,Netherlands,United States,France",95,"Non-Hodgkins Lymphoma,Chronic Lymphocytic Leukemia",2011-03-22,1
550,NCT01209130,Phase 1,"Genentech, Inc.",,"rituximab,DCDT2980S",United States,91,"Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia",2010-10-01,1
551,NCT00962767,Phase 3,Wyeth is now a wholly owned subsidiary of Pfizer,,"Arm A,Arm B,gemtuzumab ozogamicin,ATRA plus 6-MP and MTX",,168,"Leukemia, Myelocytic, Acute",2002-05-01,3
552,NCT00860639,Phase 3,Nantes University Hospital,"Chugai Pharmaceutical,French Innovative Leukemia Organisation","gemtuzumab ozogamycin (MYLOTARG ®),gemtuzumab ozogamycin",France,327,Acute Myeloid Leukemia,2007-10-01,3
553,NCT00304447,Phase 4,Wyeth is now a wholly owned subsidiary of Pfizer,,Mylotarg,,30,"Leukemia, Myelocytic, Acute,Infusions, Intravenous",2002-04-01,4
554,NCT00233909,"Phase 2,Phase 1",Kanisa Pharmaceuticals,,"gemtuzumab ozogamicin,Zosuquidar",,55,"Leukemia, Myeloid",2005-10-01,2
555,NCT00003673,Phase 2,Pfizer,,"chemotherapy,gemtuzumab ozogamicin",United States,55,Leukemia,1998-03-01,2
556,NCT00003131,Phase 2,Pfizer,,"chemotherapy,gemtuzumab ozogamicin",United States,55,Leukemia,1997-02-01,2
557,NCT00079755,Phase 2,Seagen Inc.,,SGN-30 (anti-CD30 mAb),United States,80,Anaplastic Large-Cell Lymphoma,2004-02-01,2
558,NCT00017589,Phase 2,Genta Incorporated,,"oblimersen sodium,gemtuzumab ozogamicin",United States,,Leukemia,2000-12-01,2
559,NCT00044733,Phase 2,Wyeth is now a wholly owned subsidiary of Pfizer,,Mylotarg (gemtuzumab ozogamicin) Injection,United States,38,Acute Myelogenous Leukemia,2000-03-01,2
560,NCT00037583,Phase 2,Wyeth is now a wholly owned subsidiary of Pfizer,,Gemtuzumab Ozogamicin,,69,Acute Myeloid Leukemia,,2
561,NCT05687032,Phase 4,Pfizer,,"inotuzumab ozogamicin,Besponsa",China,44,Acute Lymphoblastic Leukemia,2023-02-24,4
562,NCT02423928,Phase 1,Alden Cancer Therapy II,"Norwegian Radium Hospital,Haukeland University Hospital","Sendoxan,Yervoy,ipilimumab,ACT2001,Dendritic cell based cryoimmunotherapy,Cyclophosphamide",Norway,18,Prostate Cancer,2015-05-01,1
563,NCT04553770,Phase 2,Jonsson Comprehensive Cancer Center,"Daiichi Sankyo Co., Ltd.,Translational Research in Oncology-U.S","Enhertu,WHO 10516,ZD-1033,Anastrazole,ICI-D1033,DS-8201,Therapeutic Conventional Surgery,Arimidex,Anastrozole,Fam-trastuzumab Deruxtecan-nxki,ICI D1033,DS-8201a,Trastuzumab Deruxtecan",United States,88,"Stage IIB Breast Cancer,Early-stage Breast Cancer,Stage III Breast Cancer,Stage IIA Breast Cancer,Invasive Breast Cancer,Hormone Receptor Positive Breast Carcinoma,Stage II Breast Cancer",2020-10-09,2
564,NCT03983954,Phase 1,NeoTX Therapeutics Ltd.,AstraZeneca,"Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736),Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)",Israel,60,"Colorectal Cancer Metastatic,GastroEsophageal Cancer,Cervical Squamous Cell Carcinoma,Urothelial Cancer,Hepatocellular Carcinoma,Renal Cell Carcinoma,Head and Neck Squamous Cell Carcinoma,Endometrial Cancer,Pancreatic Adenocarcinoma,Ovarian Cancer,Prostate Cancer,Bladder Cancer,Triple Negative Breast Cancer,NSCL2 Gene Mutation,NSCLC,ER+ Breast Cancer,Melanoma,HER2-negative Breast Cancer,Mesothelioma",2019-10-10,1
565,NCT00346385,Phase 1,"ImmunoGen, Inc.",,"IMGN901,BB-10901","United States,United Kingdom",97,"Ovarian Cancer,SCLC,Merkel Cell Carcinoma",2002-03-01,1
566,NCT00346255,Phase 1,"ImmunoGen, Inc.",,"IMGN901,BB-10901","United States,Argentina",37,Multiple Myeloma,2005-04-01,1
567,NCT00065429,"Phase 2,Phase 1","ImmunoGen, Inc.",,BB-10901,United States,64,Small Cell Lung Cancer,2003-04-01,2
568,NCT01363297,Phase 2,Pfizer,UCB Pharma,"CMC-544,Inotuzumab Ozogamicin",United States,72,Acute Lymphocytic Leukemia,2011-08-01,2
569,NCT00868608,Phase 2,Pfizer,UCB Pharma,"inotuzumab ozogamicin,Inotuzumab Ozogamicin (CMC-544)","Germany,Hungary,Belgium,Korea, Republic of,Netherlands,Hong Kong,Singapore,United States,Japan",81,Lymphoma,2009-07-30,2
570,NCT00717925,Phase 1,Wyeth is now a wholly owned subsidiary of Pfizer,,Inotuzumab Ozogamicin (CMC-544),,13,"Lymphoma, B-Cell",2007-03-01,1
571,NCT06155383,Phase 2,"RemeGen Co., Ltd.",,"Disitamab Vedotin,oxaliplatin,JS001,Toripalimab,RC48,Capecitabine",China,90,"Gastric Cancer,Gastroesophageal Junction Adenocarcinoma",2023-11-27,2
572,NCT00073749,Phase 1,Pfizer,,Inotuzumab ozogamicin [CMC-544],"Germany,Belgium,Spain,United States,Switzerland,United Kingdom,France",79,"Lymphoma, B-Cell",2003-08-01,1
573,NCT05089734,Phase 3,Gilead Sciences,,"Docetaxel,Sacituzumab Govitecan-hziy (SG),IMMU-132,GS-0132","Poland,Brazil,Belgium,Israel,Italy,Netherlands,United Kingdom,Mexico,Australia,United States,Japan,Germany,Puerto Rico,Austria,Portugal,Spain,Canada,Greece,Turkey,France",603,Non-Small Cell Lung Cancer,2021-11-17,3
574,NCT05006794,Phase 1,Gilead Sciences,,"GS-9716,Docetaxel,sacituzumab govitecan-hziy","Israel,United States",195,Solid Malignancies,2021-09-15,1
575,NCT01134575,Phase 2,M.D. Anderson Cancer Center,Wyeth is now a wholly owned subsidiary of Pfizer,"rituxan,CMC-544 (Inotuzumab Ozogamycin),Rituximab",United States,90,Acute Lymphoblastic Leukemia,2010-06-04,2
576,NCT00867087,Phase 2,Pfizer,UCB Pharma,"rituximab,inotuzumab ozogamicin (CMC-544),cmc-544","Germany,Korea, Republic of,Singapore,United States,United Kingdom,France",64,"Lymphoma, B-Cell",2009-06-08,2
577,NCT00724971,Phase 1,Pfizer,,"Rituximab (Rituxan),Inotuzumab Ozogamicin (CMC-544)",Japan,10,"Lymphoma, B-Cell",2008-07-04,1
578,NCT06221748,"Phase 3,Phase 2","RemeGen Co., Ltd.",,"AK104, Cadonilimab Injection,Paclitaxel Injection,Disitamab Vedotin Injection,Cadonilimab Injection,DV,RC48",China,90,"Gastric Cancer,Gastroesophageal Junction Adenocarcinoma",2024-02-22,3
579,NCT06081244,Phase 2,West German Study Group,"Merck Sharp & Dohme LLC,Gilead Sciences","Pembrolizumab,Sacituzumab govitecan,Trodelvy,Keytruda",,348,Triple Negative Breast Cancer,2024-04-01,2
580,NCT00299494,"Phase 2,Phase 1",Pfizer,UCB Pharma,"inotuzumab ozogamicin,CMC-544,Rituximab","Germany,Belgium,Poland,Italy,Korea, Republic of,Spain,Netherlands,Hong Kong,Australia,United States,Switzerland,United Kingdom,France",119,B-Cell Lymphoma,2006-05-04,2
581,NCT05675579,Phase 2,M.D. Anderson Cancer Center,Gilead Sciences,"KEYTRUDA®,Sacituzumab Govitecan,Pembrolizumab,(IMMU-132) Immunomedics",United States,25,Breast Cancer,2023-05-23,2
582,NCT05480384,Phase 2,Brown University,AstraZeneca,"ENHERTU,OPDIVO,Nivolumab,Trastuzumab deruxtecan",United States,25,"HER-2 Protein Overexpression,Esophageal Adenocarcinoma,Gastroesophageal-junction Cancer,Esophageal Cancer",2023-07-14,2
583,NCT02590263,"Phase 2,Phase 1",AbbVie,,"Temozolomide,Whole Brain Radiation,ABT-414,Mafodotin,Depatuxizumab",Japan,53,"Glioblastoma Multiforme,Malignant Glioma",2015-08-24,2
584,NCT05186974,Phase 2,Gilead Sciences,Merck Sharp & Dohme LLC,"Paraplatin®,Carboplatin,KEYTRUDA®,Cisplatin,Pembrolizumab,GS-0132,Sacituzumab Govitecan-hziy (SG),IMMU-132,Platinol®","Germany,Italy,Korea, Republic of,Spain,Canada,Hong Kong,Taiwan,Malaysia,Australia,United States,United Kingdom,France",193,Non-small Cell Lung Cancer,2022-05-30,2
585,NCT04863885,"Phase 2,Phase 1",H. Lee Moffitt Cancer Center and Research Institute,"Bristol-Myers Squibb,Gilead Sciences","Trodelvy,Ipilimumab,Opdivo,Nivolumab,Yervoy,Sacituzumab govitecan",United States,46,Metastatic Urothelial Carcinoma,2021-04-30,2
586,NCT04794699,Phase 1,IDEAYA Biosciences,,"Paclitaxel,Docetaxel,Sacituzumab govitecan,IDE397","Germany,Korea, Republic of,Spain,Taiwan,Australia,United States,France",180,Solid Tumor,2021-04-14,1
587,NCT01800695,Phase 1,AbbVie,,"ABT-414,Temozolomide,Depatuxizumab Mafodotin,Whole Brain Radiation",,202,Glioblastoma Multiforme,2013-04-02,1
588,NCT04527991,Phase 3,Gilead Sciences,,"Vinflunine,Javlor ®,GS-0132,Paclitaxel,Docetaxel,IMMU-132,Taxotere®,Sacituzumab Govitecan-hziy,Taxol®,Trodelvy™","Georgia,Belgium,Israel,Italy,Taiwan,United Kingdom,China,Hong Kong,Singapore,Australia,Ireland,Bulgaria,Switzerland,Sweden,United States,Germany,Puerto Rico,Austria,Portugal,Korea, Republic of,Croatia,Canada,Spain,Greece,Turkey,Czechia,France",696,Locally Advanced or Metastatic Unresectable Urothelial Cancer,2021-01-13,3
589,NCT04468061,Phase 2,Dana-Farber Cancer Institute,"Merck Sharp & Dohme LLC,Gilead Sciences","Trodelvy,Pembrolizumab,IMMU-132,Sacituzumab Govitecan,Keytruda",United States,110,"Breast Cancer,Triple Negative Breast Cancer,PD-L1 Negative",2020-07-20,2
590,NCT04448886,Phase 2,"Ana C Garrido-Castro, MD","Merck Sharp & Dohme LLC,Gilead Sciences","Pembrolizumab,Sacituzumab Govitecan,TRODELVY,Keytruda",United States,110,"HER2-negative Breast Cancer,Invasive Breast Cancer,Metastatic Breast Cancer,HR-Positive Breast Cancer",2020-09-23,2
591,NCT04230109,Phase 2,Massachusetts General Hospital,Gilead Sciences,"Sacituzumab Govitecan,Pembrolizumab,IMMU-132",United States,260,"PR-Negative Breast Cancer,ER-Negative Breast Cancer,Triple Negative Breast Cancer,Invasive Breast Cancer,HER2-negative Breast Cancer",2020-07-14,2
592,NCT06467357,Phase 3,AstraZeneca,"Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo","DS-8201a; T-DXd,Rilvegostomig,Cisplatin,Agilent HercepTest™ mAb pharmDx,Durvalumab,Trastuzumab deruxtecan,Ventana PD-L1 SP263 assay,Gemcitabine","Germany,Austria,Belgium,Korea, Republic of,Brazil,Canada,Netherlands,Taiwan,Japan",620,Biliary Tract Cancer,2024-06-26,3
593,NCT03533283,"Phase 2,Phase 1",Hoffmann-La Roche,,"Polatuzumab Vedotin,Atezolizumab,Glofitamab,RO7082859,Actemra,89Zr-Df-IAB22M2C,Obinutuzumab,Tocilizumab","Belgium,Israel,Italy,Spain,Denmark,United States,United Kingdom",280,Non-Hodgkins Lymphoma,2018-05-08,2
594,NCT03310957,"Phase 2,Phase 1",Seagen Inc.,Merck Sharp & Dohme LLC,"KEYTRUDA®,Pembrolizumab,LV,ladiratuzumab vedotin,SGN-LIV1A","Germany,United States,Korea, Republic of,Spain",186,Triple Negative Breast Neoplasms,2018-02-27,2
595,NCT00132379,Phase 1,Active Biotech AB,,"CD3; 5T4FabV18-SEA/E-120; naptumomab estafenatox; Anyara,ABR-217620,Taxotere,docetaxel","Russian Federation,United States,Denmark",13,"Carcinoma, Non-Small-Cell Lung",2005-11-01,1
596,NCT02696642,Phase 1,Bayer,,Anetumab ravtansine (BAY94-9343),"Moldova, Republic of,France",54,Neoplasms,2016-04-14,1
597,NCT05417594,"Phase 2,Phase 1",AstraZeneca,,"Temozolomide,[11C]AZ1419 3391,AZD9574,Trastuzumab Deruxtecan (T-DXd),Datopotamab Deruxtecan (Dato-DXd)","Germany,Korea, Republic of,Spain,Australia,United States,Sweden,United Kingdom",490,Advanced Solid Malignancies,2022-08-04,2
598,NCT02610140,Phase 2,Bayer,ImmunoGen and MorphoSys,"Vinorelbine,Anetumab ravtansine (BAY94-9343)","Russian Federation,Poland,Belgium,United States,Italy,Korea, Republic of,Spain,Canada,Netherlands,Turkey,Australia,Finland,United Kingdom,France",248,Mesothelioma,2015-12-03,2
599,NCT04880863,Phase 2,NeoTX Therapeutics Ltd.,Translational Drug Development,"ABR-217620,Anyara,Gazyva,Docetaxel,Obinutuzumab,Taxotere,NAP (Naptumomab estafenatox)",United States,38,Non-small Cell Lung Cancer,2021-10-26,2
600,NCT04609566,Phase 2,Seagen Inc.,Merck Sharp & Dohme LLC,"pembrolizumab,KEYTRUDA®,ADCETRIS,brentuximab vedotin","Canada,United States",140,"Melanoma,Squamous Cell Carcinoma of the Head and Neck,Non-small Cell Lung Cancer",2021-01-26,2
601,NCT04539938,Phase 2,Seagen Inc.,,"TUKYSA, ARRY-380, ONT-380,tucatinib,T-DXd, Enhertu, DS-8201,trastuzumab deruxtecan",United States,70,HER2 Positive Breast Cancer,2020-12-01,2
602,NCT01609556,Phase 1,"ImmunoGen, Inc.",,"Mirvetuximab soravtansine,IMGN853","Canada,United States",206,Tumors,2012-06-28,1
603,NCT02729896,"Phase 2,Phase 1",Hoffmann-La Roche,,"Atezolizumab [TECENTRIQ],Obinutuzumab,Rituximab,Polatuzumab Vedotin","Germany,United States,Poland",36,Lymphoma,2016-11-09,2
604,NCT02684292,Phase 3,Merck Sharp & Dohme LLC,,"MK-3475,KEYTRUDA®,brentuximab vedotin,ADCETRIS®,pembrolizumab",,304,Hodgkin Lymphoma,2016-05-23,3
605,NCT02600897,"Phase 2,Phase 1",Hoffmann-La Roche,,"Polatuzumab Vedotin,Obinutuzumab,Rituximab,Lenalidomide","United States,United Kingdom,Spain",114,"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",2016-03-24,2
606,NCT02581631,"Phase 2,Phase 1",Bristol-Myers Squibb,Seagen Inc.,"Brentuximab Vedotin,Nivolumab","Italy,Spain,Canada,United States,United Kingdom,France",145,Non-Hodgkin's Disease,2016-02-11,2
607,NCT05171647,Phase 3,Hoffmann-La Roche,,"Mosunetuzumab,Oxaliplatin,Rituximab,Polatuzumab vedotin,Gemcitabine,Tocilizumab","Russian Federation,China,Mexico,Peru,Israel,Argentina,Thailand,Brazil,Korea, Republic of,Canada,Turkey,New Zealand,United States,Japan",222,Non-Hodgkin Lymphoma,2022-04-25,3
608,NCT05097599,Phase 2,Strata Oncology,"Merck Sharp & Dohme LLC,Gilead Sciences,Pfizer","encorafenib + binimetinib,lorlatinib,axitinib,talazoparib,sacituzumab govitecan",United States,700,"Cancer,Advanced Solid Tumor",2021-11-19,2
609,NCT02429375,"Phase 2,Phase 1",Memorial Sloan Kettering Cancer Center,MethylGene Inc.,"SGN-35,Mocetinostat Plus Brentuximab Vedotin,MGCD0103",United States,7,Hodgkin Lymphoma,2015-04-22,2
610,NCT04958785,Phase 2,Gilead Sciences,,"Nab-Paclitaxel,Trodelvy®,Magrolimab,GS-0132,Paclitaxel,Abraxane,Sacituzumab Govitecan-hziy,Taxol®,GS-4721","Korea, Republic of,Hong Kong,Taiwan,Australia,United States,United Kingdom",92,Triple-Negative Breast Cancer,2021-12-14,2
611,NCT02086604,Phase 1,Washington University School of Medicine,"Seagen Inc.,Celgene","Adcetris®,Revlimid®,Brentuximab vedotin,Lenalidomide",United States,37,"Lymphoma, Large B-Cell, Diffuse",2014-09-18,1
612,NCT04733118,Phase 2,MedSIR,Hoffmann-La Roche,"Trastuzumab and Pertuzumab (FDC SC) and T-DM1,Phesgo,Trastuzumab emtansine,Kadcyla","Germany,Hungary,Italy,Spain,Bulgaria",393,Early Breast Cancer,2021-08-05,2
613,NCT04622319,Phase 3,Daiichi Sankyo,"AstraZeneca,NSABP Foundation Inc,Spanish Breast Cancer Research Group (SOLTI),German Breast Group","T-DM1,Trastuzumab deruxtecan (T-DXd),DS-8201a,Trastuzumab emtansine (T-DM1)","Poland,Brazil,Belgium,Peru,Israel,Italy,Netherlands,Taiwan,Denmark,United Kingdom,Romania,Mexico,China,Argentina,Hong Kong,Singapore,Australia,Ireland,United States,Japan,Russian Federation,Germany,Portugal,Korea, Republic of,Spain,Canada,Chile,Greece,Turkey,Czechia,France",1600,"Residual Invasive Breast Cancer,HER2-Positive Primary Breast Cancer",2020-12-04,3
614,NCT04404283,Phase 3,Seagen Inc.,,"Placebo,Brentuximab vedotin,Rituximab,Lenalidomide","Germany,Poland,Belgium,Italy,Korea, Republic of,Spain,Canada,Netherlands,United Kingdom,Taiwan,Czechia,Australia,United States,Switzerland,Denmark,France",240,Diffuse Large B-cell Lymphoma,2020-08-20,3
615,NCT04182204,Phase 3,Hoffmann-La Roche,,"Polatuzumab Vedotin,Oxaliplatin,Mabthera; Rituxan,Rituximab,Gemcitabine","Germany,China,Mexico,India,United States,Italy,Korea, Republic of,Brazil,Finland,Canada,Spain,Greece,Turkey,Ireland,United Kingdom,France",270,Diffuse Large B-Cell Lymphoma,2020-02-07,3
616,NCT03742102,"Phase 2,Phase 1",AstraZeneca,,"Capivasertib,MEDI4736,AZD5363,MEDI9447,Durvalumab,Trastuzumab deruxtecan,Paclitaxel,Oleclumab,Dato-DXd; DS-1062a,DS-8201a,Datopotamab deruxtecan","Poland,Korea, Republic of,Canada,Taiwan,United States,United Kingdom",240,Triple Negative Breast Neoplasms,2018-12-21,2
617,NCT06324357,"Phase 2,Phase 1",Boehringer Ingelheim,,"Trastuzumab emtansine,T-DXd; Enhertu®,BI 1810631,T-DM1; Kadcyla®,Trastuzumab deruxtecan,Zongertinib",United States,240,"Esophageal Adenocarcinoma,Metastatic Gastric Adenocarcinoma,Metastatic Breast Cancer,Gastroesophageal Junction Adenocarcinoma",2024-05-23,2
618,NCT06313086,Phase 3,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,"T -DM1,DP303c,trastuzumab emtansine",China,442,HER2-positive Breast Cancer,2024-03-13,3
619,NCT06126640,Phase 3,"Jiangsu HengRui Medicine Co., Ltd.",,"SHR-A1811,Trastuzumab Emtansine",,1200,HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy,2023-11-01,3
620,NCT05904106,Phase 2,Technische Universität Dresden,"AbbVie,University Hospital Heidelberg","Venetoclax plus Azacitidine,standard of care chemotherapy plus gemtuzumab ozogamicin",Germany,146,Acute Myeloid Leukemia,2023-08-01,2
621,NCT05840211,Phase 3,Gilead Sciences,,"Xeloda®,Capecitabine,Abraxane®,GS-0132,Paclitaxel,IMMU-132,Nab-paclitaxel,Sacituzumab Govitecan-hziy,Taxol®,Trodelvy™","Poland,Brazil,Hungary,Belgium,Israel,Italy,Taiwan,United Kingdom,Mexico,China,Argentina,Hong Kong,Singapore,Australia,United States,Japan,Germany,Austria,Portugal,Korea, Republic of,Spain,Canada,Chile,Greece,Malaysia,Czechia,South Africa,France",654,"Stage IV Breast Cancer,Locally Advanced or Unresectable Metastatic Breast Cancer",2023-05-08,3
622,NCT05650879,Phase 1,Enliven Therapeutics,,"Trastuzumab emtansine,Enhertu,Kadcyla,T-DXd,Fam-Trastuzumab Deruxtecan-Nxki,T-DM1,ELVN-002","Italy,Korea, Republic of,Spain,Taiwan,Australia,United States,France",198,"HER2 Gene Mutation,HER2 Mutant Non-small Cell Lung Cancer,HER2-positive Metastatic Breast Cancer,HER2 Amplification",2023-03-20,1
623,NCT05633654,Phase 3,Gilead Sciences,"NSABP Foundation Inc,Alliance Foundation Trials, LLC.","Xeloda,KEYTRUDA®,Pembrolizumab,Capecitabine,GS-0132,Sacituzumab govitecan-hziy (SG),IMMU-132,Trodelvy™",United States,1514,Triple Negative Breast Cancer,2022-12-12,3
624,NCT05593094,Phase 1,Suzhou Zanrong Pharma Limited,,"ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c,ZN-A-1041 800mg BID,ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b,ZN-A-1041 50mg BID,ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c,ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c,ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b,ZN-A-1041 Enteric Capsules,ZN-A-1041 100mg BID,ZN-A-1041 1000mg BID,ZN-A-1041 200mg BID,ZN-A-1041 600mg BID,ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b,ZN-A-1041 400mg BID",United States,210,"HER2-positive Breast Cancer,Advanced Solid Tumors",2020-10-15,1
625,NCT05415215,Phase 3,Hoffmann-La Roche,,"Radiotherapy,Kadcyla®,Trastuzumab Emtansine,Perjeta®,Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC),Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf,Herceptin®,ado-trastuzumab emtansine,Pertuzumab IV,RG6264,RO0452317,Pertuzumab, Trastuzumab, and rHuPH20,Trastuzumab IV,RO5304020,T-DM1,Surgery,PHESGO®,RO7198574,RO4368451,Investigator's Choice of Chemotherapy","Costa Rica,Kenya,Mexico,India,Peru,Argentina,Korea, Republic of,Brazil,Spain,Canada,Singapore,Chile,Croatia,Bosnia and Herzegovina,Turkey,South Africa,Bulgaria",347,"Early Breast Cancer,Inflammatory Breast Cancer,Locally Advanced Breast Cancer",2022-07-05,3
626,NCT05382299,Phase 3,Gilead Sciences,,"Carboplatin,Abraxane®,GS-0132,Paclitaxel,IMMU-132,nab-Paclitaxel,Sacituzumab Govitecan-hziy,Gemcitabine,Trodelvy™","Poland,Turkey,Brazil,Hungary,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Romania,Mexico,China,Argentina,Hong Kong,Singapore,Australia,United States,Switzerland,Japan,Germany,Puerto Rico,Austria,Korea, Republic of,Spain,Canada,Chile,Malaysia,Czechia,South Africa,Slovakia,France",540,"Triple Negative Breast Cancer,PD-L1 Negative",2022-07-20,3
627,NCT05274048,Phase 1,Fox Chase Cancer Center,"National Comprehensive Cancer Network,Puma Biotechnology, Inc.","Neratinib Pill,Fam-Trastuzumab Deruxtecan-Nxki (TDxD)",United States,18,Gastric Cancer,2022-06-24,1
628,NCT02639091,Phase 1,Bayer,,"Cisplatin,BAY 94-9343,Pemetrexed","United States,Italy",36,Medical Oncology,2016-02-03,1
629,NCT02467946,"Phase 2,Phase 1",Centre Antoine Lacassagne,Millennium: The Takeda Oncology Company,"Adcetris-Levact,Bendamustine,Brentuximab Vedotin",France,60,"Clinical Efficacy,Safety",2016-01-14,2
630,NCT04893109,Phase 2,Dana-Farber Cancer Institute,"Genentech, Inc.","Kadcyla,trastuzumab-emtansine,Herceptin Hylecta,Paclitaxel,Onxal,Trastuzumab SC,Taxol,T-DM1",United States,500,"Breast Cancer,HER2-positive Breast Cancer",2021-06-16,2
631,NCT01565200,Phase 2,Jules Bordet Institute,Roche Pharma AG,"Zirconium 89 labelled trastuzumab,T-DM1,Trastuzumab-DM1,89Zr-trastuzumab","Netherlands,Belgium",90,HER-2 Positive Breast Cancer,2012-05-01,2
632,NCT03901339,Phase 3,Gilead Sciences,,"Vinorelbine,Eribulin,Capecitabine,GS-0132,IMMU-132,Sacituzumab Govitecan-hziy,Gemcitabine","Germany,Belgium,Italy,Spain,Canada,Netherlands,United States,United Kingdom,France",543,Metastatic Breast Cancer,2019-05-08,3
633,NCT03547973,Phase 2,Gilead Sciences,"Merck KGaA, Darmstadt, Germany","Carboplatin,KEYTRUDA®,Cisplatin,Pembrolizumab,Zimberelimab,Domvanalimab,BAVENCIO®,IMMU-132,Avelumab,Sacituzumab Govitecan-hziy,Gemcitabine,Trodelvy™","Germany,Italy,Korea, Republic of,Spain,Greece,Turkey,United States,United Kingdom,France",643,Metastatic Urothelial Cancer,2018-08-13,2
634,NCT00932373,Phase 1,"Genentech, Inc.",,trastuzumab-MCC-DM1,,54,Metastatic Breast Cancer,2006-04-01,1
635,NCT00928330,Phase 1,"Genentech, Inc.",,"Trastuzumab,trastuzumab-MCC-DM1,GDC-0941",United States,57,Metastatic Breast Cancer,2009-07-01,1
636,NCT03153163,Phase 1,Hoffmann-La Roche,,"Trastuzumab Emtansine,RO5304020",China,11,Breast Neoplasms,2017-06-20,1
637,NCT03102320,Phase 1,Bayer,"ImmunoGen, Inc.,MorphoSys AG","Cisplatin,Anetumab ravtansine (BAY94-9343),Gemcitabine","Belgium,Italy,Korea, Republic of,Spain,Canada,Netherlands,Singapore,Australia,United States,Switzerland,United Kingdom,France",173,Neoplasms,2017-05-26,1
638,NCT02999672,Phase 2,Hoffmann-La Roche,,"Trastuzumab Emtansine,Kadcyla","Netherlands,Slovakia,Italy,Spain",20,"Cholangiocellular Carcinoma,Pancreas Cancer,Bladder Cancer",2016-12-23,2
639,NCT02675829,Phase 2,Memorial Sloan Kettering Cancer Center,"Genentech, Inc.",ado-trastuzumab emtansine,United States,140,"Solid Tumor Cancers,Lung Cancer,Bladder Cancer,Urinary Tract Cancers",2016-02-01,2
640,NCT02658734,Phase 4,Hoffmann-La Roche,,Trastuzumab emtansine,India,70,"HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer",2016-11-01,4
641,NCT02616965,Phase 1,Fox Chase Cancer Center,"Celgene Corporation,Seagen Inc.","Romidepsin,Brentuximab vedotin",United States,16,Cutaneous T-cell Lymphoma (CTCL),2017-02-22,1
642,NCT02574455,Phase 3,Gilead Sciences,,"Vinorelbine,Eribulin,Xeloda,Trodelvy®,Capecitabine,Navelbine,IMMU-132,Gemzar,Sacituzumab govitecan,Gemcitabine,Halaven","Germany,Belgium,Spain,Canada,United States,United Kingdom,France",529,Breast Cancer,2017-11-07,3
643,NCT02420873,Phase 2,M.D. Anderson Cancer Center,"ImmunoGen, Inc.",Lorvotuzumab Mertansine (IMGN901),United States,9,Leukemia,2015-05-12,2
644,NCT02390427,Phase 1,"Otto Metzger, MD","Genentech, Inc.","Taselisib,Pertuzumab,Trastuzumab,Trastuzumab emtansine,Perjeta,Kadcyla,Paclitaxel,GCD-0032,Onxal,T-DM1,Taxol,Herceptin",United States,68,"Recurrent Breast Cancer,Metastatic Breast Cancer",2015-04-20,1
645,NCT02289833,Phase 2,Hoffmann-La Roche,,"Trastuzumab Emtansine,Kadcyla, T-DM1","Germany,Poland,Italy,Korea, Republic of,Spain,United States,Switzerland",49,Non-Small Cell Lung Cancer,2014-12-15,2
646,NCT02254018,Phase 1,Boehringer Ingelheim,,bivatuzumab mertansine,,31,Head and Neck Neoplasms,2002-09-01,1
647,NCT02254005,Phase 1,Boehringer Ingelheim,,bivatuzumab mertansine,,24,Breast Neoplasms,2002-10-01,1
648,NCT02131064,Phase 3,Hoffmann-La Roche,,"Trastuzumab,Pertuzumab,Carboplatin,Perjeta®, RO4368451,Herceptin®,Trastuzumab Emtansine,Docetaxel,Kadcyla®, RO5304020","Russian Federation,Germany,Ukraine,Belgium,Korea, Republic of,Spain,Canada,Taiwan,United States,France",444,Breast Neoplasms,2014-06-25,3
649,NCT01904903,Phase 2,Medstar Health Research Institute,"Genentech, Inc.","Trastuzumab,Pertuzumab,Perjeta,Kadcyla,Herceptin,Ado Trastuzumab Emtansine",United States,31,"HER2 Positive Breast Cancer,Left Ventricular Function Systolic Dysfunction",2013-10-01,2
650,NCT04379596,Phase 2,AstraZeneca,"Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo","Biological: Pembrolizumab,Trastuzumab,Fluorouracil (5-FU),Cisplatin,Pembrolizumab,Drug: Oxaliplatin,Biological: Trastuzumab,Biological: Durvalumab,MEDI5752,MEDI4736,Biological: Rilvegostomig,Rilvegostomig,Drug: Capecitabine,Capecitabine,Drug: Fluorouracil (5-FU),Biological: Volrustomig,Oxaliplatin,Trastuzumab deruxtecan,DS-8201a,Drug: Trastuzumab deruxtecan,AZD2936,Volrustomig,Durvalumab,Drug: Cisplatin","Russian Federation,Germany,Poland,China,Italy,Korea, Republic of,Brazil,Spain,Canada,Netherlands,United Kingdom,Taiwan,United States,Japan",413,Gastric Cancer,2020-05-05,2
651,NCT01772472,Phase 3,Hoffmann-La Roche,"NSABP Foundation Inc,German Breast Group","trastuzumab,trastuzumab emtansine","Brazil,Belgium,Peru,Israel,Italy,Taiwan,Guatemala,United Kingdom,Panama,Mexico,China,Argentina,Hong Kong,Colombia,Ireland,Switzerland,Sweden,United States,Germany,Serbia,Austria,Spain,Canada,Greece,Turkey,Czechia,South Africa,France",1487,Breast Cancer,2013-04-03,3
652,NCT01702571,Phase 3,Hoffmann-La Roche,,"Trastuzumab Emtansine,RO5304020, T-DM1, Kadcyla","Poland,Estonia,Brazil,Iceland,Dominican Republic,Slovenia,Hungary,Belgium,Peru,Italy,Netherlands,Taiwan,Guatemala,Denmark,United Kingdom,Luxembourg,Panama,Mexico,China,Argentina,Norway,Hong Kong,Australia,Ireland,Finland,Bulgaria,Venezuela,Sweden,Germany,Ecuador,Austria,Indonesia,Portugal,Korea, Republic of,Thailand,Croatia,Canada,United Arab Emirates,Spain,Greece,Turkey,Slovakia,France",2185,Breast Cancer,2012-11-27,3
653,NCT01513083,Phase 1,Hoffmann-La Roche,,trastuzumab emtansine,"Italy,Spain,Canada,United States,France",28,Breast Cancer,2012-02-01,1
654,NCT01419197,Phase 3,Hoffmann-La Roche,,"Kadcyla,Trastuzumab emtansine,T-DM1,Treatment of physician's choice","Poland,Brazil,Czech Republic,Hungary,Belgium,India,Israel,Italy,United Kingdom,Norway,Australia,United States,Sweden,Switzerland,Russian Federation,Germany,Korea, Republic of,Thailand,Spain,Canada,Slovakia,France",602,Breast Cancer,2011-09-01,3
655,NCT06486441,Phase 3,Gilead Sciences,"European Network of Gynaecological Oncological Trial Groups (ENGOT),GOG Foundation","Doxorubicin,Adriamycin,GS-0132,Paclitaxel,Sacituzumab govitecan-hziy,Taxol,Trodelvy™",,520,Endometrial Cancer,2024-09-01,3
656,NCT01196052,Phase 2,Hoffmann-La Roche,,"Trastuzumab emtansine,T-DM1","Russian Federation,Germany,Belgium,Italy,Korea, Republic of,Spain,United States,France",153,Breast Cancer,2010-10-01,2
657,NCT01120184,Phase 3,Hoffmann-La Roche,"Genentech, Inc.","paclitaxel,docetaxel,pertuzumab-placebo,trastuzumab emtansine,pertuzumab,trastuzumab [Herceptin]","Poland,Turkey,Brazil,Bosnia and Herzegovina,Hungary,Belgium,Peru,Italy,North Macedonia,Taiwan,Guatemala,Denmark,United Kingdom,Romania,Panama,Mexico,Bahamas,Argentina,New Zealand,Colombia,Australia,United States,Switzerland,Japan,Sweden,Russian Federation,Germany,Austria,Portugal,Korea, Republic of,Thailand,Spain,Canada,Greece,Philippines,Malaysia,Czechia,France",1095,Breast Cancer,2010-07-31,3
658,NCT03552471,Phase 1,Ohio State University Comprehensive Cancer Center,"ImmunoGen, Inc.,Clovis Oncology, Inc.","8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt,C0-338,Rucaparib Camsylate,Pharmacokinetic Study,Mirvetuximab Soravtansine,PHARMACOKINETIC,Rucaparib Phosphate,PK Study,Rubraca,M9346A-sulfo-SPDB-DM4,Laboratory Biomarker Analysis,IMGN853",United States,25,"Folate Receptor Alpha Positive,Recurrent Primary Peritoneal Carcinoma,Recurrent Ovarian Carcinoma,Recurrent Fallopian Tube Carcinoma,Recurrent Uterine Carcinosarcoma,Recurrent Uterine Corpus Carcinoma,BRCA1 Gene Mutation,Platinum Resistant Ovarian Cancer,Recurrent Uterine Serous Carcinoma,BRCA2 Gene Mutation",2018-07-12,1
659,NCT00991562,Phase 1,"ImmunoGen, Inc.",,"IMGN901,huN901-DM1,BB-10901",United States,50,Multiple Myeloma,2009-12-01,1
660,NCT00951665,"Phase 2,Phase 1","Genentech, Inc.",,"trastuzumab emtansine [Kadcyla],pertuzumab [Perjeta],paclitaxel",United States,107,Metastatic Breast Cancer,2009-08-01,2
661,NCT00943670,Phase 2,"Genentech, Inc.",,"PERJETA™,pertuzumab,trastuzumab-MCC-DM1,Trastuzumab emtansine [Kadcyla],T-DM1",,51,Metastatic Breast Cancer,2009-07-01,2
662,NCT00934856,"Phase 2,Phase 1",Hoffmann-La Roche,,"Docetaxel,Trastuzumab emtansine,T-DM1,Pertuzumab","France,United States,United Kingdom,Spain",98,Breast Cancer,2009-07-01,2
663,NCT00882102,Phase 2,M.D. Anderson Cancer Center,Eisai Inc.,"Decitabine,Mylotarg®,Gemtuzumab ozogamicin,Dacogen®",United States,43,"Myelodysplastic Syndrome,Acute Myelogenous Leukemia",2009-04-01,2
664,NCT00875979,"Phase 2,Phase 1",Hoffmann-La Roche,Roche Pharma AG,"Trastuzumab emtansine [Kadcyla] 3.6 mg/kg,Perjeta,Pertuzumab 420 mg,Trastuzumab emtansine [Kadcyla] 3.0 mg/kg,trastuzumab-MCC-DM1,T-DM1,trastuzumab-DM1","Germany,Belgium,Italy,Spain,Canada,United States,France",67,Metastatic Breast Cancer,2009-05-01,2
665,NCT03334617,Phase 2,AstraZeneca,,"Drug: cediranib,Drug: Oleclumab,Drug: Olaparib,Vistusertib,Drug: Durvalumab,Drug: trastuzumab deruxtecan,cediranib,Drug: Vistusertib,Drug: AZD9150,AZD6738 (ceralasertib) (240 mg or 160 mg),Drug: AZD6738,AZD6738 (ceralasertib) 7 days monotherapy,AZD9150,Drug: AZD6738 (ceralasertib),Olaparib,trastuzumab deruxtecan,AZD6738,Drug: AZD6738 (ceralasertib) 7 days monotherapy,Drug: AZD6738 (ceralasertib) (240 mg or 160 mg),AZD6738 (ceralasertib),Durvalumab,Oleclumab","Germany,Austria,Israel,Korea, Republic of,Spain,Canada,United States,France",531,Non-Small Cell Lung Cancer,2017-09-22,2
666,NCT00766116,"Phase 2,Phase 1","University of California, San Diego","Celgene Corporation,Pfizer","5-Azacitidine,Gemtuzumab ozogamicin,Vidaz,Mylotarg",United States,50,Acute Myeloid Leukemia,2005-07-01,2
667,NCT00679341,Phase 2,Hoffmann-La Roche,,"Trastuzumab,Taxotere,Docetaxel,trastuzumab-MCC-DM1,Trastuzumab emtansine [Kadcyla],trastuzumab-DM1,Herceptin,T-DM1",,137,Breast Cancer,2008-09-01,2
668,NCT00679211,Phase 2,"Genentech, Inc.",,"Trastuzumab-MCC-DM1,Trastuzumab emtansine [Kadcyla],T-DM1",,110,Metastatic Breast Cancer,2008-08-01,2
669,NCT00509769,Phase 2,"Genentech, Inc.",,"trastuzumab-MCC-DM1,Trastuzumab emtansine [Kadcyla],trastuzumab-DM1,T-DM1",United States,112,Metastatic Breast Cancer,2007-07-01,2
670,NCT03032107,Phase 1,Dana-Farber Cancer Institute,Merck Sharp & Dohme LLC,"Pembrolizumab,T-DM1,Keytruda,Trastuzumab emtansine",United States,27,Breast Cancer,2017-02-17,1
671,NCT02927769,Phase 2,Bristol-Myers Squibb,Seagen Inc.,"Opdivo,Nivolumab,BMS-936558,brentuximab vedotin,bendamustine","Germany,Poland,United States,Italy,Spain,Canada,Netherlands,Czechia,Ireland,United Kingdom,France",72,Hodgkin Disease,2017-03-28,2
672,NCT04873362,Phase 3,Hoffmann-La Roche,,"Trastuzumab,Placebo,Atezolizumab,Kadcyla, T-DM1, RO5304020,Trastuzumab Emtansine,Tecentriq, RO5541267, MPDL3280A,Herceptin","Poland,Brazil,Dominican Republic,Vietnam,Hungary,Belgium,India,Italy,Taiwan,Denmark,United Kingdom,Romania,Ukraine,Mexico,China,Argentina,New Zealand,Hong Kong,Singapore,Australia,Bulgaria,United States,Russian Federation,Germany,Kenya,Austria,Uganda,Portugal,Korea, Republic of,Thailand,Spain,Greece,Turkey,Czechia,South Africa,France",1150,Breast Cancer,2021-05-04,3
673,NCT04740918,Phase 3,Hoffmann-La Roche,,"Placebo,Atezolizumab,Kadcyla, T-DM1, RO5304020,Trastuzumab Emtansine,Tecentriq, RO5541267, MPDL3280A","Poland,Brazil,Slovenia,Italy,United Kingdom,China,Norway,Colombia,Australia,Finland,United States,Russian Federation,Portugal,Korea, Republic of,Croatia,Canada,Spain,Greece,Philippines,Turkey,France",96,Metastatic Breast Cancer,2021-06-07,3
674,NCT05673928,Phase 2,M.D. Anderson Cancer Center,"Genentech, Inc.,Seagen Inc.","Trastuzumab emtansine,Tucatinib,Kadcyla,Trastuzumab-MCC-DM1,ONT-380,ado-trastuzumab emtansine,T-DM1,ARRY-380",United States,30,"Brain Metastases,Metastatic Solid Tumor",2023-05-16,2
675,NCT02924883,Phase 2,Hoffmann-La Roche,,"Placebo,Trastuzumab emtansine,Atezolizumab,Kadcyla®, T-DM1, RO5304020,Tecentriq, RO5541267, MPDL3280A","Germany,Italy,Korea, Republic of,Spain,Canada,Taiwan,Australia,United States,United Kingdom",202,Metastatic Breast Cancer,2016-09-26,2
676,NCT05323955,Phase 2,"Carey Anders, M.D.",Seagen Inc.,"Trastuzumab,Pertuzumab,Perjeta,Tucatinib,Trastuzumab Emtansine (T-DM1),Tukysa,Herceptin",United States,48,"Brain Metastases,Advanced Breast Cancer,Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",2023-03-23,2
677,NCT02751918,Phase 1,Bayer,,"Anetumab ravtansine (BAY94-9343),Pegylated Liposomal Doxorubicin","Moldova, Republic of,United States,Spain,Belgium",65,Ovarian Neoplasms,2016-06-08,1
678,NCT05183035,Phase 3,"LLS PedAL Initiative, LLC","Roche-Genentech,AbbVie,Princess Maxima Center for Pediatric Oncology (European Sponsor),EuPAL","Gemtuzumab Ozogamicin,Fludarabine,Venetoclax,Cytarabine,Azacitidine","Switzerland,Austria,Belgium,Israel,Italy,Portugal,United States,Spain,Canada,Netherlands,Norway,Czechia,New Zealand,Australia,Finland,Sweden,Denmark,France",98,Acute Myeloid Leukemia,2022-10-01,3
679,NCT05048797,Phase 3,AstraZeneca,Daiichi Sankyo,"Carboplatin,DS-8201a; T-DXd,Cisplatin,Pembrolizumab,Pemetrexed,Trastuzumab Deruxtecan","Poland,Brazil,Belgium,India,Italy,Netherlands,Taiwan,Denmark,Mexico,China,Hong Kong,United States,Japan,Germany,Austria,Korea, Republic of,Spain,Canada,Turkey,France",450,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,2021-10-28,3
680,NCT04833114,Phase 3,GWT-TUD GmbH,Hoffmann-La Roche,"Polatuzumab Vedotin,Carboplatin,Mabthera,Ifosfamide,Etoposide","Germany,Austria,United Kingdom,Spain",334,"Refractory Diffuse Large B-Cell Lymphoma,Relapsed Diffuse Large B-cell Lymphoma",2021-04-30,3
681,NCT04457596,Phase 3,Alliance for Clinical Trials in Oncology,"Seagen Inc.,National Cancer Institute (NCI)","Questionnaire Administration,Tucatinib,Quality-of-Life Assessment,Trastuzumab Emtansine,Placebo Administration","Canada,United States,Puerto Rico",1031,"Prognostic Stage III Breast Cancer AJCC v8,Anatomic Stage IIIA Breast Cancer AJCC v8,Anatomic Stage III Breast Cancer AJCC v8,Anatomic Stage IIIB Breast Cancer AJCC v8,Synchronous Bilateral Breast Carcinoma,Prognostic Stage IIIC Breast Cancer AJCC v8,Prognostic Stage IA Breast Cancer AJCC v8,Multifocal Breast Carcinoma,Prognostic Stage I Breast Cancer AJCC v8,Anatomic Stage IIA Breast Cancer AJCC v8,Anatomic Stage IA Breast Cancer AJCC v8,Anatomic Stage IIB Breast Cancer AJCC v8,Prognostic Stage IIIA Breast Cancer AJCC v8,Prognostic Stage II Breast Cancer AJCC v8,HER2 Positive Breast Carcinoma,Invasive Breast Carcinoma,Prognostic Stage IB Breast Cancer AJCC v8,Anatomic Stage IIIC Breast Cancer AJCC v8,Prognostic Stage IIB Breast Cancer AJCC v8,Prognostic Stage IIA Breast Cancer AJCC v8,Prognostic Stage IIIB Breast Cancer AJCC v8,Anatomic Stage II Breast Cancer AJCC v8",2021-01-06,3
682,NCT01976169,Phase 1,University of Texas Southwestern Medical Center,"University of Pennsylvania,Pfizer","KADCYLA=T-DM1,PD-0332991 and T-DM1,Palbociclib=PD-0332991",United States,29,Advanced Breast Cancer,2014-01-24,1
683,NCT01562990,"Phase 2,Phase 1",The Lymphoma Academic Research Organisation,Pfizer,"Rituximab, CMC544, Gemcitabine and Oxaliplatine","France,Belgium",11,Diffuse Large B-Cell Lymphoma,2012-12-01,2
684,NCT06389006,Phase 2,"RemeGen Co., Ltd.",,"Disitamab Vedotin for Injection,Epirubicin,JS001,Toripalimab,RC48,CTX,Cyclophosphamide",China,79,Breast Cancer,2024-04-29,2
685,NCT06100705,Phase 2,Yale University,Dendreon,"Sipuleucel-T,Testosterone Cypionate,Provenge,DEPO-Testosterone",United States,26,Metastatic Castration-resistant Prostate Cancer,2023-12-20,2
686,NCT00781612,Phase 2,"Genentech, Inc.",Hoffmann-La Roche,"Trastuzumab,Pertuzumab,Perjeta,Atezolizumab,Kadcyla; T-DM1,Tecentriq,Paclitaxel,Docetaxel,Trastuzumab Emtansine,Herceptin","Poland,Brazil,Slovenia,Hungary,Belgium,Peru,Israel,Italy,North Macedonia,Taiwan,Guatemala,Denmark,United Kingdom,Panama,Mexico,China,New Zealand,Norway,Hong Kong,Singapore,Australia,Bulgaria,Switzerland,Japan,Sweden,United States,Russian Federation,Germany,Austria,Portugal,Korea, Republic of,Thailand,Croatia,Canada,Spain,Chile,Philippines,Czechia,France",720,Neoplasm Metastasis,2008-10-16,2
687,NCT05382286,Phase 3,Gilead Sciences,Merck Sharp & Dohme LLC,"Carboplatin,KEYTRUDA®,Pembrolizumab,Abraxane®,GS-0132,Paclitaxel,IMMU-132,nab-Paclitaxel,Gemzar,Sacituzumab Govitecan-hziy,Taxol®,Gemcitabine,Trodelvy™","Poland,Turkey,Brazil,Hungary,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Mexico,Argentina,Hong Kong,Singapore,Australia,United States,Switzerland,Japan,Germany,Puerto Rico,Austria,Korea, Republic of,Spain,Canada,Chile,Malaysia,Czechia,South Africa,France",440,"PD-L1 Positive,Triple Negative Breast Cancer",2022-07-25,3
688,NCT02686346,"Phase 2,Phase 1",The Lymphoma Academic Research Organisation,"Millennium Pharmaceuticals, Inc.","BV,SGN35,Brentuximab Vedotin,Ifosfamide,Carboplatine,Etoposide","France,Belgium",53,Hodgkin Disease,2016-03-01,2
689,NCT00037596,Phase 2,Wyeth is now a wholly owned subsidiary of Pfizer,,"cytarabine.,Gemtuzumab Ozogamicin",,,Acute Myeloid Leukemia,2000-08-01,2
690,NCT03869190,"Phase 2,Phase 1",Hoffmann-La Roche,"Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas","Enfortumab Vedotin,Atezolizumab,Cisplatin,Magrolimab (Hu5F9-G4),Sacituzumab Govitecan,Tiragolumab,Niraparib,Gemcitabine,Tocilizumab","Korea, Republic of,Spain,Greece,Taiwan,United States,United Kingdom,France",645,"Bladder Cancer,Urothelial Carcinoma",2019-06-01,2
691,NCT02505269,Phase 2,Massachusetts General Hospital,Seagen Inc.,"Doxorubicin,DTIC-Dome®,DIC,Adcetris,Rubex ®,Adriamycin,Imidazole Carboxamide,Dacarbazine,Brentuximab Vedotin,DTIC",United States,34,Hodgkin Lymphoma,2015-08-07,2
692,NCT04704934,Phase 3,Daiichi Sankyo,AstraZeneca,"CYRAMZA®,Trastuzumab deruxtecan,Paclitaxel,T-DXd,Drug: Paclitaxel,Ramucirumab,ENHERTU®,Drug: Trastuzumab deruxtecan,DS-8201a,Drug: Ramucirumab","Poland,Brazil,Hungary,Belgium,Israel,Italy,Taiwan,United Kingdom,Romania,Ukraine,China,Argentina,Hong Kong,Singapore,Ireland,Japan,Russian Federation,Germany,Portugal,Korea, Republic of,Spain,Chile,Turkey,France",490,"Gastric Cancer, Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma",2021-05-21,3
693,NCT04274426,Phase 2,AGO Research GmbH,,"Carboplatin,Mirvetuximab Soravtansine,Pegylated liposomal doxorubicin (PLD),Paclitaxel,Gemcitabine",Germany,136,"Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma",2021-10-13,2
694,NCT05922904,Phase 2,M.D. Anderson Cancer Center,"Merck Sharp & Dohme LLC,Seagen Inc.","DTIC-Dome®,Adcetris,Pembrolizumab,Adriamycin®,Rubex®,Brentuximab vedotin,SGN-35,Doxorubicin Hydrochloride,Dacarbazine,Adriamycin RDF™,Adriamycin PFS®",United States,50,Hodgkin Lymphoma,2023-12-14,2
695,NCT03839446,Phase 2,"Robert Redner, MD",Pfizer,mitoxantrone + etoposide + gemtuzumab ozogamicin,United States,16,Acute Myeloid Leukemia,2019-02-28,2
696,NCT05633667,Phase 2,Gilead Sciences,"Arcus Biosciences, Inc.","Carboplatin,Cisplatin,GS-0132,Paclitaxel,Docetaxel,GS-0154,Etrumadenant (ETRUMA),Nivolumab,GS-0122,Nab-paclitaxel,Domvanalimab (DOM),AB928,Zimberelimab (ZIM),AB154,Sacituzumab govitecan-hziy (SG),Pemetrexed,AB122,IMMU-132,GS-0928","Israel,Korea, Republic of,Hong Kong,Taiwan,United States,United Kingdom",397,"Resectable Non-Small-Cell Lung Cancer,Lung Cancer,Advanced or Metastatic Non-Small-Cell Lung Cancer",2023-03-16,2
697,NCT05558124,Phase 1,H. Lee Moffitt Cancer Center and Research Institute,Jazz Pharmaceuticals,"CPX-351,Gemtuzumab Ozogamicin,daunorubicin-cytarabine,Vyxeos,Mylotarg",United States,18,Acute Myeloid Leukemia,2023-02-16,1
698,NCT04685616,Phase 3,"University College, London","Australasian Leukaemia and Lymphoma Group,European Organisation for Research and Treatment of Cancer - EORTC,Canadian Cancer Trials Group,Takeda,University of Miami,Seagen Inc.","Doxorubicin,G-CSF,Bleomycin,Brentuximab vedotin,Pegfilgrastim,Vinblastine,Dacarbazine,Haematopoietic growth factor,Involved site radiotherapy,Filgrastim","Belgium,Spain,New Zealand,Australia,United States,United Kingdom",1042,Hodgkin Lymphoma,2022-04-14,3
699,NCT02314481,Phase 2,"University College, London",Hoffmann-La Roche,"Trastuzumab emtansine,MPDL3280A,Atezolizumab,Alecensa,Kadcyla,Zelboraf,Vemurafenib,T-DM1,Alectinib",United Kingdom,50,Non-small Cell Lung Cancer,2017-05-12,2
700,NCT03084939,Phase 3,Hoffmann-La Roche,,"Trastuzumab Emtansine,Kadcyla,Lapatinib,Capecitabine",China,351,Breast Cancer,2017-04-24,3
701,NCT02979522,"Phase 2,Phase 1",Takeda,,"Doxorubicin,Adcetris,Adriamycin,Brentuximab vedotin,Vinblastine,Dacarbazine","Japan,United States,Italy,Brazil",59,Hodgkin Disease,2017-09-06,2
702,NCT05016947,Phase 1,Dana-Farber Cancer Institute,AbbVie,"Hexadrol,Venclexta,Dexasone,Inotuzumab Ozogamicin,Venetoclax,Maxidex,Diodex,Besponsa,Decadron,Dexamethasone",United States,26,"B-cell Acute Lymphoblastic Leukemia,B-Cell Lymphoma,ALL",2021-09-24,1
703,NCT04632992,Phase 2,"Genentech, Inc.",,"Entrectinib,Kadcyla®,Ipatasertib,Atezolizumab,Pralsetinib,Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously,RG6114,Paclitaxel,Trastuzumab Emtansine,RO5541267,MTIG7192A,PH FDC SC,Alecensa®,PHESGO™,Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf,RG7853,RO5532961,Tecentriq®,Rozlytrek™,GDC-0077,GDC-0068,RG7440,RG6396,RG7446,RG6264,RG3502,RO5304020,RG6058,GAVRETO™,RO7198574,RO7092284,Investigator's Choice of Chemotherapy,RO7499790,Tucatinib,RG6268,RO5424802,RO7102122,RO7113755,Inavolisib,Tukysa™,Tiragolumab,Alectinib",United States,252,Advanced Unresectable or Metastatic Solid Malignancy,2021-01-13,2
704,NCT04589845,Phase 2,Hoffmann-La Roche,,"Entrectinib,GDC-6036,Trastuzumab emtansine,Ipatasertib,Atezolizumab,Pralsetinib,Camonsertib,Alecensa,Tecentriq,Kadcyla,Idasanutlin,Belvarafenib,Gavreto (US),Inavolisib,GDC-0077,Alectinib,Rozlytrek","Poland,Brazil,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Denmark,China,Hong Kong,Singapore,Australia,United States,Switzerland,Japan,Germany,Puerto Rico,Portugal,Korea, Republic of,Spain,Canada,New Zealand,South Africa,France",920,Solid Tumors,2021-01-18,2
705,NCT02292979,Phase 2,The Lymphoma Academic Research Organisation,"Millennium Pharmaceuticals, Inc.","Doxorubicin,Bleomycin,Vinblastine,Dacarbazine,Brentuximab Vedotin","Belgium,Croatia,Netherlands,Denmark,France",170,Hodgkin Lymphoma,2015-03-01,2
706,NCT04385290,"Phase 2,Phase 1",Technische Universität Dresden,"Novartis Pharmaceuticals,Pfizer","MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO,MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO,MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO,Mylotarg,Rydapt,MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin,MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin",Germany,214,Acute Myeloid Leukemia,2020-09-04,2
707,NCT01868451,,Memorial Sloan Kettering Cancer Center,"University of Rochester,Stanford University,Seagen Inc.,City of Hope Medical Center","Brentuximab vedotin (SGN-35),Vinblastine Sulfate,Doxorubicin HCL,Interim PET,Dacarbazine,Involved-Site Radiation Therapy (ISRT),consolidation volume RT (CVRT)",United States,118,Hodgkin Lymphoma,2013-05-01,
708,NCT02257567,"Phase 2,Phase 1",Hoffmann-La Roche,,"DCDS4501S,Treanda; Ribomustin; Levact,Polatuzumab vedotin (Lyophilized),DCDS4501A,Polatuzumab vedotin (Liquid),Rituxan; MabThera,GA101; Gazyva; Gazyvaro,Rituximab,Bendamustine,Obinutuzumab","Germany,Hungary,Italy,Korea, Republic of,Spain,Canada,Netherlands,Turkey,Czechia,Australia,United States,United Kingdom,France",331,Lymphoma,2014-10-15,2
709,NCT01534078,Phase 2,Massachusetts General Hospital,"Dana-Farber Cancer Institute,Seagen Inc.,H. Lee Moffitt Cancer Center and Research Institute,Beth Israel Deaconess Medical Center","Doxorubicin,Adcetris,SGN-35,SGN35,Brentuximab Vedotin,Adriamycin, vinblastine, and dacarbazine,Velban,DTIC",United States,34,Hodgkin Lymphoma,2012-03-01,2
710,NCT01494662,Phase 2,Dana-Farber Cancer Institute,"Translational Breast Cancer Research Consortium,Puma Biotechnology, Inc.","Neratinib,Xeloda,Surgical Resection,Capecitabine,HKI-272,Biopsy,T-DM1,Ado-Trastuzumab Emtansine",United States,140,Breast Cancer,2012-02-01,2
711,NCT05404945,Phase 2,University of Virginia,Merck Sharp & Dohme LLC,"Doxorubicin,Pembrolizumab,Adriamycin,Brentuximab vedotin,Vinblastine,Dacarbazine",United States,44,Classical Hodgkin Lymphoma,2022-07-26,2
712,NCT00829166,Phase 3,Hoffmann-La Roche,,"Trastuzumab emtansine,Xeloda,Capecitabine,Trastuzumab-MCC-DM1,RO5304020,Tykerb,Tyverb,Lapatinib,T-DM1","Poland,Brazil,Bosnia and Herzegovina,Slovenia,India,Italy,Taiwan,United Kingdom,Denmark,Mexico,Hong Kong,Singapore,Colombia,Finland,Switzerland,Bulgaria,Sweden,United States,Russian Federation,Germany,Portugal,Korea, Republic of,Spain,Canada,Philippines,New Zealand,France",991,Breast Cancer,2009-02-01,3
713,NCT05113251,Phase 3,AstraZeneca,Daiichi Sankyo,"Onxol,Trastuzumab,Pertuzumab,Doxorubicin,cyclophosphamide,Enhertu,Perjeta,Herzuma,Neosar,Adriamycin,Paclitaxel,T-DXd,Rubex,Taxol,Herceptin,Cytoxan,Trastuzumab Deruxtecan","Russian Federation,Germany,Poland,China,India,Peru,Saudi Arabia,Italy,Thailand,Brazil,Spain,Canada,Korea, Republic of,Philippines,Taiwan,United States,Japan,Bulgaria",912,"Breast Cancer,Breast Neoplasms,HER2-positive Early Breast Cancer",2021-10-25,3
714,NCT04341181,Phase 2,Ulrik Lassen,"Roche Pharma AG,GlaxoSmithKline,Pfizer","Trastuzumab plus Pertuzumab (combination),Atezolizumab,Zejula,Inlyta,Vemurafenib plus Cobimetinib (combination),Axitinib,Zelboraf plus Cotellic (combination),Avelumab,Erlotinib,Tarceva,Trastuzumab emtansine,Alecensa,Vismodegib,Herceptin plus Perjeta (combination),Bavencio,Erivedge,Alectinib,Tecentriq,Kadcyla,Niraparib",Denmark,300,"Neoplasia,Cancer,Tumors,Neoplasms",2020-08-24,2
715,NCT03646123,Phase 2,Seagen Inc.,Bristol-Myers Squibb,"G-CSF,Adcetris,dacarbazine,Opdivo,brentuximab vedotin,SGN-35,vinblastine,nivolumab,doxorubicin,pegfilgrastim,filgrastim","Poland,Italy,Spain,Czechia,Australia,United States",255,Hodgkin Lymphoma,2019-01-28,2
716,NCT03061812,Phase 3,AbbVie,,"Topotecan,Rova-T,Rovalpituzumab tesirine,Dexamethasone","Poland,Brazil,Hungary,Belgium,Italy,Netherlands,Taiwan,Denmark,United Kingdom,Romania,Ukraine,Mexico,China,Singapore,Australia,Bulgaria,Sweden,Japan,United States,Russian Federation,Germany,Serbia,Portugal,Korea, Republic of,Croatia,Canada,Spain,Greece,Latvia,Belarus,Turkey,Czechia,France",444,Small Cell Lung Cancer,2017-04-11,3
717,NCT06377566,Phase 2,Memorial Sloan Kettering Cancer Center,Seagen Inc.,"Vinorelbine,Doxorubicin,Pembrolizumab,Brentuximab vedotin,Vinblastine,Dacarbazine,FDG-PET/CT scan,Gemcitabine",United States,71,Hodgkin Lymphoma,2024-04-17,2
718,NCT04844866,Phase 2,Miltenyi Biomedicine GmbH,ICON plc,"MB-CART2019.1,Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab,R-GemOx or BR plus polatuzumab vedotin","Germany,Austria,Poland,Belgium,Hungary,Italy,Spain,Netherlands,Czechia,Lithuania,Sweden,France",168,Diffuse Large B-cell Lymphoma,2021-08-18,2
719,NCT03726879,Phase 3,Hoffmann-La Roche,Chugai Pharmaceutical,"Doxorubicin,Trastuzumab,Placebo,Pertuzumab,Atezolizumab,Perjeta,Tecentriq,Neosar,Kadcyla,Adriamycin,Paclitaxel,Trastuzumab Emtansine,Cyclophosphamide,Taxol,Herceptin,Cytoxan","Russian Federation,Germany,Poland,Italy,Korea, Republic of,Brazil,Spain,Canada,Taiwan,Czechia,United States,Japan",454,Breast Cancer,2019-01-11,3
720,NCT01578499,Phase 3,"Millennium Pharmaceuticals, Inc.",Seagen Inc.,"Bexarotene,Methotrexate,SGN-35,Brentuximab Vedotin","Germany,Austria,Poland,Belgium,Italy,Brazil,Spain,Australia,United States,Switzerland,United Kingdom,France",131,"Mycosis Fungoides,Cutaneous T-Cell Lymphoma,Primary Cutaneous Anaplastic Large Cell Lymphoma",2012-06-11,3
721,NCT05498220,Phase 2,UNC Lineberger Comprehensive Cancer Center,"Genentech, Inc.","Polatuzumab vedotin (PV),Cisplatin,Hyaluronidase,GCSF,Rituximab,Dexamethasone,Gemcitabine",United States,44,Diffuse Large B-cell Lymphoma,2023-02-17,2
722,NCT03274492,Phase 3,Hoffmann-La Roche,,"Doxorubicin,Polatuzumab Vedotin,Vincristine Placebo,DCDS4501A; anti-CD79b-VC-MMAE,Polatuzumab vedotin Placebo,Prednisone,Rituximab,Cyclophosphamide,Vincristine","Poland,Brazil,Belgium,Italy,Taiwan,United Kingdom,Ukraine,China,New Zealand,Hong Kong,Australia,United States,Switzerland,Japan,Russian Federation,Germany,Austria,Korea, Republic of,Spain,Canada,Turkey,Czechia,France",1000,Diffuse Large B-Cell Lymphoma,2017-11-16,3
723,NCT02605915,Phase 1,Hoffmann-La Roche,,"Trastuzumab,Pertuzumab,Trastuzumab emtansine,Carboplatin,Atezolizumab,Doxorubicin,RO4368451,RO0452317,Docetaxel,RO5304020,Tecentriq, RO5541267,Cyclophosphamide",United States,98,"HER2-Negative Metastatic Breast Cancer,HER2-Positive Metastatic Breast Cancer,Locally Advanced or Early Breast Cancer",2015-12-31,1
724,NCT06047080,Phase 3,Hoffmann-La Roche,,"Cyclophosphamide,Doxorubicin,Glofitamab,Prednisone,Rituximab,Polatuzumab vedotin","Poland,Brazil,Belgium,Italy,Taiwan,Denmark,United Kingdom,Mexico,China,Argentina,Australia,United States,Switzerland,Japan,Germany,Korea, Republic of,Spain,Canada,Turkey,France",1130,Large B-Cell Lymphoma,2023-09-18,3
725,NCT01564784,Phase 3,Pfizer,UCB Pharma,"inotuzumab ozogamicin,HIDAC (high dose cytarabine),cytarabine and mitoxantrone,FLAG (fludarabine, cytarabine and G-CSF)","Poland,Hungary,Italy,Netherlands,Taiwan,United Kingdom,China,Argentina,Singapore,Australia,Finland,Sweden,Japan,United States,Germany,Korea, Republic of,Spain,Canada,Czechia,France",326,Acute Lymphoblastic Leukemia,2012-08-02,3
726,NCT04790903,Phase 1,Hoffmann-La Roche,,"Doxorubicin,Polatuzumab Vedotin,Venetoclax,Prednisone,Rituximab,Cyclophosphamide","United States,France,Italy,Spain",50,"Lymphoma, Large B-Cell, Diffuse",2021-07-02,1
727,NCT04594798,Phase 2,University of Rochester,"Genentech, Inc.","Doxorubicin,Polatuzumab vedotin,Prednisone,Rituximab,Cyclophosphamide",United States,39,"DLBCL,Lymphoma, B-Cell",2021-09-20,2
728,NCT01966471,Phase 3,Hoffmann-La Roche,,"Trastuzumab,Pertuzumab,Epirubicin,Doxorubicin,Perjeta,Kadcyla,Paclitaxel,Trastuzumab Emtansine,Docetaxel,5-Fluorouracil,Cyclophosphamide,Herceptin","Poland,Georgia,Brazil,El Salvador,Bosnia and Herzegovina,Hungary,Belgium,Peru,Israel,Italy,Taiwan,Guatemala,United Kingdom,Romania,Ukraine,Panama,Mexico,Norway,Hong Kong,Singapore,Colombia,Australia,United States,Switzerland,Japan,Sweden,Russian Federation,Germany,Korea, Republic of,Thailand,Spain,Canada,Chile,Philippines,Czechia,France",1846,Breast Cancer,2014-01-31,3
729,NCT05673785,Phase 2,Takeda,,"Doxorubicin,Cyclophosphamide,Brentuximab Vedotin,Prednisone",China,52,Lymphoma,2023-02-10,2
730,NCT05180097,Phase 2,Canadian Cancer Trials Group,"Merck Sharp & Dohme LLC,Seagen Inc.","Cisplatin,Pembrolizumab,Brentuximab vedotin,Dexamethasone,Gemcitabine",Canada,84,Hodgkin Lymphoma,2022-11-01,2
731,NCT04679012,Phase 2,Weill Medical College of Cornell University,"Genentech, Inc.","Hydroxydoxorubicin Hydrochloride,Deltasone,etopophos,Paracort,Rituximab,toposar,VePesid,chimeric anti-CD20 monoclonal antibody,Etoposide,Hydroxydaunomycin,Cortan,VP-16,Orasone,Doxorubicin Hydrochloride,Cyclophosphamide,Polivy,Polatuzumab Vedotin,Rituxan,Prednisone,cytoxan",United States,20,"Richter Syndrome,Chronic Lymphocytic Leukemia",2021-09-24,2
732,NCT04569032,Phase 2,Seagen Inc.,,"cyclophosphamide,brentuximab vedotin,doxorubicin,prednisone,ADCETRIS","Italy,Spain,Czechia,United States,United Kingdom,France",82,Peripheral T-cell Lymphoma,2020-11-12,2
733,NCT01992653,"Phase 2,Phase 1","Genentech, Inc.",,"Doxorubicin,Polatuzumab Vedotin,MabThera/Rituxan,Prednisolone,DCDS4501A,Prednisone,Rituximab,Cyclophosphamide,Obinutuzumab,Gazyva/Gazyvaro","United States,France",85,"Lymphoma, Non Hodgkin",2013-11-29,2
734,NCT02824042,Phase 1,Bayer,,"Itraconazole,Anetumab ravtansine (BAY94-9343)","Belgium,Spain,Netherlands,Australia,United States,France",63,Medical Oncology,2016-09-07,1
735,NCT02734771,Phase 2,Patrick Reagan,Seagen Inc.,"Doxorubicin,Procytox,Adcetris,Deltasone,Adriamycin,Brentuximab vedotin,Revimmune,Rituximab,Cytoxan,SGN-35,Myocet,Endoxan,cAC10-vcMMAE,Doxil,Orasone,Lyophilizedcytoxan,Cyclophosphamide,Adasone,Caelyx,Rituxan,Neosar,Prednisone,Mabthera,Cycloblastin,Deltacortisone,Prednisonum",United States,24,Diffuse Large B-Cell Lymphoma,2016-06-01,2
736,NCT05955261,Phase 2,St. Jude Children's Research Hospital,AbbVie,"Zavedos,Vidaza,Mitoxantrone Hydrochloride,Venetoclax,Xospata,Venclextra,Azacitidine,IMI-30,L-lyxo-Hexopyranoside,Gemtuzumab Ozogamicin,Fludarabine Phosphate,FI-6339,Daunorubicin Hydrochloride,Pralifan,Etoposide,Vepesid®,Cytosar-U®,VP-16,Neotalem,Idarubicin Hydrochloride,Mylotarg,ABT-99,SH T 586,Mylosar,Ara-C,Cytarabine,Novantrone,Gilteritinib",United States,70,Acute Myeloid Leukemia,2023-07-25,2
737,NCT03677141,"Phase 2,Phase 1",Hoffmann-La Roche,,"Doxorubicin,Mosunetuzumab,Polatuzumab Vedotin,Prednisone,Rituxumab,Cyclophosphamide,Vincristine,Tocilizumab","Austria,Poland,Korea, Republic of,Spain,United States,France",117,B-cell Non-Hodgkin Lymphoma,2019-03-08,2
738,NCT03971409,Phase 2,"Hope Rugo, MD","Breast Cancer Research Foundation,Gilead Sciences,Array BioPharma,Translational Breast Cancer Research Consortium,Johns Hopkins University,Hoosier Cancer Research Network,Pfizer","ARRY-438162,PF 5082566,Trodelvy,ARRY-162,Anti-OX40 Antibody PF-04518600,Liposomal Doxorubicin,Avelumab,Binimetinib,MSB-0010718C,Utomilumab,PF-04518600,MEK162,Sacituzumab Govitecan-hziy,Lipodox,Caelyx,Bavencio,PF 05082566,PF-05082566,PF-2566,Sacituzumab Govitecan,MSB0010718C",United States,150,"Stage IV Breast Cancer,Stage IIIC Breast Cancer,Unresectable Breast Carcinoma,Stage IIIB Breast Cancer,Stage III Breast Cancer,Recurrent Breast Carcinoma,Triple-Negative Breast Carcinoma,Invasive Breast Carcinoma,Stage IIIA Breast Cancer",2019-07-08,2
739,NCT01920932,Phase 2,St. Jude Children's Research Hospital,Seagen Inc.,"etoposide,Neupogen(R),radiotherapy,Dacarbazine(R),radiation,SGN-35,radiation therapy,doxorubicin,Cytoxan(R),Adcetris(R),cyclophosphamide,Vepesid(R),VP-16,brentuximab vedotin,Adriamycin(R),prednisone,irradiation,prednisolone,quality of life assessment,Dimethyl Triazeno Imidazole Carboximide (DTIC),filgrastim",United States,77,"Stage IV Childhood Hodgkin Lymphoma,Stage III Childhood Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma",2013-08-12,2
740,NCT04914741,"Phase 2,Phase 1","Peter MacCallum Cancer Centre, Australia",Hoffmann-La Roche,"Doxorubicin,Prednisolone,Glofitamab,CD20-TCB,Polatuzumab vedotin,RO7082859,Rituximab,Cyclophosphamide,Vincristine",Australia,80,"High-grade B-cell Lymphoma,Diffuse Large B Cell Lymphoma",2021-06-29,2
741,NCT04884035,Phase 1,Celgene,,"Iberdomide,Doxorubicin,CC-220,Prednisolone,BMS-986369,Polatuzumab vedotin,BMS-986382,Prednisone,Rituximab,Cyclophosphamide,Vincristine,CC-99282","Poland,Korea, Republic of,Spain,Greece,Taiwan,Australia,United States",174,"Lymphoma, B-Cell",2021-09-15,1
742,NCT03467373,Phase 1,Hoffmann-La Roche,,"Doxorubicin,Obinutuzumab (G),Rituxan,Glofitamab,Rituximab (R),Polatuzumab vedotin,Gazyva,Prednisone,RO7082859,Actemra,Oncovin,Cyclophosphamide,Vincristine,Tocilizumab","Germany,Italy,Spain,Canada,United Kingdom,Australia,United States,Denmark,France",172,"Non-Hodgkin Lymphoma,B-Cell Lymphoma",2018-03-13,1
743,NCT03755804,Phase 2,St. Jude Children's Research Hospital,"Seagen Inc.,Teva Pharmaceuticals USA","Radiotherapy,Doxorubicin,Adcetris,TREANDA (R),Prednisolone,Blenoxane (R),Quality of Life Measurements,Vincristine,Filgrastim,Velban (R),Cytoxan (R),Adriamycin (R),Vepeside,radiation therapy,Quality of Life Measurements (QOL),Etoposide,Bleomycin,Oncovin (R),Neupogen (R),Dimethyl Triazeno Imidazole Carboximide,VP-16,Vinblastine,DACARBAZINE (R),Cyclophosphamide,DTIC,irradiation,Brentuximab Vedotin,Prednisone,bendamustine",United States,250,Hodgkin Lymphoma,2018-12-12,2
744,NCT03424005,"Phase 2,Phase 1",Hoffmann-La Roche,"Seagen Inc.,Gilead Sciences","Ipatasertib,Atezolizumab,Nab-Paclitaxel,Inavolisib,Inavolisib (9 mg),Selicrelumab,Capecitabine,Trastuzumab Deruxtecan,GDC-0077, RO7113755,Fulvestrant,Inavolisib (6 mg),SGN-LIV1A,Bevacizumab,Ribociclib,Sacituzumab Govitecan,Chemotherapy (Gemcitabine + Carboplatin or Eribulin),Abemaciclib,Tocilizumab","Germany,Israel,Korea, Republic of,Spain,Australia,United States,United Kingdom,France",242,Breast Cancer,2018-04-02,2
745,NCT01679119,Phase 2,"University College, London","Cancer Research UK,Pfizer","Prednisolone,Inotuzumab Ozogamicin,MabThera,Rituximab,Cyclophosphamide,Vincristine,Gemcitabine",United Kingdom,129,Diffuse Large B Cell Lymphoma,2013-10-01,2
746,NCT03991884,Phase 1,University of Washington,Pfizer,"Doxorubicin,Hydroxyldaunorubicin,Paracort,Cyclophosphamid monohydrate,WR- 138719,33419-42-0,Vincristine,Prednicort,Mitoxan,Cyclophosphamidum,VP 16-213,Decorton,Cicloxal,VP 16,Etoposide,Vepesid,Adriablastin,Ciclofosfamide,Rayos,VP16,Clafen,Neosar,Cortancyl,Demethyl Epipodophyllotoxin Ethylidine Glucoside,14-Hydroxydaunomycin,Predniment,EPEG,Prednidib,Inotuzumab Ozogamicin,Delta-Dome,Way 207294,635715-01-4,Prednitone,Vincrystine,VP-16,23214-92-8,Ofisolona,Adasone,Hydroxyl Daunorubicin,Predicorten,Ciclofosfamida,Syklofosfamid,Besponsa,Prednisonum,Cyclostine,Carloxan,Fosfaseron,Prednilonga,SK-Prednisone,Servisone,Prednisone Intensol,LEUROCRISTINE,VP-16-213,Decortisyl,Cyclostin,Cycloblastine,Claphene,Genuxal,Cyclophosphane,Orasone,Genoxal,Cyclophospham,VCR,Delta 1-Cortisone,Cyclophosphan,Toposar,141540,Lastet,2-Dehydrocortisone,Revimmune,Predicor,Cytoxan,22-Oxovincaleukoblastine,WAY-207294,Ledoxina,Metacortandracin,Promifen,CTX,CP monohydrate,Hydroxydaunomycin,Dacortin,DeCortin,Cyclophosphamide,CMC-544,Prednisone,Cycloblastin",United States,24,"Refractory B Lymphoblastic Lymphoma,Recurrent B Lymphoblastic Lymphoma,Recurrent B Acute Lymphoblastic Leukemia,Refractory B Acute Lymphoblastic Leukemia",2019-09-24,1
747,NCT02243436,"Phase 2,Phase 1",Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea,"Millennium Pharmaceuticals, Inc.","Ara C,Methylprednisolone,Cisplatin,Cytarabine,Soludomerin,Brentuximab Vedotin,ADCETRIS,Etoposide",Spain,67,CLASSICAL HODGKIN LYMPHOMA,2014-11-11,2
748,NCT05283720,Phase 2,Genmab,AbbVie,"Imbruvica,ABT-199,ABBV-GMAB-3013;,Polatuzumab Vedotin,Epcoritamab,Venclexta;,Doxorubicin Hydrochloride [HCl],Ibrutinib,Venetoclax,GDC-0199,Prednisone,Rituximab,Cyclophosphamide,CC-99282,Lenalidomide","Germany,Hungary,Japan,Israel,Korea, Republic of,Spain,Netherlands,Taiwan,Czechia,United States,Denmark,France",394,Non-Hodgkin Lymphoma,2022-06-14,2
749,NCT04486352,"Phase 2,Phase 1","Alliance Foundation Trials, LLC.","Genentech, Inc.,Foundation Medicine,Eli Lilly and Company,Pfizer","Abemaciclib,Ipatasertib,L01XC32,Verzenio,Talazoparib,Femara,Bevacizumab,GDC-0077,GDC-0068,RG7440,Trastuzumab emtansine,L01XX60,Talzenna,Atezolizumab - 28 Day Cycle,Letrozole,T-DM1,GDC-9545,Tecentriq,Kadcyla,Atezolizumab - 21 Day Cycle,Giredestrant,Inavolisib,Tiragolumab,L01XC07,Avastin",United States,148,Endometrial Cancer,2021-10-20,2
750,NCT01055496,Phase 1,Pfizer,UCB Pharma,"inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone,inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone,CMC-544","Belgium,Japan,Korea, Republic of,Canada,Hong Kong,Singapore,United States,United Kingdom,France",103,"Lymphoma, B-Cell",2010-03-01,1
751,NCT04307576,Phase 3,Mats Heyman,"NordForsk,The Swedish Research Council,Aamu Pediatric Cancer Foundation,Karolinska Institutet,Belgium Health Care Knowledge Centre,Assistance Publique - Hôpitaux de Paris,Pfizer,The Swedish Childhood Cancer Foundation,Danish Cancer Society,German Society for Pediatric Oncology and Hematology GPOH gGmbH,The Novo Nordic Foundation,Servier,Amgen,Fundação Rui Osório de Castro,Cancer Research UK,Clinical Trial Center North (CTC North GmbH & Co. KG),Grupo Português De Leucemias Pediátricas,Direction Générale de l'Offre de Soins,Acreditar - Associação de Pais e Amigos das Crianças com Cancro,Nova Laboratories Limited,Danish Child Cancer Foundation","Omitted Doxorubicin,Imatinib,6-tioguanine+Standard Maintenance Therapy,Blinatumomab,Omitted Vincristine+Dexamethasone pulses,Besponsa+Maintenance Therapy,Blincyto,Inotuzumab Ozogamicin+Standard Maintenance Therapy","Germany,Belgium,Ireland,Estonia,Portugal,Finland,Netherlands,Norway,United Kingdom,Iceland,Lithuania,Sweden,Denmark,France",6430,"Leukemia, Acute Lymphoblastic",2020-07-13,3
752,NCT04931342,Phase 2,Hoffmann-La Roche,"European Network of Gynaecological Oncological Trial Groups (ENGOT),GOG Foundation","Luteinizing Hormone-Releasing Hormone (LHRH) Agonists,Ipatasertib,Atezolizumab,RO4876646, Avastin,Paclitaxel,Trastuzumab Emtansine,Cobimetinib,Palbociclib,RO5541267, Tecentriq,RO5514041,RO5532961,Bevacizumab,Olaparib,RO5304020,Cyclophosphamide,Letrozole,Giredestrant,Inavolisib,Abemaciclib","Russian Federation,Germany,Italy,Korea, Republic of,Spain,Canada,Turkey,Czechia,Australia,United States,Switzerland,United Kingdom,France",176,Ovarian Cancer,2021-10-07,2
753,NCT03962465,Phase 1,University of Virginia,"Vanderbilt University,Virginia Commonwealth University,University of Wisconsin, Madison,Pfizer","rubidomycin,Deltasone,Prednisone Pill,Methotrexate,Rheumatrex,Cytosar-U,Otrexup,Vincristine,Leurocristine,daunomycin,Amethopterin,Oncovin,Rasuvo,Inotuzumab ozogamicin,Vincasar,Cerubidine,MTX,Daunorubicin,Oncospar,Ara-C,Trexall,Besponsa,Pegaspargase,Cytarabine",United States,36,B-cell Acute Lymphoblastic Leukemia,2022-07-22,1
754,NCT03337698,"Phase 2,Phase 1",Hoffmann-La Roche,,"Carboplatin,Atezolizumab,Ipatasertib,Docetaxel,Cobimetinib,Radiation,Evolocumab,CPI-444,Camonsertib,Bevacizumab,Gemcitabine,RO6958688,XL092,Linagliptin,Tocilizumab,Pemetrexed,Sacituzumab Govitecan,Tiragolumab,Zanzalintinib","Israel,Korea, Republic of,Spain,Taiwan,Australia,United States,United Kingdom,France",675,"Carcinoma, Non-Small-Cell Lung",2018-01-02,2
755,NCT03913559,Phase 2,St. Jude Children's Research Hospital,Pfizer,"Methylprednisolone,Hydrocortisone,Solu-Medrol,Acetaminophen,Methotrexate,CMC-544,Tylenol,Ara-C,Diphenhydramine,Besponsa,Benadryl,Trexall®,Cytarabine,Inotuzumab ozogamicin,Cortisol",United States,32,Acute Lymphoblastic Leukemia,2019-05-14,2
756,CTIS2023-508832-68-00,"Phase 3,Phase 2,Phase 1",Genmab A/S,,"Product Name: HuMax-TF-ADC,Product Code: PRD952264,Pharmaceutical Form: SOLUTION FOR INFUSION,Other descriptive name: ,Strength: Tisotumab Vedotin 10mg,Product Code: SCP10337134,Pharmaceutical Form: ,Other descriptive name: ,Product Code: SCP6094344,Pharmaceutical Form: ,Other descriptive name: ,Product Code: SCP29096188,Pharmaceutical Form: ,Other descriptive name:","Belgium,Italy,Spain,Netherlands,Czechia,Ireland",143,"MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864,Recurrent or stage IVB cervical cancer  MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864,Therapeutic area: Diseases [C] - Neoplasms [C04]",2024-02-26,3
757,CTRI/2024/01/061671,Phase 4,ESIC Dental College,,"Intervention1: Local Application of Ozone oil ( ADC INCLUSIVE DENT OZONE INDIA, OZONOINDS) at tooth extraction site.: Normal tooth extraction, ozone oil is locally applied at extraction site for 5 min and then mouth is rinsed. then patient to apply ozone oil 3 times a day locally at extraction site for 3 days. Control Intervention1: Local application of Glycerin at tooth extraction site as a placebo.: Normal tooth extraction, Glycerin is locally applied at extraction site for 5 min and then mouth is rinsed. then patient to apply glycerin 3 times a day locally at extraction site for 3 days.",India,82,"Health Condition 1: K069- Disorder of gingiva and edentulousalveolar ridge, unspecified",2024-01-19,4
758,JPRN-jRCT2031230569,,Hibi Kazushige,,Drug: AZD0901 Antibody-drug conjugate/Biologic Other Name: CMG901,"Republic of Moldova,Poland,Georgia,Spain,Canada,Singapore,Republic of Korea,United Kingdom,Taiwan,Malaysia,United States of America,Australia,Japan",186,"Gastric cancer, Gastroesophageal junction cancer",2024-01-16,
759,NL-OMON56595,,Amsterdam UMC,,"Supramarginal resection will be guided by ADC/FET. To make sure that the  standard treatment is always guaranteed, T1c MRI abnormalities will be included  in the surgical target.",Netherlands,30,"10029211,10009720,brain tumor  glioblastoma",2023-12-22,
760,NCT06178601,Phase 2,Shanxi Province Cancer Hospital,,"Drug: AK104,Drug: RC48-ADC",China,36,Urothelial Carcinoma,2023-12-12,2
761,ChiCTR2300077064,,Hu'nan Cancer Hospital,,",DWI guided DP-RT group (DWI group):The target volume GTV-DWI is defined as the area <ADC mean within the GTV. Radiation dose to GTV-DWI is escalated to 77Gy, and the fractional dose is escalated to 2.2 Gy/F.,Anatomic imaging group (control group):The standard radiotherapy dose of 70.0Gy was given to the target volume PGTV, with a fractional dose of 2.0Gy/F.",China,,head and neck squamous cell carcinoma,2023-10-27,
762,NCT06121557,Phase 1,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,"Biological: Camrelizumab,Biological: Tumor-draining lymph node-derived lymphocyte (LNL),Drug: Fludarabine,Drug: Cyclophosphamide,Procedure: Surgery for harvesting tumor-draining lymph nodes,Biological: Interleukin-2,Drug: Chemotherapeutic drug, ADC or PARP inhibitor",China,24,Breast Neoplasms,2023-10-26,1
763,NCT06112041,Phase 2,Second Affiliated Hospital of Soochow University,,"Drug: ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin",China,29,"Solid Tumor,Carcinoma",2023-10-23,2
764,NCT06074484,Phase 2,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,"Drug: AK104,Drug: RC48-ADC",China,36,Muscle Invasive Bladder Carcinoma,2023-08-22,2
765,PER-062-22,,AstraZeneca AB,,"Participants in the Dato-DXd in combination with durvalumab and carboplatin group will receive Dato-DXd 6.0 mg/kg plus durvalumab 1120 mg plus carboplatin AUC 5 mg/mL/minute as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with Dato-DXd 6.0 mg/kg plus durvalumab 1120 mg as i.v. infusions Q3W on Day 1 of every subsequent cycle. Dato-DXd must be administered prior to durvalumab at each cycle. Carboplatin must be administered after durvalumab at each of the first 4 cycles.  -                      Participants in the histology-specific therapy group will receive either: ? Regimen 1 (participants with non-squamous NSCLC): Pembrolizumab 200 mg plus pemetrexed 500 mg/m2 plus platinum chemotherapy (carboplatin AUC 5 mg/mL/minute or cisplatin75 mg/m2) as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with pembrolizumab 200 mg (with or without pemetrexed 500 mg/m2) as i.v. infusions Q3W on Day 1 of every subsequent cycle, or ? Regimen 2 (participants with squamous NSCLC): Pembrolizumab 200 mg plus paclitaxel 200 mg/m2 plus carboplatin (AUC 5 or 6 mg/mL/minute) as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with pembrolizumab 200 mg monotherapy as an i.v. infusion Q3W on Day 1 of every subsequent cycle. For both regimens in the control arm, pembrolizumab must be administered first and platinum chemotherapy (carboplatin or cisplatin) last. Paclitaxel or pemetrexed must be administered after pembrolizumab, and carboplatin or cisplatin must be administered after paclitaxel or pemetrexed.","Poland,Brazil,Korea South,Vietnam,India,Peru,Italy,Taiwan,Hungaria,Denmark,Mexico,China,United Kindgdom,United States,Bulgaria,Japan,Sweden,Germany,Austria,Spain,Canada,Greece,Turkey,France",1000,"C349,C349 Bronchus or lung, unspecified  Bronchus or lung, unspecified",2023-08-08,
766,NCT05955209,Phase 2,Peking University Cancer Hospital & Institute,,Drug: Disitamab Vedotin(RC48-ADC),,40,Metastatic Castration-resistant Prostate Cancer,2023-07-13,2
767,NCT05917158,Phase 2,"Jinling Hospital, China",,Drug: RC48-ADC and JS001,China,30,"Carcinoma,UTUC,Upper Tract Urothelial Carcinoma",2023-06-15,2
768,ChiCTR2300071941,,General Hospital of Northern Theater Command,,"Gold Standard:Postoperative pathological results or stereotactic intracranial electroencephalogram (SEEG) results ,,Index test:3D-T1WI sequence: gray matter volume (GMV), gray matter concentration (GMC), cortical thickness  DTI sequence: fractional anisotropy (FA), mean diffusivity (MD), apparent diffusion coefficient (ADC)  BOLD sequence: amplitude of low-frequency fluctuation (ALFF), ratio amplitude of low-frequency fluctuation (fALFF)  PET image:Standardized uptake value ratio ( SUVr)  ",China,,Drug-refractory epilepsy,2023-05-30,
769,NCT05785325,Phase 2,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,Drug: RC48-ADC plus Bevacizumab,China,30,Colorectal Cancer,2023-03-13,2
770,NCT05824325,"Phase 2,Phase 1",Fudan University,,"Drug: TROP2 ADC,Drug: SHR-A1811",China,56,Breast Cancer,2023-05-03,2
771,NCT05749588,Phase 2,Fudan University,,"Drug: A1: SHR-A1811,Drug: B2: TROP2 ADC with Camrelizumab,Drug: C1: SHR-A1811,Drug: D1: TROP2 ADC,Drug: A2: SHR-A1811 with Camrelizumab,Drug: E1: SHR-A1811,Drug: F1: TROP2 ADC,Drug: G1: SHR-A1811,Drug: D2: TROP2 ADC with BP102,Drug: C2: SHR-A1811 with BP102,Drug: H1: TROP2 ADC,Drug: B1: TROP2 ADC",China,120,Triple-negative Breast Cancer,2023-02-19,2
772,RBR-23dgvk8,,Escuela de Osteopatia de Madri - Brasil Ltda,,"E02.190.599.280,It is a two-arm, double-blind, randomized controlled clinical trial. The selected patients will be referred by the collaborating neurologists to perform the Nuclear Magnetic Resonance (MRI) with diffusion at Centro Hospitalar Unimed Joinville (imaging department). After performing MRI with apparent diffusion coefficient (ADC) and diffusion-weighted imaging (DWI) and undergoing rehabilitation in a clinic chosen by the volunteers, all will be submitted to assessments of Basic Automatic Reactions (RAB), Functional Independence Measure (MIF), Dynamic Balance Test (Timed Up and Go  TUGt), Fugl-Meyer Scale (EFM), Barthel Index (IB) and Quality of Life Questionnaire (SF-36). For the calculated sample size (n=16), the blinding of the research will be done by the evaluation and intervention, in which researcher 1 will carry out the evaluation and researcher 2 will apply the intervention. Double blinding will be performed using the Randomizer program (www.random.org) and allocated to an experimental group (EG) and a control group (CG). The EG (n=8) will be treated with Osteopathic Manipulative Techniques. The control group (GP) (n=8) will not be treated with Osteopathic Manipulative Techniques. The EG will be undergoing treatment with the OMT proposed by the researchers in 12 (twelve) osteopathic physiotherapeutic consultations, distributed in 1 (one) weekly consultation, totaling 12 (twelve) weeks and with an estimated duration of 60 (sixty) minutes per Query. You will be interviewed via telephone weekly to complete the Barthel functional scale, sleep guidelines and ensure that they are undergoing neurofunctional rehabilitation. The CG will be interviewed weekly by telephone to complete the Barthel functional scale, sleep guidelines and ensure that they are undergoing neurofunc",Brazil,,"C23.550.470.544,Ischemic Stroke",2023-01-23,
773,EUCTR2022-002680-30-DE,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: Datopotamab Deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN:  Datopotamab Deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Trade Name: Pembrolizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853-91-4  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-,"Germany,Belgium,China,Argentina,Korea, Republic of,Brazil,Spain,Canada,Italy,United Kingdom,Greece,Taiwan,Denmark,United States,Sweden,Japan,France",1075,"Stage I-III triple-negative breast cancer with residual invasive disease after neoadjuvant therapy.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2022-10-11,3
774,NCT05601401,Phase 2,Peking Union Medical College Hospital,,Drug: RC48-ADC,China,10,Salivary Gland Tumors,2022-10-17,2
775,NCT05594095,Phase 2,Fudan University,,"Drug: Carrelizumab,Drug: Everolimus,Drug: TROP2 ADC,Drug: RTK Inhibitor,Drug: Famitinib,Drug: Dalpiciclib,Drug: Goserelin,Drug: Aromatase Inhibitors or Fulvestrant,Drug: AKT inhibitor,Drug: Fluzoparib,Drug: PIK3CA inhibitor,Drug: SHR-A1811,Drug: TPC",China,140,"Breast Cancer,Breast Neoplasm,Advanced Breast Cancer,Hormone Receptor Positive Tumor,HER2-negative Breast Cancer",2022-10-13,2
776,NCT05578287,Phase 2,Sun Yat-sen University,,Drug: Anti-HER2 ADC,China,29,Colorectal Cancer,2022-08-10,2
777,NCT05571618,,Fudan University,,Drug: ADC,China,100,Breast Cancer,2022-05-10,
778,NCT05582499,"Phase 2,Phase 1",Fudan University,,"Drug: Camrelizumab,Drug: SHR-1316,Drug: Trastuzumab,Drug: Epirubicin,Drug: Trophoblast cell-surface antigen 2 (TROP2) ADC,Drug: HER2 ADC,Drug: Dalpiciclib,Drug: Pertuzumab,Drug: Goserelin,Drug: Carboplatin,Drug: Nab paclitaxel,Drug: Cyclophosphamide,Drug: Pyrotinib,Drug: Letrozole,Drug: Fluzoparib,Drug: SHR-A1811",China,716,"Breast Cancer,Breast Neoplasm,Early-stage Breast Cancer,HER2-positive Breast Cancer,Breast Tumors,Locally Advanced Breast Cancer,Hormone Receptor Positive Tumor,Hormone Receptor Negative Tumor,HER2-negative Breast Cancer,Triple-Negative Breast Cancer (TNBC)",2022-09-25,2
779,ChiCTR2200063088,,"Jinshazhou Hospital, Guangzhou University of Chinese Medicine",,",Interest&#32,PET-MR&#32,D&#32,Maximum&#32,used&#32,apparent&#32,(ROI)&#32,prostate&#32,and&#32,maps,&#32,of&#32,(SUVmax)&#32,patients&#32,localized&#32,were&#32,in&#32,was&#32,ADC&#32,integrated&#32,Gold Standard:All patients met the relevant diagnostic criteria for PC in the European Society of Urogenital Radiology. All patients were diagnosed as PC by pathological puncture, and the tumor was visible and clearly displayed.,Index test:All&#32,values&#32,machine&#32,minimum&#32,diffusion&#32,standard&#32,by&#32,Regions&#32,Syngo&#32,examined&#32,PET&#32,with&#32,workstation&#32,Siemens&#32,True&#32,uptake&#32,coeffici,for&#32,Germany.&#32,lesions&#32,integrate&#32,to&#32,selected.&#32",China,,PET-MR,2022-08-30,
780,EUCTR2022-000776-19-PL,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,"Product Code: AZD5305 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N/A CAS Number: 2589531-76-8 Current Sponsor code: AZD5305 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-  Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Datopotamab deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Product Name: Flourouracil (5-FU) Pharmaceutical Form: Solution for injection INN or Proposed INN: fluorouracil CAS Number: 51-21-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Bevacizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Bevacizumab CAS Number: 216974-75-3 Current Sponsor code: FKB238 Other descriptive name: A recombinant, humanized IgG1 mAb specific for VEGF Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-  Product Name: Carboplatin Pharmaceutical Form: Concen","Germany,Poland,China,Japan,Italy,Korea, Republic of,Spain,Canada,Taiwan,Turkey,United States,Switzerland,United Kingdom,France",540,"various Advanced/Metastatic solid tumour types  - Endometrial Cancer  - Gastric Cancer  - Ovarian Cancer - Metastatic castration-resistant prostate cancer - Colorectal cancer  MedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2022-08-29,3
781,ChiCTR2200062091,,"West China Hospital,Sichuan University",,"Index test:Fat&#32,,value,&#32,Gold Standard:Results of routine large magnetic resonance quantitative examination of liver fat,ADC&#32,fraction,T2&#32,T1&#32,value.",China,,liver disease,2022-07-21,
782,ChiCTR2200061944,,The First Hospital of Jiaxing,,"multi-modal&#32,,D*,&#32,including&#32,obtain&#32,double-exponential,&#32,include:&#32,Gold Standard:Histopathological diagnosis,double&#32,value),&#32,and&#32,single-exponential,&#32,single&#32,stretched&#32,(ADC&#32,DWI&#32,model&#32,parameters&#32,(D,&#32,a&#32,models,&#32,non-Gaussian&#32,(DDC&#32,indicators. Indicators&#32,multi-parameter&#32,exponential&#32,Index test:Construct&#32,f&#32,distribution&#32,value),&,to&#32,models&#32,stretched-exponential&#32",China,,thyroid nodules,2022-07-12,
783,NCT05417230,Phase 2,Jiangsu Cancer Institute & Hospital,,"Drug: Envafolimab,Drug: RC48-ADC",,29,Biliary Tract Cancer,2022-09-06,2
784,CTRI/2022/05/042713,Phase 2,GlaxoSmithKline Research  Development Limited,,"Intervention1: Single-Agent Belantamab Mafodotin (GSK2857916): GSK2857916 for injection, 100 mg, Biologic/drug (antibody-drug conjugate) ,Lyophilized powder in single-use vial for reconstitution, 100 mg/vial, IV infusion over at least 30 minutes  Intervention2: Single-Agent Belantamab Mafodotin (GSK2857916: The study has 5 arms: Arm A, a control arm (2.5 mg/kg Q3W) Intervention3: Single-Agent Belantamab Mafodotin (GSK2857916): Arms B through D, 3 arms with dosing alternatives Intervention4: Single-Agent Belantamab Mafodotin (GSK2857916): Arm E, a fifth exploratory arm to evaluate the feasibility of dosing 1.9 mg/kg every 6 weeks (Q6W) based on ocular symptoms (patient-reported symptoms using the OSDI), visual acuity assessments (Snellen chart or equivalent), and corneal findings (KVA scale). Control Intervention1: There is no comparator agent in the study and this monotherapy study.: There is no comparator agent in the study and this monotherapy study.","Germany,Russian Federation,Poland,India,Argentina,Italy,Brazil,Spain,Canada,Thailand,Republic of Korea,Greece,Taiwan,United States of America,Australia,Ireland,United Kingdom,France",288,Health Condition 1: -  Health Condition 2: D758- Other specified diseases of bloodand blood-forming organs Health Condition 3: D758- Other specified diseases of bloodand blood-forming organs,2022-05-20,2
785,NCT05403242,"Phase 2,Phase 1",Chinese PLA General Hospital,,"Drug: S-1,Drug: RC48-ADC",China,42,Advanced Gastroesophageal Adenocarcinoma,2022-06-05,2
786,NCT05349383,,Central South University,,"Drug: Antibody-Drug Conjugate,Drug: Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate",China,24618,"Opportunistic Infections,Agranulocytosis,Sepsis (SMQ)",2022-04-21,
787,NCT05356351,Phase 2,Tianjin Medical University Cancer Institute and Hospital,,Drug: RC48- ADC,,30,Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance,2022-04-18,2
788,NCT05331326,Phase 2,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,Drug: RC48-ADC,China,64,Metastatic Breast Cancer,2022-08-04,2
789,EUCTR2021-005223-21-IT,"Phase 3,Phase 2,Phase 1",ASTRAZENECA AB,,Trade Name: Carbo-Cell 10 mg/ml concentrate for solution for infusion Product Name: Carboplatin Product Code: [Carboplatin] Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CARBOPLATINO CAS Number: 41575-94-4 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Product Name: Eribulin mesylate Product Code: [Eribulin mesylate] Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: ERIBULINA CAS Number: 441045-17-6 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-  Product Name: Nab-paclitaxel Product Code: [Nab-paclitaxel] Pharmaceutical Form: Powder for suspension for injection INN or Proposed INN: PACLITAXEL ALBUMINA CAS Number: 153212-75-1 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Glucocorticoids Product Code: [Glucocorticoids] Pharmaceutical Form: Powder and solvent for solution for injection Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Abraxane 5 mg/ml powder for dispersion for infusion Product Name: Nab-paclitaxel Product Code: [Nab-paclitaxel] Pharmaceutical Form: Dispersion for infusion INN or Proposed INN: PACLITAXEL ALBUMINA CAS Number: 153212-75-1 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: HALAVEN 0.44 mg/ml solution for injection Product Name: Eribulin mesylate Product Code: [Eribulin mesylate] Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: ERIBULINA CAS Number: 441045-17-6 Current Sponsor code: n/a Concentr,"Poland,Brazil,Hungary,Belgium,India,Italy,Taiwan,United Kingdom,China,Mexico,Argentina,Singapore,United States,Japan,Russian Federation,Germany,Korea, Republic of,Thailand,Spain,Canada,Turkey,South Africa,France",600,"Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2022-03-24,3
790,NCT05320380,"Phase 2,Phase 1",Children's Oncology Group,,"Drug: Fludarabine Phosphate,Drug: Prednisolone,Drug: Liposome-encapsulated Daunorubicin-Cytarabine,Procedure: Bone Marrow Aspiration and Biopsy,Drug: Methotrexate,Drug: Hydrocortisone Sodium Succinate,Drug: Cytarabine,Drug: Anti-CD123 ADC IMGN632",,,"Recurrent T Acute Lymphoblastic Leukemia,Recurrent Mixed Phenotype Acute Leukemia,Recurrent Acute Myeloid Leukemia,Refractory B Acute Lymphoblastic Leukemia,Refractory Acute Myeloid Leukemia,Refractory Mixed Phenotype Acute Leukemia,Recurrent B Acute Lymphoblastic Leukemia,Refractory T Acute Lymphoblastic Leukemia",2022-03-22,2
791,ACTRN12622000080729,,St. Vincent's Private Hospital,,"Multi-parametric MRI scans will be performed as per standard of care for patients on active surveillance and assessed as per this protocol at Baseline, 1 year, 2 years and 3 years including follow-up up to 7 years consistent with the highest standards of prostate MRI: 	3-Tesla magnet field strength 	32-channel system with 14-channel spine coil and 18-channel pelvic phased array coil arrangement 	T1-weighted gradient spine echo sequence to identify biopsy haemorrhage artifact 	T2-weighted, high spatial resolution, anatomical imaging to identify and precisely localise areas of suspicion, and direct MRI-guided biopsy where performed, 	 Diffusion-Weighted Imaging with software derived Apparent Diffusion Co-efficient (ADC) quantitative analysis maps, and multiple B-values (0, 400, 800, 1400), 	Dynamic Contrast Enhanced imaging (DCE) with automatically-delivered IV gadolinium DTPA bolus 10ml at 3ml/ second followed by rapid sequences with temporal resolution of between 4-7 seconds between scans, 	Detailed quantitative analysis of DCEI imaging using K-trans colour maps and curve analysis according to PIRADS DCEI analytic guidelines, 	T2-weighted imaging in 3 planes with sagittal, coronal, axial and TSE images,  	No use of Endo-rectal coils or MR Spectroscopy as per current guidelines 	Dedicated MRI physicists present for all scans to optimise protocols 	Approximate scan time 30minutes.",Australia,300,"  Prostate Cancer,Cancer - Prostate,Prostate Cancer",2022-01-21,
792,ChiCTR2200055827,,"Department of Biotherapy, Tumor Center, West China Hospital, Sichuan University",,",Experimental group:Videsetuzumab for injection (RC48-ADC)",China,,HER2-expressing locally advanced or metastatic malignant solid tumor,2022-01-20,
793,EUCTR2021-005873-25-ES,"Phase 3,Phase 2,Phase 1",SOTIO Biotech a.s.,,"Product Name: SOT102 Product Code: SOT102 Pharmaceutical Form: Solution for infusion INN or Proposed INN: antibody-drug conjugate of an anti-CLDN18.2 mAb and the cytotoxic drug PNU159682, coupled by a Gly2-EDA linker Current Sponsor code: SOT102 Other descriptive name: SOT102 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-","Belgium,Spain,Czechia,United States,France",269,"Gastric and pancreatic adenocarcinoma  MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 100000004864   MedDRA version: 21.1 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 100000004864 ,Therapeutic area: Diseases [C] - Cancer [C04]",2022-01-17,3
794,NCT05115500,Phase 2,Second Affiliated Hospital of Soochow University,,"Drug: ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2",China,55,"Solid Tumor,Carcinoma",2021-04-11,2
795,EUCTR2020-005620-12-ES,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: Datopotamab deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Eribulin mesylate Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Eribulin mesylate CAS Number: 441045-17-6 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.44-  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9  Product Name: Gemcitabine Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Gemcitabine CAS Number: 95058-81-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 38-  Product Name: Vinorelbine Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Vinorelbine CAS Number: 71486-22-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-,"Poland,Brazil,Hungary,Belgium,India,Italy,Netherlands,Taiwan,United Kingdom,Mexico,China,Argentina,United States,Japan,Russian Federation,Germany,Korea, Republic of,Spain,Canada,South Africa,France",700,"Therapeutic area: Diseases [C] - Cancer [C04],Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy  MedDRA version: 23.0 Level: PT Classification code 10083232 Term: HER2 negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",2021-06-10,3
796,CTRI/2021/08/035674,,Tata Memorial Hospital,,Intervention1: Adc b 4000: Additional mri sequence to be taken along with adc b 0 and b1000,India,245,Health Condition 1: C718- Malignant neoplasm of overlappingsites of brain,2021-08-16,
797,NCT05016973,Phase 2,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,,"Drug: Triplizumab,Drug: RC48-ADC",China,25,Bladder Cancer,2021-07-25,2
798,NCT04983121,Phase 2,Shengjing Hospital,,Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788),China,30,Breast Neoplasms,2021-09-07,2
799,EUCTR2019-004531-22-PL,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: Trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: paclitaxel CAS Number: 33069-62-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6-  Product Name: Pertuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: pertuzumab CAS Number: 380610-27-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-,"Russian Federation,Germany,Poland,India,Turkiye,Korea, Republic of,Italy,Brazil,Spain,Canada,Taiwan,Australia,United States,United Kingdom,France",450,"Therapeutic area: Diseases [C] - Cancer [C04],HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",2021-06-28,3
800,NCT04928846,Phase 3,AbbVie,,"Drug: Docetaxel,Biological: Telisotuzumab Vedotin","Poland,Brazil,Hungary,Belgium,Israel,Italy,Netherlands,Taiwan,Denmark,United Kingdom,Romania,Ukraine,China,Mexico,Argentina,Australia,United States,Bulgaria,Japan,Sweden,Switzerland,Germany,Russian Federation,Austria,Portugal,Korea, Republic of,Spain,Canada,Chile,Greece,Turkey,Czechia,South Africa,Slovakia,France",698,Non Small Cell Lung Cancer,2021-06-14,3
801,NCT05160714,Phase 1,University Hospital Tuebingen,,Radiation: Real-time ADC-guided response adaptive Boost in HNC,Germany,24,Head and Neck Cancer,2021-01-06,1
802,CTRI/2021/03/032107,,Pacific dental college and hospital,,Intervention1: Use of ozone as irrigant in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India used without activation Control Intervention1: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India activated by manual agitation Control Intervention2: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone Ozonator by ADC India activated by ultra-sonic agitation Control Intervention3: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India activated by pro agitator tips system (PATS),India,120,Health Condition 1: K041- Necrosis of pulp,2021-03-18,
803,EUCTR2020-001574-29-BE,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,"Russian Federation,Belgium,India,Poland,Italy,Thailand,Brazil,Spain,Canada,Netherlands,Korea, Republic of,Taiwan,Czechia,Australia,United States,United Kingdom",280,"Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2021-03-16,3
804,NCT04814758,,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",,Diagnostic Test: MRI DWI sequence (ADC values),Russian Federation,230,Nephroblastoma (Wilms Tumour),2021-04-03,
805,EUCTR2020-003427-42-NL,"Phase 3,Phase 2,Phase 1","Daiichi Sankyo, Inc.",,Product Name: Trastuzumab deruxtecan for injection 100 mg Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,"Italy,Korea, Republic of,Spain,Canada,Netherlands,Taiwan,Australia,United States,Japan,France",150,"HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864 ,Therapeutic area: Diseases [C] - Cancer [C04]",2021-03-03,3
806,NCT04697628,Phase 3,Seagen Inc.,,"Drug: vinorelbine,Drug: pemetrexed,Drug: gemcitabine,Drug: irinotecan,Drug: tisotumab vedotin,Drug: topotecan","Poland,Brazil,Hungary,Belgium,Peru,Italy,Netherlands,Taiwan,Denmark,United Kingdom,China,Mexico,Argentina,Norway,Singapore,Ireland,Finland,Japan,United States,Sweden,Germany,Austria,Korea, Republic of,Spain,Canada,Czechia,France",568,Cervical Cancer,2021-04-01,3
807,EUCTR2020-003427-42-FR,"Phase 3,Phase 2,Phase 1","Daiichi Sankyo, Inc.",,Product Name: Trastuzumab deruxtecan for injection 100 mg Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,"Korea, Republic of,Italy,Spain,Canada,Netherlands,Taiwan,Australia,United States,Japan,France",150,"HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864 ,Therapeutic area: Diseases [C] - Cancer [C04]",2020-12-24,3
808,EUCTR2020-005182-14-FR,"Phase 3,Phase 2,Phase 1",Alligator Bioscience AB,,"Product Name: mitazalimab Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: mitazalimab  Other descriptive name: ADC-1013, JNJ-64457107 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Oxaliplatin Product Code: Eloxatine  Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Leucovorin Product Code: Calcium Folinate Zentiva  Pharmaceutical Form: Solution for injection/infusion  Product Name: Irinotecan Product Code: Campto  Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Flurouracil Product Code: Flurouracil Teva Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Gemcitabine Product Code: Gemcitabine Accord Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Abraxane Product Code: Abraxane Pharmaceutical Form: Powder for solution for injection/infusion",France,80,"Metastatic Pancreatic Ductal Adenocarcinoma  MedDRA version: 20.0 Level: PT Classification code 10073364 Term: Ductal adenocarcinoma of pancreas System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2020-12-23,3
809,EUCTR2019-004531-22-FR,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: Trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: paclitaxel CAS Number: 33069-62-4  Product Name: Pertuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: pertuzumab CAS Number: 380610-27-5,"Russian Federation,Germany,Poland,India,Korea, Republic of,Italy,Brazil,Spain,Canada,Taiwan,Turkey,Australia,United States,United Kingdom,France",350,"Therapeutic area: Diseases [C] - Cancer [C04],HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",2020-12-22,3
810,NCT04656652,Phase 3,Daiichi Sankyo,,"Drug: DS-1062a,Drug: Docetaxel","Poland,Brazil,Hungary,Belgium,Italy,Netherlands,Taiwan,United Kingdom,Romania,China,Mexico,Argentina,Hong Kong,Singapore,Australia,United States,Switzerland,Japan,Germany,Russian Federation,Puerto Rico,Korea, Republic of,Spain,Canada,Czechia,France",590,Non-small Cell Lung Cancer,2020-11-19,3
811,EUCTR2020-001574-29-PL,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,"Russian Federation,Poland,India,Belgium,Italy,Thailand,Brazil,Spain,Canada,Netherlands,Korea, Republic of,Taiwan,Czechia,Australia,United States,United Kingdom",280,"Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2020-11-09,3
812,NCT04506333,,University of Louisiana Monroe,,"Device: A&D UA-651 Blood Pressure Monitor,Device: ADC 740-N Manual Sphygmomanometer",United States,50,Blood Pressure,2020-06-08,
813,ACTRN12620000773932,,"Arterica, Inc.",,"The device used is the Arterica Closure Device (ACD). The ACD is a medical device used to close large-bore vascular access sites following endovascular or interventional procedures. It is a handheld device operated by a trained clinician or doctor. The device has a handle and a nose with an extended tip. The tip of the device is inserted into the access site where it brings together the surrounding tissue and closes the wound.   The investigational procedure will be performed in an operation room or catherization lab, by an experienced and trained device operator.    The ADC procedure will take approximately 30 minutes.   The device must be used per the Instructions for Use. The sponsor will ensure all device operators are trained.",New Zealand,21,"Surgery - Other surgery,  large-bore common femoral access site,large-bore common femoral access site",2020-07-28,
814,ACTRN12620000757910,,Dr Myo Min,,"This study will evaluate the feasibility of a diffusion-weighted magnetic resonance imaging (DW-MRI) guided radiotherapy boost for locally advanced rectal cancer.   Patients will undergo pre-treatment MRI in the fortnight prior to commencing radiotherapy (+/- chemotherapy). Boost volume will be defined quantitatively according to intratumoural apparent diffusion coefficient (ADC) value. This volume will be targeted for a single-fraction 5-10Gy boost 3-5 days prior to commencing standard radiotherapy (50Gy delivered in 25 fractions).   Treatment will be administered by the Radiation Oncology department at Sunshine Coast University Hospital (SCUH), Birtinya. Each treatment takes approximately 15 minutes per day. Patients will be reviewed once per week by radiation oncology medical staff as per normal practice. Patients will also be asked to complete a quality of life questionnaire at several timepoints prior to, during and following completion of the treatment course, which will take an additional 5-10 minutes on each occasion.",Australia,30,"  Rectal cancer,Cancer - Bowel - Back passage (rectum) or large bowel (colon),Rectal cancer",2020-07-23,
815,NCT04484142,Phase 2,Daiichi Sankyo,,Drug: DS-1062a,"Germany,Hungary,Italy,Korea, Republic of,Spain,Netherlands,Taiwan,United States,Japan,France",137,Non-small Cell Lung Cancer,2020-07-20,2
816,NCT04431739,,Mohamed Ibrahim Abbas,,"Device: MRI including conventional MRI, DWI with multiple ADC values",,50,Vertebral Lesion,2020-11-06,
817,ACTRN12620000592943,Phase 1,Conjugate Light (Australia) Pty Ltd,,"The name of the drug being administered is GQ1001. GQ1001 is an Antibody-Drug Conjugate used to treat patients with HER2-positive advanced solid tumors. GQ1001 will be administered by the licensed medical staff at the clinical site as a single intravenous dose on Day 1 of a 21-day treatment cycle. Patient medical records, routine safety lab tests and other necessary medical monitoring will be conducted by the investigators and site medical staff during the study.  Eligible patients will be enrolled into one specific dose cohort following the study progress. Intra-patient dose escalation will not be allowed. Dose cohorts planned for the dose escalation are 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg, and 6.0 mg/kg. Eight cycles treatment was planned for each enrolled patient. The safety review by the Safety Review Committee (SRC) will occur on a continual basis through the duration of the study. The SCR will monitor the safety and provide decisions as to dose escalations and exploring intermediate or higher doses. Patients may stay on the study treatment longer, until disease progression occurs, unacceptable toxicity occurs, or voluntarily withdraw the consent.",Australia,13,"HER2-Positive Advanced Solid Tumors,Cancer - Any cancer,  HER2-Positive Advanced Solid Tumors",2020-05-21,1
818,ACTRN12620000534987,,Dr Myo Min,,"This study aims to assess the feasibility of diffusion weighted magnetic resonance imaging (DW-MRI) guided radiation therapy dose escalation in head and neck cancer (HNC). Participants will need to attend an MRI scan at the Sunshine Coast University Hospital within one week prior to their standard radiotherapy planning CT. This scan will be performed with the participant lying in the radiation therapy treatment position with a custom fit immobilisation mask in place and may take up to an hour to perform.   Based on the quantitative information from this scan, a high-risk volume within the tumour will be identified. A boost dose of 5-7Gy in one fraction will be delivered to this tumour subvolume defined by an area of low apparent diffusion coefficient (ADC) value, representative of increased cellular density. This is followed by a 3-5 day break then the standard fractionated radiation therapy schedule of 66-70Gy over 6-7 weeks is delivered. Each individual treatment takes approximately 15 minutes.  The study will be conducted by the Radiation Oncology department at the Sunshine Coast University Hospital in Birtinya, Queensland. The participant will be asked to complete quality of life questionnaires at 5 different timepoints before, during and after the treatment period. These questionnaires may take up to 5mins to complete each time. Patients will be monitored closely by the treating team for any acute or late treatment side effects.",Australia,30,"Head and Neck Cancer,  Head and Neck Cancer,Cancer - Head and neck",2020-04-30,
819,NCT04264936,"Phase 2,Phase 1",Beijing Cancer Hospital,,Drug: RC48-ADC and JS001,China,36,Urothelial Carcinoma,2020-01-15,2
820,EUCTR2019-001655-39-ES,"Phase 3,Phase 2,Phase 1",Genmab A/S,,"Product Name: Tisotumab Vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Tisotumab Vedotin CAS Number: 1418731-10-8 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Gemcitabine 1000 mg, powder for solution for infusion Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: GEMCITABINE CAS Number: 95058-81-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-  Trade Name: Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: IRINOTECAN CAS Number: 97682-44-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Trade Name: Potactasol (Topotecan Actavis)4 mg Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TOPOTECAN CAS Number: 123948-87-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4-  Trade Name: Vinorelbin Aurobindo 10 mg/ml Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: VINORELBINE CAS Number: 71486-22-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-","Estonia,Brazil,Czech Republic,Hungary,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Denmark,Ukraine,Argentina,Norway,Singapore,Lithuania,Ireland,Finland,United States,Japan,Germany,Sweden,Austria,Korea, Republic of,Spain,Canada,Croatia,Greece,France",482,"Therapeutic area: Diseases [C] - Cancer [C04],Second- or Third-Line Recurrent or Metastatic Cervical Cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",2019-12-20,3
821,NCT04146610,Phase 1,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,Drug: an antibody drug conjugate,China,30,Neoplasms,2019-10-28,1
822,EUCTR2019-001219-22-IE,"Phase 3,Phase 2,Phase 1","Seagen, Inc.",,Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Tistotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-,"Belgium,United States,Italy,Spain,Ireland,Denmark",222,"Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)  MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10080244 Term: Peritoneal cancer index System Organ Class: 10022891 - Investigations ,Therapeutic area: Diseases [C] - Cancer [C04]",2019-10-22,3
823,EUCTR2019-002991-15-ES,"Phase 3,Phase 2,Phase 1",SOLTI,,Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201A Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,Spain,180,"Her2-positive, unresectable and/or metastatic breast cancer.,Therapeutic area: Diseases [C] - Cancer [C04]",2019-04-09,3
824,EUCTR2019-001219-22-ES,"Phase 3,Phase 2,Phase 1","Seattle Genetics, Inc.",,Product Name: Tisotumab vedotin                 Product Code: HuMax-TF-ADC                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: TISOTUMAB VEDOTIN                 CAS Number: 1418628-81-5                 Other descriptive name: HuMax-TF-ADC                 Concentration unit: mg/kg milligram(s)/kilogram                 Concentration type: equal                 Concentration number: 90-                  Product Name: Tisotumab vedotin                 Product Code: HuMax-TF-ADC                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: TISOTUMAB VEDOTIN                 CAS Number: 1418628-81-5                 Other descriptive name: HuMax-TF-ADC                 Concentration unit: mg/kg milligram(s)/kilogram                 Concentration type: equal                 Concentration number: 200-,"Belgium,United States,Italy,Spain,Ireland,Denmark",142,"Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)                   MedDRA version: 20.0                 Level: PT                 Classification code 10033128                 Term: Ovarian cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10016180                 Term: Fallopian tube cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10080244                 Term: Peritoneal cancer index                 System Organ Class: 10022891 - Investigations             ,Therapeutic area: Diseases [C] - Cancer [C04]",2019-04-09,3
825,EUCTR2019-001512-34-BE,"Phase 3,Phase 2,Phase 1",Daiichi Sankyo Inc.,,Product Name: DS-8201a Product Code: DS-8201a Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan  Current Sponsor code: DS-8201A Other descriptive name:  Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,"Belgium,Italy,Spain,United States,United Kingdom",72,"Therapeutic area: Diseases [C] - Cancer [C04],Unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumab-containing regimen     MedDRA version: 21.1 Level: LLT Classification code 10071114 Term: Metastatic gastric adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",2019-08-30,3
826,NCT03859752,Phase 1,"Open Innovation Partners, Inc.",,Biological: TR1801-ADC,United States,15,"Unspecified Adult Solid Tumor, Protocol Specific",2019-02-26,1
827,EUCTR2018-002816-29-DE,"Phase 3,Phase 2,Phase 1",GlaxoSmithKline Research & Development Ltd,,Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: belantamab mafodotin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: Pembrolizumab Product Code: MK-3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: MK-3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-,"Canada,Germany,United States,Spain",40,"Therapeutic area: Diseases [C] - Cancer [C04],Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ",2019-02-25,3
828,EUCTR2018-000764-29-PL,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: MEDI9447 CAS Number: NA Current Sponsor code: MEDI9447 Other descriptive name: MEDI9447 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 160-200  Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab Deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 Antibody-Drug Conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Datopotamab deruxtecan Product Code: Dato-DXd Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,"Poland,Korea, Republic of,Canada,Taiwan,United States,United Kingdom",320,"First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-12-19,3
829,NCT03763370,,GlaxoSmithKline,,Drug: Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate,,,Multiple Myeloma,2018-11-30,
830,EUCTR2017-004758-40-DK,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Keytruda Product Name: Pembrolizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: Keytruda Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-  Trade Name: Carboplatin Product Name: Carboplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Carboplatin Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Avastin Product Name: Avastin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BEVACIZUMAB CAS Number: 216974-75-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-,"Germany,Belgium,United States,Italy,Netherlands,United Kingdom,Turkey,Czechia,Ireland,Denmark,Czech Republic",140,"recurrent or stage IVB cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-11-16,3
831,EUCTR2018-000764-29-GB,"Phase 3,Phase 2,Phase 1",AstraZeneca AB,,Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: MEDI9447 CAS Number: NA Current Sponsor code: MEDI9447 Other descriptive name: MEDI9447 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 80-200  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 160-200  Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab Deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 Antibody-Drug Conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-,"Poland,Korea, Republic of,Canada,Taiwan,United States,United Kingdom",191,"First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-10-15,3
832,EUCTR2018-001772-38-IE,"Phase 3,Phase 2,Phase 1",AbbVie Deutschland GmbH & Co. KG,,Product Name: Telisotuzumab Vedotin Product Code: ABBV-399 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Telisotuzumab Vedotin Current Sponsor code: ABBV-399 Other descriptive name: ABT-700-vcMMAE ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-,"Poland,Czech Republic,Hungary,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Romania,China,Australia,Ireland,United States,Switzerland,Japan,Bulgaria,Russian Federation,Korea, Republic of,Canada,Greece,Turkey,Czechia,France",270,"Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-11-10,3
833,EUCTR2018-001772-38-HU,"Phase 3,Phase 2,Phase 1",AbbVie Deutschland GmbH & Co. KG,,Product Name: Telisotuzumab Vedotin Product Code: ABBV-399 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Telisotuzumab Vedotin Current Sponsor code: ABBV-399 Other descriptive name: ABT-700-vcMMAE ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-,"Poland,Hungary,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,China,New Zealand,Australia,Ireland,Bulgaria,United States,Switzerland,Japan,Russian Federation,Korea, Republic of,Canada,Greece,Turkey,Czechia,France",310,"Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-09-10,3
834,EUCTR2018-000221-31-CZ,"Phase 3,Phase 2,Phase 1",Daiichi Sankyo Inc.,,Product Name: trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: Herceptin Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab CAS Number: 180288-69-1 Other descriptive name: trastuzumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Tyverb Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lapatinib CAS Number: 231277-92-2 Other descriptive name: lapatinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Capecitabine Accord Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-  Trade Name: Capecitabine Dr. Reddy's Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade,"Germany,Belgium,Israel,Korea, Republic of,Italy,Brazil,Spain,Greece,United Kingdom,Turkey,Australia,France,United States,Japan,Czech Republic",600,"Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-09-13,3
835,EUCTR2018-000221-31-BE,"Phase 3,Phase 2,Phase 1",Daiichi Sankyo Inc.,,Product Name: trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: Herceptin Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab CAS Number: 180288-69-1 Other descriptive name: trastuzumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Tyverb Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lapatinib CAS Number: 231277-92-2 Other descriptive name: lapatinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Capecitabine Accord Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-  Trade Name: Capecitabine Dr. Reddy's Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade,"Germany,Belgium,Czech Republic,Japan,Israel,Italy,Korea, Republic of,Brazil,Spain,Netherlands,Greece,Turkey,Czechia,Australia,United States,United Kingdom,France",600,"Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-11-09,3
836,NCT03539536,Phase 2,AbbVie,,Drug: Telisotuzumab vedotin,"Poland,Hungary,Belgium,Israel,Italy,Netherlands,Taiwan,United Kingdom,Romania,China,Australia,Ireland,United States,Bulgaria,Japan,Switzerland,Germany,Russian Federation,Puerto Rico,Korea, Republic of,Spain,Canada,Greece,Turkey,Czechia,France",270,Non-small Cell Lung Cancer,2018-05-17,2
837,EUCTR2017-004810-25-DE,"Phase 3,Phase 2,Phase 1",GlaxoSmithKline Research & Development Ltd,,"Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate  CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 for Injection, 100mg Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-","Germany,Italy,Spain,Canada,Australia,United States,United Kingdom,France",230,"Therapeutic area: Diseases [C] - Cancer [C04],Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ",2018-05-14,3
838,JPRN-jRCT2080223860,,"DAIICHI SANKYO Co.,Ltd.",,investigational material(s) Generic name etc : DS-8201a INN of investigational material : trastuzumab deruxtecan Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Intravenous  control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code :  Dosage and Administration for Investigational material : -,"Europe,Japan,North America",170,HER2-over-expressing or HER2-mutated unresectable and/or metastatic non-squamous NSCLC,2018-09-04,
839,EUCTR2017-003413-25-IT,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-,"Germany,Belgium,Italy,Spain,United States,Sweden,Denmark,Czech Republic",100,"recurrent or metastatic cervical cancer  MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-03-13,3
840,NCT03485209,Phase 2,Seagen Inc.,,"Drug: cisplatin,Drug: tisotumab vedotin,Drug: carboplatin,Drug: pembrolizumab","Germany,Puerto Rico,Italy,Spain,Canada,United States,United Kingdom,France",692,"Carcinoma, Squamous Cell of Head and Neck,Colorectal Neoplasms,Carcinoma, Non-Small-Cell Lung,Exocrine Pancreatic Cancer",2018-08-03,2
841,EUCTR2017-003413-25-DE,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-,"Germany,Belgium,Italy,Spain,Czechia,United States,Sweden,Denmark,Czech Republic",100,"recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-01-03,3
842,EUCTR2017-003413-25-DK,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-,"Germany,Belgium,Italy,Spain,Czechia,United States,Sweden,Denmark,Czech Republic",100,"recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-02-27,3
843,EUCTR2017-003413-25-CZ,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-,"Germany,Belgium,Italy,Spain,United States,Sweden,Denmark,Czech Republic",100,"recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2018-02-27,3
844,ChiCTR-DND-17012404,,"Central Hospital of Minhang District,Shanghai",,",TERT&#32,ADC,&#32,BRAF&#32,Index test:T1WI,&#32,mapping,&#32,Gold Standard:Pathological diagnosis,K-trans,&#32,DWI,&#32,T2WI,&#32,T2&#32,DCE,&#32,gene,gene,&#32",China,,Papillary thyroid carcinoma,2017-08-18,
845,NCT03243331,Phase 1,Kathy Miller,,"Drug: PTK7-ADC,Drug: Gedatolisib",United States,18,"Triple Negative Breast Cancer,Metastatic Breast Cancer",2017-03-08,1
846,NCT03192501,,Second Affiliated Hospital of Guangzhou Medical University,,"Drug: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.",China,250,"Cancer,Lung Cancer,Gene Abnormality,Gene Product Sequence Variation",2017-06-15,
847,ChiCTR-DDD-17010744,,Jinling Hospital,,"Vp,&#32,FA,&#32,,D*,&#32,ADC,&#32, B. histologically proven disease.,MK,&#32,Index test:Ktrans,&#32,D,&#32,CBF,f,&#32,Gold Standard:Use long-term clinical follow-up results or pathology as gold standard. Within 12 weeks after concurrent chemoradiotherapy was completed, the progress of disease can be diagnosed as following: A.There is new enhancement outside of the radiation field,Ve,&#32,Kep,&#32",China,,Glioma,2017-02-27,
848,EUCTR2016-004743-37-BE,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: Tisotumab vedotin                 Product Code: IgG1-1015-011-1006                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: tisotumab vedotin                 CAS Number: 1418731-10-1                 Current Sponsor code: IgG1-1015-011-1006                 Other descriptive name: HUMAX-TF-ADC                 Concentration unit: mg/ml milligram(s)/millilitre                 Concentration type: equal                 Concentration number: 10-,"Hungary,Belgium,Denmark,United States,Sweden,United Kingdom",25,"Therapeutic area: Diseases [C] - Cancer [C04],Cancer of the ovary, cervix, endometrium, bladder, prostate (castrationresistant prostate cancer [CRPC]), esophagus, lung (non-small cell lung cancer [NSCLC]), and Squamous cell carcinoma of the head and neck (SCCHN)                   MedDRA version: 20.0                 Level: PT                 Classification code 10060862                 Term: Prostate cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: HLT                 Classification code 10014742                 Term: Endometrial neoplasms malignant                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10008342                 Term: Cervix carcinoma                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10023774                 Term: Large cell lung cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10062878                 Term: Gastrooesophageal cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10005003                 Term: Bladder cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: SOC        ",2017-01-30,3
849,NCT02738424,,Centre Hospitalier Universitaire de Saint Etienne,,Other: Calculate the ADC scores,France,98,Low Back Pain,2016-11-04,
850,EUCTR2015-001120-29-DK,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: HuMax-TF-ADC Product Code: IgG1-1015-011-1006 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-,"Hungary,Belgium,Denmark,United States,United Kingdom",44,"Therapeutic area: Diseases [C] - Cancer [C04],Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), esophagus or lung (non-small cell lung cancer [NSCLC])  MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",2015-07-15,3
851,NCT02379741,Phase 1,Alligator Bioscience AB,,Biological: ADC-1013,"United Kingdom,Sweden,Denmark",24,"Solid Tumors,Neoplasms",2015-02-16,1
852,NCT02341625,"Phase 2,Phase 1",Bristol-Myers Squibb,,"Biological: Nivolumab,Drug: BMS-986148","Belgium,Italy,Korea, Republic of,Canada,Netherlands,Hong Kong,Australia,United States,United Kingdom",126,Advanced Cancer,2015-01-14,2
853,NCT02312037,,Pfizer,,Biological: Antibody Drug Conjugate Chemotherapeutic,"United States,Spain",,CD33 Positive Acute Myelogenous Leukemia,2014-04-12,
854,ISRCTN68413407,,Wellcome Trust/DBT India Alliance (India),,"Current interventions as of 31/10/2014:                 Cluster definition:                 A cluster in this study is defined as a village in the geographic area of this trial that is randomly allocated to one of the study arms, its ADC or one of its ADCs, the LHW in charge of the selected ADC, all children aged 12 ? 59 months registered in the ADC and the mothers/care givers of these children.                  In particular, the following activities will take place in the intervention group:                 1. Distribution of supplementary IFA (20 mg, 1 tablet taken biweekly) to the mother/care giver of all non anemic children (supplied at 8 tablets/month, for a duration of 6 months of the trial, total 48 tablets).                 2. Distribution of therapeutic IFA (20 mg/day) 20 tablets/month to the mother/care giver of all anemic children for a total duration of 5 months meant for consumption by the anemic child (total 100 tablets).                 3. Monthly education and counselling of mothers of anemic children by the LHW trained for delivery of this intervention covering the following topics regarding:                 3.1. Symptoms and signs of anemia                 3.2. Treatment with IFA and its side effects                 3.3. Education regarding IFA compliance and its monitoring                 3.4. Information about local iron rich foods and dietary diversification                 3.5. Information about personal hygiene and deworming                 The education and counselling with occur either at the ADC or at the mother?s home at the discretion of the LHW.                 4. Ensuring that all children attend the village ADC for retesting at the end of 6 months.                  Control arm (treatment as usual or CA):                 T",India,2520,"Anemia  Haematological Disorders  Anaemia, unspecified",2013-12-17,
855,ISRCTN77650947,Phase 2,University of Birmingham (UK),,Brentuximab vedotin: Antibody-drug conjugate                 30 patients will be recruited from hospitals across the UK and will receive a maximum of 16 doses over 48 weeks.,United Kingdom,30," Disease: Lymphoma (Hodgkin's)  Cancer  Hodgkin lymphoma, Subtopic: Lymphoma,Topic: National Cancer Research Network",2013-10-16,2
856,EUCTR2013-001074-15-GB,"Phase 3,Phase 2,Phase 1",Genmab A/S,,Product Name: HuMax-TF-ADC Product Code: IgG1-1015-011-1006 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: HuMax-TF-ADC CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-,"Belgium,Denmark,United States,Sweden,United Kingdom",217,"Therapeutic area: Diseases [C] - Cancer [C04],Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (non-small cell lung cancer [NSCLC]  MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",2013-07-24,3
857,RBR-3vwfjs,,Universidade Federal do Tocantins,,"HP3.073.433.101,This is a double blind study. Subjects: We wil select individuals with crack cocaine addiction diagnosis, males, and with minimum age of 18 years, and maximum age 50 years old, and capable of consenting. The intervention will be held for 12 weeks. Study groups: 20 individuals who make use of topiramate and 20 individuals who make use of placebo. Randomization: The sample will be randomized by permuted block technique. The total sample will have 40 participants. Patients will be randomly selected from the Psychosocial Care Center of Palmas, Brazil. Randomization will be performed according to a computer generated random list by the method exchanged in blocks. The first five participants will be allocated in the group who use the medication topiramate. The next five in grup that use placebo. Following five in the second group topiramate and so on until the total number of 40 individuals. Medications that will be used: 25 to 200 mg of topiramate (increased at doses every 7 days 25mg) for 12 weeks. Placebo for 12 weeks single capsule. Urine test to confirm the negative use of the drug: Be quantified for each group (arm) the number of individuals testing negative urine after 12 weeks of intervention. The urine test for cocaine is an immunoassay based on the competitive binding between the antibody drug conjugate immobilized on the membrane and the drug or its metabolites which may be present in the urine sample. The test strip has immobilized drug conjugate in the area of test and antibodies conjugated to gold colloidal conjugate to the membrane. During the examination, a urine sample migrates by capillary action. The benzoylecgonine, if the sample Urine below 300 ng / ml did not saturate the binding sites of antibodies conjugated to gold in the test strip. Antibodies conjug,D27.505.954.427.080,Drug",Brazil,,"D02.145.074.722.388.250,Cocaine crack addiction.,F01.145.527.100.120",2013-06-13,
858,DRKS00002954,,Universitatsklinikum Freiburg,,"Group 1: Study protocol MRI (3.0 Tesla): 1. Localizer sequence to plan scan orientations 2. high-resolution T2-weighted images in sagittal, coronal and axial orientation 3. diffusion-weighted (DWI) images with different diffusion weighting, to determine apparent diffusion coefficient (ADC) 4. T2-weighted images with different echo times in the axial orientation in order to determine the relaxation time T2. 5. T2 *-weighted images with different echo times in the axial orientation in order to determine the relaxation time T2 *. 6. T1-weighted MR images with different T1-weighted image in order to determine the relaxation time T1 7. Time series (dynamic) T1-weighted MR images before, during and after contrast agent administration in order to evaluate the tissue-perfusion (dynamic contrast-enhancement, DCE)",Germany,20,"Malignant neoplasm of prostate,C61",2012-09-05,
859,EUCTR2010-020729-42-PL,"Phase 3,Phase 2,Phase 1",Helix BioPharma Corp,,Product Name: Lyophilised L-DOS47 Product Code:  L-DOS47 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Lyophilised L-DOS47 Current Sponsor code: L-DOS47 Other descriptive name: AFAIKL2-urease immunoconjugate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1.7-,Poland,74,"Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer  MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ,Therapeutic area: Diseases [C] - Cancer [C04]",2011-07-19,3
860,ACTRN12608000462381,,The Royal Childrens' Hospital Mebourne,,"The randomised cross over trial will aim to determine if additional priming of a haemofilter circuit with 5 u/ml heparinised 4% albumin increases circuit life (compared to only 5 u/ml heparinised saline).  This additional priming will be performed before the circuit is connected to the patient. The study will also determine if there is a difference between regional citrate and global heparinised anticoagulation on circuit life.  The dose of citrate (in the form of ADC-A) will be titrated with a calcium chloride infusion to maintain circuit calciums of less than 0.3 mmol/L and a patient calcium of 1.0-1.3 mmol/L. Upon recruitment all participants will be randomly assigned to one of 8 sequences of varying anticoagulation and priming methods as recommended for a four period crossover design with 2 factorial treatments.  Their first 4 circuits will consist of two heparin and two citrate circuits, one of each will be primed with heparinised saline and the other with an additional heparinised albumin prime, with the order of the treatments determined by their pre-assigned randomised sequence. As hemofiltration is necessary to maintain these patients there will be no intentional ""wash out"" period as with holding treatment may be detrimental to the patient. Each circuit will run until TMP (Transmembrane Pressure) reaches 280mmHg, treatment needs to be interrupted for longer than two hours or a significant adverse event occured.  The participant will be in the trial for a maximum of eight circuits.",Australia,100,"Renal and Urogenital - Kidney disease,Acute renal failure,  Acute renal failure",2008-09-16,
861,NCT00077493,Phase 1,MedImmune LLC,,"Procedure: antibody-drug conjugate therapy,Procedure: monoclonal antibody therapy,Procedure: immunotoxin therapy,Drug: BL22 immunotoxin",United States,95,"Leukemia,Lymphoma",2004-10-02,1
862,NCT00051584,Phase 2,"Seattle Genetics, Inc.",,"Drug: Gemzar (Gemcitabine),Drug: SGN-15 (cBR96-Doxorubicin Immunoconjugate)",United States,60,Ovarian Neoplasms,2003-01-13,2
863,NCT00028483,Phase 2,"Seattle Genetics, Inc.",,"Drug: cBR96-doxorubicin immunoconjugate,Drug: docetaxel",United States,,Breast Cancer,2002-04-01,2
864,ISRCTN17161961,,Cardiff University (UK),,"1. (R1) Patients with acute promyelocytic leukemia (APL) will be randomised to receive oral retinoic acid together with either MRC H-DAT chemotherapy or the Spanish Intermittent Idarubicin. Following confirmation of remission, patients will continue with the MRC (DAT:MACE:MIDAC) or Spanish chemotherapy but will be randomised to receive CMA-676/Myelotarg (Immunoconjugate) on day 1 of course 3 or not. (Patients will be monitered molecularly by Reverse Transcription (RT) and real time Polymerase Chain Reaction (PCR) to predict relapse. Three quality of life assessments will be made at 3, 6 and 9 months and resource use information will be collected for cost benefit analysis.)                 2. (R2) Non-APL patients will be randomised to receive induction cources 1 and 2 with H-Dat (Daunorbicin:Ara-C, Thioguanine) or FLA_G IDA (Fludarabine, Ara C, G-CSF, Idarubicin) and to receive CMA-676 (Myelotarg) on day 1 of course 1 or not.                 3. Following the first course of chemotherapy the risk profile of each patient will be determined (based on cytogenetics, blast clearance after course 1). Good risk patients (15%) will leave AML15 and will enter the MRC AML High Risk Trial.                 4. (R3)(R4) Patients who have completed course 2 and are allocated to the chemotherapy comparisons will be randomised to receive CMA-676 (Myelotarg) on day 1 of course 3.                 5. (R5) All patients allocated to allogenic transplant up to 35 years will receive standard conditioning (Cyclophosphamide/TBI) with stem cells obtained from peripheral blood or bone marrow as course 3. For patients 36-50 investigators may choose a conventional transplant or a non-ablative transplant. Patients over 50 years will receive a non-ablative transplant. The non-ablative","Wales,United Kingdom",3000,Leukaemia  Cancer  Leukaemia,2001-02-05,
865,NCT00004858,Phase 1,Parker Hughes Cancer Center,,Biological: B43-genistein immunoconjugate,United States,,"Leukemia,Lymphoma",2000-07-03,1
866,NCT00002163,Phase 3,Glaxo Wellcome,,Drug: Abacavir sulfate,"Canada,United States",,"AIDS Dementia Complex,HIV Infections",1999-02-11,3
